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Aim: This study investigated the use of granulated sugar in the management of sloughy, 
necrotic and infected exuding wounds. 
Method: The investigation followed the Medical Research Council (MRC, 2007) framework 
for investigation of complex interventions. This recommends investigating the scientific 
mechanisms underlying the intervention; reviewing existing evidence; then investigating 
effectiveness.  
Pre-clinical: The study was registered with MHRA, followed by development and design of 
the mode of sugar delivery to patient use. The amount of sugar to be used on different sizes 
of wounds was determined and single use containers were designed to prevent of cross-
infection 
Evidence review: A systematic review and meta-analysis identified, assessed and 
synthesised the evidence for the clinical effectiveness of sugar treatment in the treatment of 
acute and chronic sloughy, necrotic and infected exuding wounds. The review found four 
randomised controlled trials, three of which reported rates of wound healing. Meta-analysis 
was carried out of these three and found no statistically significant difference in rates of 
wound healing. The identified trials were of poor quality. It was concluded that there was no 
existing good quality evidence to support the routine use of sugar dressings to promote 
wound healing in non-healing acute or chronic sloughy, necrotic and infected exuding 
wounds. 
Phase I: Laboratory studies to determine the effects of sugars on microorganisms were 
carried out. These included a range of in vitro tests, evaluating the activities of three sugars (2 
white granulated (Cane and Beet) and one Demerara/ un-refined sugar) against a range of 
Gram-negative and Gram-positive bacteria 
These studies found that all three sugars showed relatively equal activity against all the 
bacteria tested although Demerara sugar was slightly less active. The sugars were only active 
in solution, which supports a lowering of bioavailability of water for bacterial growth as a 
mechanism of action. There was little variation in the concentration of sugar needed to inhibit 
growth of any of the strains (i.e. efflux mutants were no more susceptible) indicating the 
mechanism of antimicrobial action of sugar is non-specific. Pseudomonas aeruginosa (G1) 
was slightly more susceptible than other species. 
 
Phase II:  A feasibility study of 22 patients selected from an NHS vascular ward and 
vascular out-patient department in Birmingham UK was undertaken. All patients had acute or 
chronic sloughy, necrotic and infected exuding wounds. Patients with diabetes had their 
blood sugar level checked daily as per trust protocol until the end of the study, to investigate 
the effects of sugar. This study was carried out to assess the practical aspects of using sugar 
treatment in a modern NHS hospital. At the end of the study and following the results, a RCT 
working protocol was developed, including the amount of sugar required and measurement of 
wound outcomes.  
Twenty two patients completed this study. The study found that both insulin and non-insulin 
treated diabetic patients can be treated with sugar dressing without affecting their blood sugar 
levels.  
The study determined the amount of sugar required for different wound sizes and. Wounds 
were categorised as small- medium (5 – 19.9 cm
2
) and medium to large (20 – 40 cm
2
) 
required doses of 15 and 30 grams respectively. Although this study was not aimed at 
exploring debridement effect, sugar was noticed to be effective on wound debridement 
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Phase III: A randomised controlled trial evaluated the clinical effectiveness of granulated 
sugar therapy compared with standard autolytic debridement dressings.  





 in size and at least 25% slough were recruited from NHS hospital and community 
settings 
The primary outcome was the proportion debrided at 4 weeks follow up. A number of 
secondary outcomes were assessed including wound area, wound pain, odour, exudate and 
health related quality of life. 
The study failed to recruit the intended numbers and final analysis was carried out on 22 
patients randomised to sugar and 19 randomised to usual care. 19 (86%) achieved 
debridement at 4 weeks in the sugar group compared to 6 (32%) standard care group 
(Fisher’s exact test: p<0.001). There were statistically significant improvements in a number 
of secondary outcomes including pain, wound exudate appearance and wound area. 
The data from this RCT though small in sampled patient numbers showed that granulated 
sugar applied topically is an effective debriding agent and well tolerated treatment option in 
patients with exuding necrotic or sloughy wounds. 
Overall conclusion: Sugar does have an effect on micro-organisms. It is possible to use it in 
modern hospitals and community settings. There is now a replicable and adaptable sugar 
treatment protocol. There is some evidence for the effectiveness of sugar, however this study 
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 Why sugar? A reasoned exposition by the author 1.1.
This thesis is the result of my experiences as a child in Zimbabwe, where my father used 
sugar to treat my wounds as well as those of others in the community. The author has seen 
several fascinating results from the traditional ways of treating diseases, including the use of 
sugar on wounds, but there was no recorded scientific backing to these treatments identified 
from explored literature. The author’s father had recognised expertise in the use of different 
herbs to be used for different ailments but the dose was never consistent, although there were 
good results. The community around him believed in his herbs. Hence, the interest of the 
author lies in the science behind these traditional treatments such as treating wounds with 
granulated sugar, i.e. scientific epistemology (Fay, 1996; Root, 1999; Bowling, 2014). One 
would argue that there is often deeper truth and better new evidence that disturbs the status 
quo and that forces us to revise or reject some of our traditional treatments. This according to 
Pojman (2002), Root (1999) and Fay (1996) is the theory of knowledge, or epistemology. 
The author wanted to enquire into the nature of knowledge and justification of his father’s 
belief on managing wounds (using granulated sugar) having seen many different modern 
wound management products. He had experienced his father’s conviction that granulated 
sugar was effective on managing sloughy, necrotic and infected exuding wounds, but could 
not claim to know the truth to justify these effects. It was vital for the author to avoid the 
feeling that Rene Descartes pondered later in his life as cited by Pojman (2002): 
“Several years have now passed since I first realised how many were the opinions that 
in my youth I took to be true and thus how doubtful were all the things that I 
subsequently built upon these opinions”  
(Pojman, 2002 p.144). 
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Therefore, the thesis is written with alternative traditional remedies in mind because these 
methods of treating wounds are sometimes based on myths and assumptions. Because of 
these myths, they are sometimes discounted because of their lack of scientific basis, even 
though their results can be of benefit into modern medicine (Chiwenga, et al., 2009, Nakao, et 
al., 2006, Shi, et al. 2007). Many modern day health care professionals are not aware of this 
traditional remedy; however, in my opinion even if they were aware, they will be discouraged 
from using sugar remedy because there has not been any rigorous researched evidence to 
support its use. It is therefore important that rigorous research is undertaken into the 
effectiveness of sugar on sloughy, necrotic and infected exuding wounds. 
 
 Historical perspective of sugar as a wound care product 1.2.
Methods of healing wounds using sugar have been studied for many years. Documents dating 
back to 1679, describe Edwin Smith Surgical Papyrus (dated around 1700 BC) treating battle 
wounds in Egypt with molasses and honey (Breasted, 1930) and Zorin in 1714, reported on 
the value of sugar in promoting the healing of wounds and ulcers. Furthermore, Sculteus 
(1679) reported using finely powdered sugar for cleansing and promoting wound and ulcer 
healing (Dawson, 1996; Pieper and Caliri, 2003). In the same way as Egypt, the Middle-East 
(Mesopotamians) now called Iraq and Iran are reported to have been using sugar as a wound 
dressing for about 4, 000 years ago (Majno, 1975). Documents showed the procedure 
involved the application of honey mixed with greases such as lard or resins (Majno, 1975) or 
use of sugar/molasses and honey (Selwyn and Durodie, 1985). Despite these early reports 
showing that sugar had been valued throughout the world (Wiseman et al., 1989; Rostenberg 
Jr., 1958; Duffet and Viau, 1986; Silvetti, 1981,  Viau et al., 1986;  Viau et al., 1985) as a 
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wound healing product, there has been little evidence published on trials exploring in depth 
this product to date. 
 Recently reported studies on sugar as a wound healing product 1.3.
Currently, sugar as a wound healing product is reported in several studies ranging from 1981 
to 2011 with prospective studies being those of (Herszage et al., 1980; Knutson et al., 1981; 
Chirife et al., 1982; Chirife et al., 1983; Gordon, 1985; Mphande et al., 2007; De Foe et al., 
2000; De Foe et al., 2003; Murandu et al., 2011), Despite this documented evidence, the use 
of sugar for wound healing seems to be overlooked even though there is increasing indication 
of its value. In spite of this slow development some areas of Africa, Asia, Latin America, 
Europe and United States are becoming interested in exploring sugar as a wound healing 
product, as studies demonstrate   (Dawson, 1996); Mphande et al., 2007; Biswas et al., 2009; 
Chirife et al., 1982; Chirife et al., 1983; Herszage et al., 1980; Middleton and Seal, 1985; 
Haddad et al., 1983; Drouet, 1983; Duffet and Viau, 1986 ; Haddad et al., 2000 ; De Feo et 
al., 2000; Tophan, 2000; De Foe et al., 2000; De Feo et al., 2003; Murandu et al., 2011 and 
Knutson et al., 1981) respectively. 
 The importance of undertaking the study 1.4.
There have been various reported investigations into the study of wound healing using sugar 
as mentioned above, but despite this plethora of evidence, there has not been any conclusive 
agreement to the clinical significant of sugar on wound healing. From these sporadic reports 
and studies, there is a general agreement that, sugar assists with wound debridement of 
exudating wounds and facilitates wound healing (Archer et al., 1990; Tanner, 1998; Tophan, 
2002; Booth, 2004). Nonetheless, there have not been large and sufficiently powered 
randomised controlled studies that explored granulated sugar and its effect on 
microorganisms and wound healing. In addition the knowledge of the effects of the different 
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sugars’ action such as (Cane, Beet, White and Demerera/Brown sugars) on microorganisms 
has not been document from any of the reviewed studies. Only one study was found by 
Herszage and colleagues 1982 exploring the science behind the sugar and its effect on 
microorganisms. This study resulted in the understanding of the theory of water activity, 
where microorganisms are said to be competing with sucrose for water when it is applied on 
the wound topically. There is no reported studied exploring the difference in the effectiveness 
of the types of sugar on various microorganisms either in vitro or clinically. 
 
The researcher believe that an understanding of the effectiveness of different sugars (beet, 
cane, brown/Demerara and white granulated sugars) on wound healing of exudating wounds 
will provide valuable information that will help health care professionals, make informed 
decisions when deciding on the choice of wound-care products. The increasing numbers of 
wound care products on the market presents a dilemma for nurses and doctors when making a 
choice of the appropriate dressing for a specific wound. For these reasons, it is necessary to 
carry out an investigation that contributes to an understanding of the effectiveness of sugar on 
wound healing in context of differing sugars, and the applicability in modern day NHS 
hospitals and health care settings and patient acceptability. Furthermore, my interest in the 
effectiveness of sugar on wound healing lies in the assumption that it is cheap and can be 
easily be accessible to both developed and developing countries. 
 
Overall aim of the Research is to: 
Investigate the use of granulated sugar in the management of sloughy, necrotic and infected 
exuding wounds. 
There are several secondary aims of this project. These are to investigate: 
 Existing evidence for the effectiveness of sugar dressings 
 The microbiological effects of sugar in vitro 
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 The feasibility of a RCT of sugar dressing  
 Undertake an RCT of sugar dressing 
The investigation follows the Medical Research Council (MRC, 2007) framework for 
investigation of complex interventions. This recommends investigating the scientific 
mechanisms underlying the intervention; reviewing existing evidence; then investigating 
effectiveness (see  
Table 1.1 adapted framework). 
 
Table 1.1: Sugar trial framework adapted from MRC (2000) 





designing mode of 













Testing of effects 








of RCT both in 
community and 
acute settings  
Pre-clinical Phase I Phase II Phase III 
 
Primary Question 
How effective is sugar dressing in reducing the time to debridement of sloughy, necrotic and 





Does the use of sugar dressing reduce the bacterial load in a wound to a greater extent 
than standard treatment? 
Does the use of sugar dressing improve the quality of life of patients with sloughy, 
necrotic and/or infected wounds? 
Is the use of sugar dressing feasible in a modern day NHS Hospital setting? 
Is patient satisfaction improved when using sugar dressing? 
Is sugar dressing cost-effective alternative to standard dressings? 
Is sugar dressing acceptable to nursing staff? 
 Outline of the Thesis 1.5.
This study will investigate the effectiveness of granulated sugar dressings on sloughy necrotic 
and infected exuding wounds. Chapter 2 examines the laboratory studies on microbiological 
effects of sugar. The researcher will examine “in vitro” the effectiveness of different sugars 
derived from Beet and Cane as well as Demerara/Brown and White sugar formulas; to 
determine their effectiveness on eradicating microorganisms. 
 
Chapter 3 presents a systematic review of the literature on the RCTs using granulated sugar 
on sloughy necrotic and infected exuding wounds. Specifically, it provides the literature 
search strategy used, and systematically reviews the randomised controlled trial papers on 
sugar and wound healing. 
 
Chapter 4 presents the first clinical exploration. In this chapter, ethical and the Medicine and 
Health Regulatory Authority issues will be explored. In addition, the feasibility of using 
sugar as a dressing for necrotic sloughy, infected exudating wounds in a modern day National 
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Health Service Hospital (NHS) will be outlined. The attitude of both health care professionals 
and patients towards sugar dressing will be highlighted. 
 
Chapter 5 outlines the second clinical study. This chapter describes a randomised controlled 
trial (RCT) of sugar compared to standard treatment for sloughy, necrotic and infected 
exuding wounds. 
 
Chapter 6 presents an overview of all the studies that make up the doctoral thesis. The 
researcher will explore implications, recommendations, reflections and significance of these 





2. Chapter: Laboratory studies on microbiological effects of sugar 
 Granulated Sugar (Sucrose) 2.1.
Yudkin and colleagues (1971) describe sucrose as a carbohydrate consisting of glucose and 
fructose. It is the predominant constituent of sugar cane and sugar beet. They go on to suggest 
that this substance sucrose is of great versatility and of commercial importance (Yudkin et al., 
1971). It is consequently of interest to a wide range of specialists areas including the chemist, 
the biochemist, the animal and plant physiologist, the clinician, the historian, the sociologist, 
the nutritionist, the psychologist and above all the food manufacturer. Whatever the future 
utilisation of sucrose may be, it will always be remembered as a constituent of man’s diet. 
According to Hough (1968) sucrose is a non-reducing disaccharide of unique structure 
containing eight alcoholic groups, three of which are primary hydroxyls (at carbons 6, 1’, and 
6), the remaining five being secondary hydroxyls. It is a white odourless, crystalline powder 
with a sweet taste (Yudkin et al., 1971; Lombardo et al., 1996) (see Figure 2.1). 
Figure 2.1: Molecular formula of sucrose 
 
This special linkage prevents bonding with other saccharide units, hence chemically it is a 


































fructose, but sucrose is reasonably stable in the presence of strong bases and alkalis (Yudkin 
et al., 1971). However, hydrolysis is so slow that solutions of sucrose can sit for years with 
negligible change, but if enzyme sucrase is added the reaction will proceed rapidly. 
Sugar is almost ubiquitous. It is produced by all known land plants and is recovered 
commercially from a root (44%), several grasses (56%), and tree (˂1%) (Yudkin et al., 1971). 
 Other uses of sucrose 2.2.
Refined sugar has been a significant factor on international trade for more than 20 centuries 
(Yudkin et al., 1971) which seem to span the entire evolution of the organic chemicals 
industry. It is without doubt that there have been several attempts to harness this abundant, 
low priced, pure disaccharide as a raw material for chemical applications. A few of its 
applications are listed below; foods for human consumption; feeds for animals; fuels, though 
because 51% of the weight of sucrose is oxygen, this stops sugar from being realistic fuel. 
However, small amounts are used to make explosives as the octanitrate in nitroglycerine and 
mannitol hexanitrate. There are other uses such as lubricants, preservatives, surfactants, 
surface coatings and many others. In this study we shall ignore all other usages and focus on 
the sucrose’s role on wound healing. 
 Assessment of antimicrobial activity of Cane, Beet, Demerara 2.3.
(unrefined) and White (refined) sugars against a range of bacteria 
It is acknowledged that sugar/molasses has been known for centuries in the management of 
wounds (Pieper and Caliri, 2003; Breasted, 1930), but little is known of specific sugars such 
as that derived from beet or cane. Also of interest is knowledge of unrefined (Demerara) and 
(White) sugars on microorganisms. Following discussion with a microbiologist a range of in 
vitro tests were used to evaluate the activity of three sugars (2 white granulated (Cane and 
Beet) and one Demerara) against a range of Gram-negative and Gram-positive bacteria.  
22 
 
 In Vitro Test Methods 2.4.
Strains: A panel of 16 strains representing Gram-negative and Gram-positive bacteria were 
used in the experiments. These included representative of wild-type strains for each species. 
In addition a set of Salmonella mutants with defined disruptions in efflux genes (responsible 
for intrinsic resistance to numerous agents) were evaluated in order to identify whether active 
efflux is required for tolerance to sugar. Strains are listed in Table  2.1 below. 
Table  2.1: Strains used in the study. 
Strain code  Species Genotype/ source 
I114  E. coli NCTC 10538 
F77  S. aureus  NCTC 8532 MSSA 
F410  S. aureus NCTC 12493 MRSA 
G1  P. aeruginosa NCTC 10662 
H42  K. pneumoniae NCTC 10896 
H43  K. pneumoniae NCTC 9633 
L354  S. Typhimurium Wild-type (SL1344) 
L109  S. Typhimurium SL1344∆tolC  
L785  S. Typhimurium Wild-type ATCC 15277  
L828  S. Typhimurium Wild-type ATCC 14028s 
L829  S. Typhimurium ATCC 14028s ∆tolC 
L830  S. Typhimurium ATCC 14028s ∆acrB 
L831  S. Typhimurium ATCC 14028s  ∆acrAB 
L3  S. Typhimurium Human pre-therapy clinical isolate 
L10  S. Typhimurium Human post-therapy clinical isolate, MDR 
A1  E. cloacae NCTC 10005 
B14  S. marcescens NCTC 2847 
J29  M. morgani NCTC 235 
 
 
 Susceptibility testing. 2.5.
Antimicrobial susceptibility testing of all agents to the three sugars supplied used a variety of 
methods. These were:  
 The agar dilution method (incorporation of sugar at doubling dilutions into a range of 
iso-sensitest agar plates; following the recommendations of the BSAC
1
 and that 
described by Schillinger and Lucke, (1989). 
 An agar diffusion assay (100mg of pure sugar placed onto a well bored into an iso-
sensitest agar plate which was then overlaid with bacteria and incubated). 
                                                 
 
1
 BSAC – The British Society for Antimicrobial Chemotherapy  
23 
 
 Broth microdilution microtitre tray susceptibility assays (bacteria were inoculated into 
iso-sensitest broth containing doubling dilutions of sugar concentrations again 
following BSAC guidelines). 
 Growth kinetics (Luria-bertani broth containing varying concentrations of each sugar 
was inoculated with bacterial cultures and incubated for 12 hours. Growth was 
monitored automatically in a FLUOstar OPTIMA by measuring the optical density of 
cultures at 600nm, similar to that described by Jacobsen et al., (1999). 
 Results 2.6.
2.6.1. Susceptibility testing in agar 
None of the sugars showed any antimicrobial activity when incorporated at a range of final 
concentrations (w/v) into agar plates with all strains growing on plates containing a final 
concentration of 25% (w/v) of sugar. Similarly in the diffusion assays, all strains were able to 
grow up to the wells containing sugar, there was no zone of inhibition seen for any strain. 
2.6.2. Susceptibility testing in broth 
In contrast to the agar experiments, all the strains were inhibited by sugar in solution. All 
three sugars tested were able to prevent growth of all the species at final concentrations from 
6 – 25% (Table 2.2) below. The activity of all three sugars was similar, the granulated sugars 
showed some slight increased activity when compared to Demerara sugar. The pattern of 
inhibition of strains was similar and efflux mutants were not more susceptible to sugar than 
their parent strains indicating efflux is not likely to contribute to intrinsic resistance to sugar. 
Pseudomonas aeruginosa G1 was somewhat more sensitive to the granulated sugars than the 




Table 2.2: Minimum inhibitory concentration of sugar against strains tested (in broth). 
 MIC (% sugar w/v) 
Strain 
Granulated 
(Tate and Lyle)  
Granulated 
(British Sugar)  Demerara 
I114 25  25  25 
F77 25  25  25 
F410 25  25  25 
G1 12  6  25 
H42 25  25  25 
H43 25  25  25 
L354 12  25  25 
L109 25  25  25 
L785 25  25  25 
L828 25  25  25 
L829 25  25  25 
L830 25  25  25 
L831 25  25  25 
L3 25  25  25 
L10 25  25  25 
A1 25  6  25 
B14 25  25  25 
J29 25  25  25 
 
2.6.3. Growth inhibition by sugar 
Growth kinetics in the presence of various sugar concentrations revealed a very similar 
pattern to the micro broth dilution susceptibility testing. The strains were able to grow well in 
low concentrations of sugar. However, these strains were completely inhibited by higher 
concentrations which correlated well with the inhibitory concentrations seen in the MIC 
testing. Figure 2.2 shows an example of one growth curve illustrating inhibition of E. coli 




Figure 2.2: Growth inhibition of Escherichia coli I114 by Demerara sugar in 





All three sugars showed relatively equal activity against all the bacteria tested although 
Demerara sugar may be slightly less active. The sugars were only active in solution which 
supports a lowering of availability of water as a mechanism of action. There was little 
variation in the concentration of sugar needed to inhibit growth of any of the strains (i.e. 
efflux mutants were no more susceptible) indicating the mechanism of antimicrobial action of 
sugar is non-specific. Pseudomonas aeruginosa (G1) was slightly more susceptible than other 
species. 
 Theory related to sugar on microorganisms 2.8.
The above study results support Engelsen and Peres’ (1997) conclusion that sugar is a 
disaccharide of fructose and glucose which will combine with other polar substances such as 
water by hydrogen bonding. Micro–organisms require water to grow and reproduce and such 
                                                 
 
2
 Optical Density 600nanometre (OD 600)-Spectrometer is used to measure the optical density at 600 
nanometre of bacterial culture to monitor bacterial growth 
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water requirements can be defined in terms of water activity (aw) of the substrate rather than 
water concentration (Chirife et al., 1983, Chirife et al., 1982). The water activity of a solution 
is expressed according to Chirife (1983) as aw = p/po where p is the water vapour pressure of 
the solution and po is the vapour pressure of pure water at the same temperature. When a 
solute such as sugar is added to an aqueous solution in which a micro-organism exists, it will 
have the effect of lowering the aw, with a concomitant effect upon cell growth (see Figure 
2.2). Every micro-organism has a limiting aw below which it will not grow (Herszage et al., 
1980; Chirife et al., 1983; Tophan, 2000 Biswas et al., 2010). 
 Water requirements for microorganisms 2.9.
As briefly described earlier, the water requirements for all microorganisms and all other 
forms of life can be defined in terms of water activity, and every living organism has a 
limiting aw below which it cannot proliferate. When the aqueous solution in the 
microorganisms’ environment is concentrated by the addition of a solute such as sugar, the 
effects on microbial growth are mainly due to the change in aw. the minimum aw for most 
bacterial pathogens (E. Coli, Pseudomonas, Klebsiela, to name a few, (see Table 2.2) for full 
range) is 0.91 or more but for Staphylococcus Aureus is 0.86 (Chirife et al., 1982). In their 
study Chirife and associates (1983) discovered that all bacterial growth was inhibited at an aw 
of 0.858 (i.e. 195g sugar/100ml of water). They further compared a test medium of brain-
heart infusion in which the aw was 0.993 which supported rapid bacterial growth. The 
medium was adjusted to an aw  of 0.858 by adding sugar which caused complete inhibition of 
bacterial growth (Chirife et al., 1982). Therefore a concentration of 195g sugar/100g water 
would theoretically inhibit the proliferation of all bacteria. By following this rationale, the 
bacterial effect of sugar would also limit the bacterial production of ammonia, amines, and 
sulphur all which cause malodour (Tovey, 1991), (Nakao et al., 2006). This theory is 
supported by Molan and Cooper (2000) who suggest that sugar has a deodorising action, 
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whereby the infecting bacteria utilize the sugar instead of the amino acids, resulting in the 
production of lactic acid rather than malodorous compounds. In conclusion, bacteria need 
water to proliferate, if starved of water then there is inhibition of growth. 
Figure 2.3: In vitro theory of Bacterial vs. sugar 
 
 
In light of this evidence, it can be suggested that sugar may prevent microbial growth in vivo. 
Having looked at the potential of sugar as a wound dressing from the laboratory perspective, 
it is important to consider the clinical evidence. The next chapter presents the literature 
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3.  Chapter: Systematic review /Meta-analysis of sugar for exudating 
wounds 
  Introduction 3.1.
There is a plethora of widespread existing evidence of non-healing wounds that has 
substantial cost implications to the NHS. Many interventions, new dressing products and 
wound care technologies are being developed and used to help to achieve optimum wound 
healing and eliminate infections. Many are very expensive. However, no one wound 
management product has been fully guaranteed to be of optimum effect. Therefore it is 
imperative to find out an intervention that has both therapeutic effects on the wound healing 
process as well as being cheap. This chapter reviews data that support the use of sugar in 
wound healing and its ability to manage infected wounds. 
3.1.1. Description of the condition understudy  
It is understood (Lammers, Christopher, and John, 2001) that the main wound care objective 
must be the provision of optimal conditions for the individual body to use its natural 
reparative processes. Chronic wounds are a major NHS Health care burden and they also 
affect the quality of life of those who live with them (Kilic, 2001). Lazarus (1994) suggested 
that acute wounds proceed through to healing in an orderly and timely reparative process. 
Dealey (1994) and Dealey (2005) suggests that chronic wounds are wounds where the orderly 
biological progression to healing has been disrupted and healing delayed. Phillips (1996) 
concluded that the microenvironment of a chronic wound has a negative effect on the healing 
of a wound resulting in prolonging the healing process. It is therefore a challenge to ensure 




3.1.2. Chronic wounds and microorganisms  
Moist chronic skin ulcers and sinuses are believed to be ideal medium for bacterial growth 
and a variety of micro-organisms can be cultured from wound swabs collected from these 
lesions. Studies on cultured swabs have shown that over 80% of chronic leg ulcers may be 
contaminated with bacteria (Griffiths and Wieman, 1990; Pecoraro, 1991; Edmond, 1987). 
The commonest isolates are Staphylococcus aureus and Pseudomonas aeruginosa (Griffiths 
and Wieman, 1990; Apqelvist, Larsson and Agardh, 1993; Levin, O’Neal, 1983). Pressure 
ulcers are understood to have bacterial flora with aerobic organisms cultured more frequently 
than anaerobes, and as further reported by Boulton., et al (1995), Colagiuri et al., (1995), 
Pecoraro., et al (1990), that most moist chronic wounds isolates are Staphylococcus Aureus, 
Streptococcus species, Proteus species, Escherichia coli, Pseudomonas, Klebsiella and 
Citrobacter species. Apqelvist, Larsson and Agardh (1993) and Larsson (1994) believes that 
Pseudomonas aeruginosa and anaerobes may mainly be cultured from diabetic foot ulcers 
whereas anaerobes are often present in cultured exudate from chronic pilonidal sinuses 
(Cooppan and Habershaw, 1995). 
 The role of sugar in wound healing 3.2.
The role of sugar in the healing of acute and chronic wounds is unclear. This lack of clarity is 
due in part to the different types and formulas of the sugar. Clinicians have used caster sugar 
in the form of sugar paste (Matthew and Binnington, 2002 Booth, 2004), povidone –iodine 
sugar paste (Knutson et al., 1981; Shi et al., 2007; ) and granulated sugar (Chirife et al., 1982; 
Chirife et al., 1983; Keith & Knobel, 1988; Ambrose et al., 1991; Haughton & Young, 1995; 
Grauwin, Cartel & Lepers, 1999; Topham, 2000; Mathews & Binnington, 2002; Topham, 
2002; De Feo et al., 2003; Hampton, 2007 and Mphande et al., 2007). While most of these 
studies indicate positive association between wound debridement and use of sugar, other 
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studies reported that alternative products were better than sugar (Mphande et al., 2007; Bajaj 
et al., 2009) honey and Eusol respectively. 
 
In these studies clinicians used sugar treatment as a last resort on difficult necrotic, sloughy 
and infected exudating wounds. It is important to note that wound type can influence the 
choice of dressing product especially when the result of wound aetiology is potentially 
serious. For example, infectious diabetic foot ulcer that can lead to gangrene and amputation 
or death (Mueller et al., 1989; Wieman, Griffiths and Polk, 1992), infected pressure ulcers 
may lead to septicaemia or osteomyelitis (Boulton Connor and Cavanagh, 1995). 
Furthermore, the type and size of wound can be a deciding factor on the amount and 
frequency of dressing change as large necrotic, sloughy infected exuding chronic wounds 
require considerable amounts of sugar and frequent dressing change (Debure et al., 1987; 
Tophan, 2000). 
 The possible mechanism of sugar  3.3.
It was found that solutions of high osmolality, such as sucrose and honey or sugar paste 
inhibit microbial growth because the sugar molecules tie up water molecules so that bacteria 
have insufficient water to grow (Yudkin et al., 1971; Molan, 2006). Therefore, high 
osmolality is valuable in the treatment of infections because it prevents the growth of bacteria 
and encourages healing (Archer et al., 1990). Chirife et al (1982) posit that sucrose creates a 
low water content (or high osmolality) when applied in a wound. This high osmolality of 
sugar is believed to draw lymph into a wound and dissolves nutrients within the lymph there 
by providing nutrition for the regeneration of tissue (Molan and Cooper, 2000). 
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 Why it is important to do this review 3.4.
There have already been two reviews of the use of sugar as a dressing. These previous 
reviews that were carried out by Pieper and Caliri (2003) who explored the use sugar and 
papaya/papain and that of Biswas and colleagues (2010) explored the use of sugar on diabetic 
foot ulcers only. The more recent review of Biswas and colleagues included only studies up 
to 2007. Therefore an updated summary of the effect of sugar on necrotic, sloughy and 
infected exuding wounds in all patients was warranted. 
 
The Aim 
The aim of this review was to assess systematically the evidence for the clinical effectiveness 
of sugar treatment in the treatment of acute and chronic wounds. Included in these wound 
categories are chronic leg ulcers, pressure ulcers, diabetic foot ulcers, pilonidal sinuses, 
chronic cavity wounds and those of non-healing surgical wounds. 
 Methods  3.5.
3.5.1. Participants 
Studies which involved humans of any age (children or adults), with an acute or chronic 
wound were included. For the purpose of this review an acute wound was considered to be 
the following; burns, lacerations, or other skin injuries resulting from minor trauma, and 
minor surgical wounds healing by primary or secondary intention. Chronic wounds were 
considered to be the following; skin ulcers of any type, pressure ulcers and infected wounds 




The primary intervention was any sugar topically applied by any means, alone or in 
combination with other dressing components to an acute or chronic wound. Comparison 
interventions were dressings or other topical agents applied to the wound. 
3.5.3. Outcomes considered 
The primary outcome was wound healing. However, measures of wound healing can be 
subjective; therefore studies had to incorporate an objective assessment such as change in 
wound/ulcer size, rate of healing, frequency of complete healing or time to complete healing. 
It was also acceptable if studies reported percentage or absolute change of wound healing 
over a period of time. The accepted objective methods of measuring wounds/ulcers size were 
those of tracing the outline of wound/ulcer by counting the grids on a graph paper or 
measuring the longest length and width using the clinical measuring ruler; then multiplying 
the two in centimetres to get the total wound surface area in centimetre squared. Other 
methods measuring accepted were those of computerised wound image analysis. Pilonidal 
sinuses and cavity wounds outcomes of interests were healing rates, recurrence of disease, 
time to complete healing. Also included were rates of incidence of surgical complications. 
Studies were excluded if reporting on wound cultures, sensitivity of micro-organisms, 
bacterial counts and bacterial eradication because these outcomes have not shown to be 
accurate and reliable indicators of healing (Gotzesche et al., 1996). This review of use of 
sugar also focused on the rate of the number of patients reporting reduction in pain sensation 
using the objective visual pain analogue scale, cost and quality of life measured using 






Comparisons/control group were participants who received any dressing product or usual 
treatment that facilitated wound debridement. 
3.5.4. Types of studies  
Randomised controlled trials (RCTs) and quasi- randomised controlled trials were included 
for meta-analysis. A quasi-randomised controlled trial was any trial that used a quasi-random 
allocation strategy such as alternate days, date of birth or hospital number. RCTs are 
considered to give the most reliable estimates of the effectiveness of interventions (Friedman, 
Furberg and DeMets, 1998, Jadad and Enkin (2007). This is because randomisation increases 
the likelihood that differences in outcomes are due to differences in the interventions received 
rather than to variations in other factors such as patient characteristics. Jadad and Enkin, 
(2007) supported by Gray, (2014) concluded that, RCTs that incorporates single or double-
blind procedures help to control for the biases in health outcomes brought about by the 
preconceived expectations of patients and assessors. 
 
It is also understood that useful data can be obtained from results of non-RCTs or Controlled 
Clinical Trials (CCTs). However, this must be considered with caution as groups may not be 
of homogenous nature at baseline and these studies may provide less reliable information 
compared to RCTs. If CCTs are to be considered, it is advisable that only prospective CCTs 
with concurrent control group should be accepted. Furthermore for both RCTs and CCTs, the 
units of allocation must be patients, limbs, or lesions. Studies of which none of these were 
considered were excluded because of the possibility of non-comparability of the standard 




3.5.5. Data sources  
A comprehensive and sensitive search strategy was developed and used this review. Searches 
of the following electronic databases were undertaken: 
 Cochrane Wounds Group Specialised Register (Searched 10/3/14) 
 The Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane 
Library Issue  
 Ovid MEDLINE 1947 to March Week 1 2014 
 Ovid EMBASE 1976 to March Week 1 2014 
 Ovid CINAHL 1980 to March Week 1 2014 
 
The following search strategy was used in the CENTRAL and adapted where appropriate for 
other databases: (see Table  3.1). 
 
The MEDLINE search was combined with either Cochrane Highly Sensitive Search Strategy 
for the identifying randomised trials in MEDLINE sensitivity and precision maximizing 
version (2008 revision); Ovid format (Lefebvre, 2008). The EMBASE and CINAHL searches 
were combined with the trial filters developed by the Scottish Intercollegiate Guidelines 
Network (SIGN, 2008). Additionally, LILACS (1982 to March 2014), AMED (1980 to 
March 2014) and Google Scholar were searched using the text word “sugar”.  
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Table  3.1: Search strategy. 
#1 MeSH descriptor Burns explode all trees 
#2 MeSH descriptor Skin Ulcer explode all trees 
#3 MeSH descriptor Wounds Penetrating explode all trees 
#4 MeSH descriptor Pilonidal Sinus explode all trees  
#5 MeSH descriptor Lacerations explode all trees 
#6 MeSH descriptor Wound Infection explode all trees  
#7 MeSH descriptor Surgical Wound Dehiscence explode all trees 
#8 ((plantar or diabetic or heel* or foot or feet or ischaemic or venous or 
varicose or stasis or arterial or decubitus or pressure or skin or leg or mixed 
or tropical Cell) NEAR/5 (wound* or ulcer*)):ti.ab.kw 
#9 (bedsore* or ulcer (bed NEXT sore*):ti.ab.kw 
#10 (pilonidal sinus* or pilonidal cyst*):ti.ab.kw 
#11 (cavity wound* or sinus wound*):ti.ab.kw 
#12 (laceration* or gunshot stab or stabbing or stabbed or bite*):ti.ab.kw 
#13 (“burn” or “burns” or “burned” or scald*):ti.ab.kw 
#14 (surg* NEAR/5infection*):ti.ab.kw 
#15 (surg* NEAR/5wound*):ti.ab.kw 
#16 (wound* NEAR/5 infection*):ti.ab.kw 
#17 (malignant wound* or experimental wound* or traumatic wound*):ti.ab.kw 
#18 (skin abscess* or skin abcess*):ti.ab.kw 
#19 (infusion site* or donor site* or wound site* or surgical site*):ti.ab.kw 
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#20 (hypertrophic scar* or keloid*):ti.ab.kw 
#21 (#1 OR #2 OR #3 OR#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
OR #12 
#22 MeSH descriptor Sugar explode all trees 
#23 sugar:ti.ab.kw 
#24 MeSH descriptor sugar cane explode all trees 
#25 sugar cane:ti.ab.kw 
#26 MeSH descriptor sugar beet explode all trees 
#27 sugar beet:ti.ab.kw 
#28 (#22 OR #23 OR #24 OR #25 OR 26 #27) 
#29 (#21 AND #28) 
 
3.5.6. Searching other resources 
There was hand search of four journals specialising in wound care (Care – Science and 
Practice 1981 to 1990; Decubitus 1987 -2014; Journal of Tissue viability 1991-2014; Journal 
of wound care 1991-2014). The bibliographies of all obtained studies and review articles 
were searched for potentially eligible trials. Contact was made with experts in the field and 
one author of the included trials. No language or date restrictions were applied to the trials 
and both published and unpublished trials were sought. 
3.5.7. Decision on study inclusion 
Decision on the inclusion of the primary studies was made independently by two reviewers; 
the researcher and reviewer. Disagreements were resolved by discussion. 
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3.5.8. Data extraction and management 
Data were extracted from included trials by one reviewer (MM) and recorded on a 
standardised form. The extracted data were independently reviewed for accuracy by the 
second reviewer (CC) and disagreements resolved by discussion. If the data from the trial 
report were inadequate or ambiguous, additional information was attempted to be sought 
from the trial authors. 
3.5.9. Quality assessment of selected studies 
All included studies were assessed by one reviewer against a comprehensive checklist for 
methodological quality. The Jadad and Enkin (2007) checklist covered the following; method 
of randomisation for RCTs, criteria for selecting participants, use of blinding or allocation 
concealment, baseline comparability of groups, sample size, outcomes assessment, reporting 
of withdrawals and use of intention to treat (ITT) analysis. Quality assessment was then 
checked independently by a second reviewer and discrepancies were resolved by discussion. 
Use of intention to treat analysis is defined in this review as analysis that included all 
participants in the groups to which they were randomised regardless of whether they received 
the treatment, completed treatment or were found not to meet entry criteria after 
randomisation (Hollis and Campbell, 1999; Jadad et al., 1996). 
 Data analysis and synthesis  3.6.
A narrative overview of the studies was conducted. The results of trials that were sufficiently 
alike in terms of population and comparison interventions were pooled using a meta-analysis, 
using the Review Manager 5 software (RevMan Version 5.0 (2008). A random effects model 
was used, to account for the fact that the studies being compared were based on the treatment 
of different types of wound, and used a variety of wound care products and protocols. 
The overall difference between the sugar and control arms across the studies was represented 
using an odds ratio, with 95% confidence intervals. A Forest plot was produced to visualise 
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the results of the individual studies, as well as the pooled total. Statistical heterogeneity was 
assessed using the I squared statistic (Huedo-Medina et al., 2006). 
 Results  3.7.
Eighty six (n=86) citations were identified as a result of the initial electronic and internet 
searches. Once titles and where available abstracts had been assessed 30 papers were 
considered. Further analysis through reading and applying exclusion criteria resulted in 9 
studies being excluded because they did not explore use of sugar on wounds but gave general 
information related to different uses on sugar. Of the 21 papers identified as potential studies 
for inclusion into this review 17 were of poor quality. A total of 4 papers (see Table 3.2) met 
the inclusion and quality assessment for the review and meta-analysis; however, one study 
had a different outcome and was excluded from the meta-analysis (see Figure 3.1). The four 
trials explored use of sugar on wounds. The trials originated from developed and developing 
countries Japan; (Toba et al., 1997); Uganda; (Dawson, 1996): Malawi; (Mphande et al., 
2007) and Nepal; (Bajaj et al., 2009). In terms of wound type all studies explored mixed 
aetiologies, however Dawson focused more on post infected surgery wounds while Toba and 
colleagues and Bajaj and colleagues (2009) focused mainly on pressure ulcers. Mphande and 





















3.7.1. Excluded studies  
From searching electronic databases there seem to be several studies involving sugar 
treatment. However, many of those identified papers were not eligible for inclusion. The 
common reasons for exclusion were study design (non-comparative observational and single 
or multiple case studies) and outcomes assessments were not clear. At times trials focused on 
subjective measure of wound healing. Table 3.2 overleaf show studies that were closely 
considered for inclusion, but eventually excluded. All studies explored sugar on wounds but 
the sugar used was not standardised. The studies originated both from developed and 
developing countries. 
  
Studies retrieved for more 
detailed evaluation. n=30 
Trials meeting quality assessment 
criteria and considered for meta-
analysis. n=4 
Potentially relevant citations identified as a result of initial 
electronic and internet searches. n= 86 
Citation that provided general background 
information not specific to sugar. n= 56 
Studies excluded after 
application exclusion 
criteria. n= 9 
Studies excluded after 
assessment of quality. n=17 
Studies included. n=21 
Trials included in meta-analysis. n=3 
Excluded because it 









Country Type of Study  
Population (what type of 
participant,  












Reported outcome/conclusion Reported disadvantage 
Knutson 
et al 1981 
USA Case series  Various infected wounds Sugar povidone-iodine Both  
Debridement and 
wound healing 
605 5 years Decrease drainage 
Concern about contaminates in 
the sugar product 
Chrife et 
al 1982 
Argentina Laboratory  Granulated sugar Acute  
Wound debridement 
and wound healing 
  
Granulated sugar debridement infected 
wounds 
Multiple dressing changes 
Haddad et 
al 1983 
Brazil Descriptive   Granulated sugar  Both    
Not 
specified 
Inhibit bacterial growth  None reported  
Troullet et 
al 1985 
France Descriptive   Granulated  Both     Inhibit bacterial growth  None reported  
Debure et 
al 1987 
USA Case study Infected surgical wound Granulated sugar Chronic  
Debridement and 




Decrease odour  
Lack of standardization on 
type of sugar product of the 
substance to which is added 
Wiseman 
1989 
South Africa Descriptive  Infected leprosy ulcers  Granulated sugar  Chronic     Inhibit bacterial growth  None reported 
Archer et 
al 1990 
UK laboratory  Controlled wound model Sugar paste Acute     Wound debridement None reported 
Seal et al 
1991 
UK Descriptive  Infected cavity wounds Sugar paste Chronic  
Debridement and 




Stimulate granulation  May disrupt granulation tissue 
Szerafin 
et 1991 
Hungary Observational Mediastinitis after open heart surgery Granulated sugar Both   
Wound debridement 
and wound healing 





Observational  Deep infected wounds Ordinary table sugar  Chronic   
Wound debridement 
wound healing  
1   Encourage epithelialization  
May elevate blood sugar in 
persons with diabetes  
Valls et al 
1996 
 Observational  Infected pressure ulcers  Sugar paste  Chronic   1  Stimulate granulation  May disrupt granulation tissue  
Grauwin 
et 1999 
Senegal Observational Osteitis and septic arthritis  Granulated sugar Both  Rate of wound healing 36 2 years 
Granulated Sugar debrided osteitis and 
septic arthritis wounds 
Lack standardisation; type of 
sugar 
De Feo et 
al 2000 
Italy Observational 
Recurrent Post open heart surgery  
Mediastinitis 
Granulated sugar Both  Rate of wound healing; 9 96 months 
Granulated sugar is effective treatment  
option in patients with mediastinitis 
refractory to closed irrigation 
Frequent dressing change 
De Feo et 
al 2003 
Italy observational 
Recurrent Post-open heart surgery  
mediastinitis 
 Both      Frequent dressing change  
Ralf et al 
2005 
Netherlands Observational Post hernia repair- infected 1 kg granulated sugar  Acute  
Debridement and 
wound healing 




et al 2009 
Malawi Audit Various infected wounds Granulated sugar Both  
Wound debridement 
and wound healing 
71  
Reduced wound pain 
Wound odour removed 
Cheap  
None reported  
Ruhullah 
et al 2013 
Nepal Observational Grade 3 & 4 Pressure ulcers Granulated sugar Chronic  
Rate of wound healing; 
Reduction in wound 
size; 
Wound debridement 
14 5-14 days 
Wound debridement 
































































No No Not reported Not reported 
Not 
reported 
























































































3.7.1. Quality of included studies 
Of the 4 studies selected Table 3.3 shows the details of the quality assessment. Sample sizes 
were highly variable ranging from 11-50 patients. All studies failed to report a priori sample 
size power calculation. Other aspects of quality were also variable with two trial providing 
their criteria inclusion and exclusion criteria (Bajaj et al., 2009 and Toba et al., 1997). Three 
studies (Dawson, 1996; Toba et al., 1997 and Mphande et al., 2007) did not include base-line 
comparability between groups. All studies reported collecting wound size as a baseline data, 
however only one study (Dawson, 1996) reported this characteristic on the results. 
Demographic data was poorly reported in three studies with only one study (Bajaj et al., 
2009) providing such data. 
Randomisation and allocation concealment 
All four trials were described as randomised controlled trials, but only 2 trials reported how 
their allocation sequence was generated using a random number table; (number system, with 
corresponding registration numbers applied which was divided into two groups) (Toba et al., 
1997). Mphande and colleagues used alternating admission for their allocation to either sugar 
or honey. 
Allocation concealment  
This was not reported in any of the trials. 
Loss to follow up  
Loss to follow up was not reported in any of the four trials. 
Intention to treat analysis (ITT) 
There were no reports of using ITT analysis in any of the studies.  
Blinding  




Baseline equivalence of the treatment groups was not reported in two of the trials. Two trials 
(Toba et al., 1997; Bajaj et al., 2009) reported baseline data, although the reported data was 
limited.  
Risk of bias  
Overall, the methodological quality of the trials was variable, with most trials failing to 
adequately report on randomisation or allocation concealment, study design elements that are 
known to decrease the risk of bias (Jadad et al., 1996; Schultz et al., 1995; Moher et al, 1998). 
Therefore, all trials were considered to have a moderate to high risk of bias. 
Quality of life (QoL) assessment 
None of the four trials reported on the QoL issues. 
Studies Selected for Meta-analysis 
Of the four RCTs (see Table 3.3), three reported the rates of wound healing as outcomes 
(Dawson, 1996; Toba, et al., 1999; Bajaj et al., 2009). Therefore, this was the common 
outcome that was included in the meta-analysis. One study was excluded as it reported a 
different outcome (Mpande et al., 2007) 
Statistical results 
Figure 3.2: Meta-analysis and Forest Plot 
 
 
Figure 3.2 reports the results of the meta-analysis. It shows evidence of heterogeneity 
between studies (I
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this significance test would have had low statistical power. Furthermore, the result of the 
Dawson study differed considerably from the other two, with an odds ratio for wound healing 
of 20.0 (95% CI=0.9 – 429.0), in favour of sugar. However, the small sample size in this 
study meant that, even though the difference between treatments was so large, it was not 
significant. 
The overall pooled odds ratio for wound healing was 1.56 (95% CI=0.35 – 6.98) in favour of 
sugar. However, this overall effect was not found to be statistically significant (p=0.56). 
 Discussion 3.8.
3.8.1. Treating wounds with sugar 
Existing evidence does not support the treatment of exuding necrotic or sloughy wounds with 
sugar. The available evidence from RCTs (Dawson, 1996; Toba et al., 1997; Mphande et al, 
1997; and Bajaj et al, 2009) does conclude that sugar has an effect on desloughing wounds 
but the findings are based on small studies where the possibility of type II error could not be 
excluded. Therefore, the role of sugar treatment in the management of exuding necrotic or 
sloughy wounds remains unclear due to methodological problems of the primary literature 
and lack of detail on baseline characteristics of participants. It must be pointed out that from 
the reviewed literature available there are no clear guidelines on the prescribing of the sugar 
products. The current available data is not standardized and lack of clarity on the type of 
sugar, dosage, or formula and frequency of dressing change pose difficulties in replicating 
studies. In addition; there are no clear guidelines on treating patients with diabetic foot ulcers. 
Sporadic reports suggest that use of sugar on diabetic foot ulcer wounds does not interfere 
with their blood sugar level (Tophan, 2000), but there are also other conflicting accounts of 
small elevation of blood sugar levels when treating these patients with sugar (Mphande et al., 
2007). Furthermore, available research outcomes suggested that the use of sugar treatment is 
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not better than already available products such as honey (Mphande et al, 2007) and Eusol 
(Bajaj et al., 2009). Once again the methodological quality of these studies is poor. Both 
sample sizes were small with possibilities of type II error.  
The above results (Figure 3.2) are all from small studies (range 11-50) in the smallest and the 
largest and it is likely that evaluations on this scale lack the statistical power to detect true 
treatment effects. It would be useful to replicate this area of research with a larger well-
designed study. A further problem is lack of detail relating to baseline characteristics of 
participants and inadequate presentation of inclusion and exclusion criteria. In such trials 
focusing on sloughy, necrotic and infected exuding wounds of mixed aetiologies, it is 
important to have detailed reporting of baseline characteristics and results should be 
presented according to wound aetiology as well as in summary. Similarly, it is also necessary 
to report other adjuvant treatment. 
3.8.2. Dosage of sugar 
Various formulas of sugar have been reported by different researchers; sugar paste (caster 
sugar and polyethelene glycyrine) Matthew and Binnigton 1985; sugar paste (Povodone-
iodine plus sugar) Knutson et al., 1981; Toba et al., 1997; Bajaj et al., 2009 and others used 
pure granulated sugar (Heszarge et al., 1983; Mphande et al., 2007; De Feo et al., 2000 and 
De Feo et al., 2003) but the dose and frequency is not replicable. It is imperative that further 
research is undertaken to determine the best preparation and dose of sugar and the type of 
sugar that are most likely to benefit from this product. To date there are several debriding 
wound care products in use, such as hydrogels, Eusol and hydrogen peroxide which has 
traditionally been used on cleaning exuding necrotic or sloughy wounds (Bajaj et al., 2009). 
Eusol and Hydrogen peroxide are no longer in use in the UK and many other developed 
countries because hydrogen peroxide and Eusol both have a caustic action that is dependent 
on the steady release of oxygen and can sting when applied on wounds. The damage may also 
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cause maceration to the surrounding healthy skin. There is also suggestion that there is a 
possibility of air embolism resulting from the action of the pressurised irrigation or used in 
enclosed body cavity wounds (Yarkony, 1994; Morgan, 1993). Hydrogel wound dressings 
have been used significantly when treating diabetic foot ulcers (Vuorisalo et al., 2009), 
however the variety of preparations used in the control group makes the results difficult to 
interpret. Furthermore, none of the control group included sugar. In Allen et al (1991) and 
Mphande and colleagues (2007) studies honey is considered to have antibacterial properties 
and has been compared with silver sulphadazine (Subrahamanyam, 1991) in the treatment of 
burns. Mphande and colleagues compared the honey and sugar in the treatment of wounds of 
mixed aetiologies (Mphande et al., 2007). In one of the longest and largest studies of 605 
participants, Knutson and colleagues concluded that sugar combined with povidone-iodine 
was found to be beneficial in treating wounds of mixed aetiologies (Knutson et al., 1981). 
However, the type of sugar used and baseline characteristics were not described (Knutson et 
al., 1981). In 1997 Toba and colleagues undertook a RCT study to explore patients with 
pressure ulcers using sugar paste of povidone-iodine and findings supported those of Knutson 
et al (1981). But like previous studies the type of sugar used was not described. It can be 
argued that alternative approaches to managing exuding necrotic or sloughy wounds is of 
benefit, but their effectiveness and safety needs to be established with well-designed 
comparative studies before any conclusions can be made. 
3.8.3. Complete healing 
The frequency or rate of complete healing is the proportion of participants achieving 
complete healing (in most studies this means lesion closure), relative to the total number in 
the treatment arm. Between comparisons are then made by looking for statistically significant 
difference between the proportions of healed lesions in each arm. While this can be a useful 
measure, it can be argued that the choice of follow-up time can influence outcomes as 
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complete healing is more likely to occur with longer follow-up even in the absence of an 
intervention. To resolve this issue Altman (1997) advises using survival analysis strategy. 
This involves the estimate by regression of the time taken for all wounds to heal beyond the 
follow-up period and this according to Altman is the most reliable strategy if an account is 
taken of the frequency of healing and rate of healing. None of the four trials reviewed 
included a survival analysis model. This is important because if time to healing is chosen as 
the primary outcome a group that has predominance of smaller wounds/ulcers is most likely 
to achieve better results because larger wounds/ulcers take longer to close. It is therefore 
important to match groups for wound/ulcer size by using baseline wound/ulcer size as a 
stratification variable (Stacey et al., 1991). From the reviewed literatures it is apparent that 
other difficulties that can be encountered in this kind of research is subjectivity of 
measurement and different definitions of complete healing. Subjectivity can be that of 
judging whether complete healing has occurred or not and the inter-rater reliability may be 
poor, even when assessors are experienced in wound care management. Using definitions of 
complete healing per participant per limb and per wound may give different results in cases 
where patients have more than one wound included in the study. 
3.8.4. Mean change in wound/ulcer size 
In both studies Dawson (1996), Toba et al (1997), Mphande et al (1997) and Bajaj et al 
(2009) a between group comparison of the mean change in wound/ulcer size relative to 
baseline was used as one of the outcome. The wound/ulcer outline may be traced directly 
onto paper or acetate, or a photograph or slide may be used. If photographs or slides are used 
the image can be calibrated by placing a centimetre scale at the side of the wound. The area 
within the tracing can be calculated by counting grids on graph paper, uniform density tracing 
paper planimetry or by using computerised image analysis. Technologies, such as 
computerised image analysis or the use of digitisers have now advanced and are slowly 
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replacing most of the traditional methods of wound measurement. However, the most 
commonly reported method is that of measuring the longest and shortest part of the wound 
using a clinical ruler and multiplying the two readings to find the surface area of the wound 
in centimetres or millimetres. Although these are the most commonly used methods of 
measurement in wound care a comparison of different measurement tools showed that direct 
acetate tracing produce more accurate measurements as compared with photographs 
combined with image analysis (Thomas and Wysocki, 1990). 
3.8.5. Bias arising from wound/ulcer size 
Bias may arise unless treatment groups are matched at baseline for wound/ulcer size. Failure 
to do so may render results unreliable. This is because a group containing many smaller 
wounds/ulcers which are likely to heal quickly will be favoured if complete healing and time 
to healing are selected as study-end point. Groups with predominance of small ulcers are also 
likely to achieve better treatment outcomes if the primary outcome is the change percentage 
in wound/ulcer surface area. Conversely, a participant group with mainly large wounds/ulcers 
will appear to produce better healing outcomes if absolute change in wound/ulcer surface 
healed is the outcome of interest (Stacey and Burnand, 1991; Gorin et al., 1997). In the 
evaluations of pressure ulcers and cavity wounds the baseline comparability of wound 
volume should also be considered. Although the reviewed RCTs explored wounds of mixed 
aetiologies Mphande et al (2007) and Bajaj et al (2009) and Toba and colleagues (Pressure 
ulcers) the comparable surface area and volume baselines respectively were not mentioned. 
Average baseline estimates of wound sizes within groups can mask the true distribution and 
heterogeneity between groups. Therefore, more detailed information on the relative 
frequencies of different categories of wound size per group is necessary. In the reviewed 
trials, the researchers did not mention any wound categories and this indicates poor quality of 
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the methodology that can affect the findings, considering that wound measurements are taken 
on estimates. 
3.8.6. Comparison with other systematic reviews  
Two systematic reviews concerned with the use of sugar on wounds were identified. Pieper 
and Caliri (2003) undertook a review on non-traditional wound care products including sugar, 
papaya/papain and fatty acids from 1981-2000. The findings were that sugar was safe to use 
on necrotic exuding wounds. It helped debride wounds, reduce wound oedema, decrease 
exudate, inhibit bacterial growth, caused little pain on dressing change and encouraged 
epithelialisation. The review also highlighted the disadvantages as a lack of standardisation 
on the type of sugar; difficulties in holding sugar in place may disrupt granulation tissue. 
There were issues related to lack of description of subjects/patients wounds, contaminates in 
the sugar and multiple dressings changes. Some studies were concerned about elevation of 
blood sugar levels, renal insufficiency and lack of randomised clinical trials. Although the 
findings of this review were encouraging, overall, the review is very basic and a multifocal 
(sugar, papaya/papain and fatty acids) lacking depth in sugar on its own. Because the 
review’s focus was on several different products there is justification for further exploration 
of literature focusing on sugar as a wound care product. 
A more recent review was done by a group of American surgeons (Biswas et al., 2010) into 
the wound management of diabetic foot ulcers. The review is divided into two parts. The first 
part reviewed fifteen studies of the physiological rationale for the use of sugar in wound 
healing, ranging in date from 1953 to 2007. There was clearly a peak of interest in sugar from 
the mid-1980 to the end of the 1990’s. The 15 studies in this section cover a wide range of 
material, from the anecdotal to the scientific. Two studies have honey as their focus, two are 
animal studies and three are in vitro. There is a clear account of the material used and the 
theories that are postulated. There was an overall conclusion that multiple reports 
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documented the effect and the ability of sugar to reduce wound exudate, odour, and oedema. 
But, this evidence lacked evidence on cellular and molecular interactions between sugar and 
wound environment. 
The second section reviewed eleven case studies. Again the dates range from 1958 to 2001, 
with the majority in the mid 1980’s. There is a critical appraisal of the material and a detailed 
account of case studies. However, the focus in this section is on diabetic foot ulcers, which is 
understandable given the aim and the title of the review. 
The reviewers Biswas and colleagues (2010) did not comment on the quality of the papers or 
the statistical significance of the evidence or whether sugar treatment affects blood sugar 
levels of diabetic patients, instead concluding that more evidence was needed in this area. 
They further suggested a prospective trial for the treatment of diabetic foot ulcers. This was a 
fairly comprehensive review of the state of knowledge in 2010. However a few studies were 
missed (Keith & Knobel, 1988; Haughton & Young, 1995; Topham, 2000; Mathews and 
Binnington, 2002; Topham, 2002; De Feo, 2003; Booth, 2004; Hampton, 2007 and Ambrose 
et al., 1991; Grauwin, Cartel & Lepers, 1999; Mphande et al., 2007 and further work has now 
been done Ammons, Ward & James 2011, Al-Waili, Salom & Al-Ghamdi, 2011; Murandu et 
al., 2011; and Ruhullah et al., 2013). 
In both reviews there were notable methodological problems. The search strategy as well as 
search terms were not clearly stated in both studies. In addition, only English language 
reports were mentioned. Both studies’ inclusion criteria were not specified. In Biswas and 
colleagues’ review two of the included studies overlap with this review Dawson (1996) and 
Toba et al (1997). 
Quality of life 
No trial was found reporting data on health related quality of life (HRQoL) using a specific 
(HRQoL) tool. It is important that future research incorporates this aspect of wound care as it 
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allows participant concordance and assessment of patients’ acceptance of the intervention 
treatment. 
 Adverse events  3.9.
None of the studies included reported adverse events associated with sugar intervention or 
comparator. It is important that future research studies address this issue as the incidence of 
adverse events may impact on the extent to which patient feel able to adhere with treatment 
regiments. In particular localised skin reactions may be a problem for people using topical 
preparations such as sugar or sugar-paste. 
 Conclusion  3.10.
At present, there is no existing good quality evidence to support the routine use of sugar 
dressings to promote wound healing in non-healing acute or chronic exuding necrotic or 
sloughy wounds. The lack of reliable evidence means that it is not possible to recommend the 
use or the discontinuation of the sporadic use of the sugar reported in different formats from 
different developing and developed countries. It is possible that sugar treatment may be 
effective as reported in some literature (Dawson, 1996, Toba et al., 1997, Mphande et al., 
2007 and Bajaj et al., 2009), however rigorous evaluation is needed. 
The four RCT studies gave promising results however the small sample size as well as the 
poor methodological quality of the studies raises many questions. There is no clear evidence 
on the type of sugar, dose and frequency of use as mentioned earlier. 
 Implications for future research  3.11.
All results reviewed are from small trials with methodological problems. Therefore, future 
research should focus on the following: 
 Larger well-designed studies.  
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 Clearly define the inclusion and exclusion criteria for participants.  
 Consider sample size with sufficient power to detect true treatment effects. 
 Clearly report on a priori power calculations of the sample.  
 The trial must make use of true random numbers with clear method of randomisation 
with allocation concealment.  
 Consider using either opaque sequentially numbered sealed envelopes or computer-
generated codes. 
 Must stratify wound/ulcer size and aetiology.  
Future researchers must guard against factors that may affect healing outcomes by using 
survival analysis, intention to treat protocol and analysing complete healing rates. It is also 
important to report of incidence of adverse events and detailed numbers and characteristics of 
withdrawals from the treatment group. 
 
It will be of use to carry out comparisons between other debriding agents such as hydrogels in 
order to evaluate both the relative effectiveness and the cost-effectiveness. The cost-
effectiveness of sugar treatment needs to be established taking into account the patterns of 
healing and recurrence that can occur with non-healing acute and chronic exuding necrotic or 
sloughy wounds. 
 
The next chapter is the feasibility study. The researcher will explore the suitability of using 
sugar as a wound care product in an NHS hospital. It is also important to determine the 
effects of sugar treatment on diabetic patients’ blood sugar levels. In addition, the study 
explored both nurses and patients’ acceptance of the treatment. Finally, a sugar dressing 




4. Chapter: Feasibility study 
 Introduction 4.1.
Chronic sloughy, necrotic and infected exuding wounds are a major problem in any wound 
care setting. They affect the quality of life of patients (Gardner and Cook, 2004; Madeo, 
2001) to the extent that, some patients decide to isolate themselves. These wounds at times 
are the cause of extended hospital stay for patients as acknowledged by (Plowman et al., 
2001). Finding an appropriate dressing product that can facilitate healing and improve the 
quality of life of these patients is an ongoing process. To this effect sugar has been explored 
previously when managing these types of wounds (Herszage et al., 1980; Chirife et al., 1983; 
Archer et al., 1990; Mphande et al., 2007; Chiwenga et al., 2009). The researcher had had an 
experience of using sugar precedingly in Zimbabwe. However, there was uncertainty as to 
how its use would translate to NHS hospital; therefore this study was proposed to assess the 
feasibility and acceptability of sugar treatment on a vascular ward in a modern NHS hospital. 
It must be pointed out that sugar (in the form of sugar paste) had been used before in the UK 
as a wound care product with sporadic reported case studies (Middleton, 1985; Gordon et al 
1985; Booth, 2004) available. There was not specific sugar protocol developed from the 
reported sugar studies. That made it very difficult to adopt this method of wound treatment. 
Furthermore, there does not seem to be any mention of the relationship of diabetic patients 
receiving sugar treatment and the level of their blood sugar. Does sugar treatment raise blood 
sugar level of diabetic patients? To date not many nurses in the UK are aware of the use of 
sugar treatment on wounds therefore it is important to determine their perception of the 
acceptability of this method of treatment. Patients suffering from long standing wounds often 
times accept any alternative treatment especially when the wound has been delayed in 
healing. However, this assumption was to be determined before any further large studies were 
to be conducted as patients might be sceptical in opting to use sugar. Although there is 
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theoretical basis to support the use of sugar (Chirife et al., 1983), there is no data upon which 
to base a design for a definitive randomised controlled trial to test its efficacy in the UK, so 
this study is undertaken to assess the possibility of using sugar treatment in a modern NHS 
hospital and develop a standard sugar dressing protocol. 
Aims/Objectives summary 
The study aims to: 
 Determine wound sizes, sugar dosage and acquisition of single use aliquots 
 Make sure the study complies with Ethical and MHRA guide-lines 
 Train doctors and nursing staff on the use of sugar dressing 
 Establish types of patients and research site appropriate for a full trial 
 Monitor recruitment and drop-outs rates 
 Determine acceptability of sugar to patients 
 Determine the effects of sugar on microorganisms 
 Determine effects on diabetic blood sugar levels  
 Determine appropriateness of methods of data collection 
 Determine appropriateness of the dressing in an NHS hospital  
 Calculate the appropriate sample size for a randomised controlled study 
 Develop a protocol for managing exudating wounds with granulated sugar. 
Outline of overall outcomes of the study 






Table 4.1 Summary of primary & secondary outcomes 
Primary outcomes Secondary outcomes 
Effects on wound--- debridement, 
malodour, exudate and pain (using TELER 
indicators) 
Acceptability to patients, doctors & nurses 
(using purposely designed questionnaire) 
see Appendix 11. 
Effects on wound infection (laboratory 
wound swab analysis) 
Completeness of data and appropriateness 
of data (using case report form) 
Effects on diabetic patients’ blood sugar 
level (using routine diabetic blood sugar 
test) 
Ease of dressing change (using TELER) 
Serious adverse effects 
(using adverse effects report forms) 
 
 Determining wound sugar dosage and acquisition of single patient 4.2.
dose aliquots 
It was vital that wound sizes and sugar dosages were determined prior to commencing the 
feasibility study. This was to help in developing an appropriate sugar treatment protocol. In 
order to achieve this task, ‘White’ cane/beet granulated sugar (see Figure 4.1 A) was 
acquired from Tate & Lyle and British Sugar companies respectively, and was supplied with 
certificates of conformity (see Appendix 5: Tate & Lye Certificate of conformity). The 
researcher undertook assimilation of wound dressing using sugar on wound models in the 
clinical skills laboratory (see Figure 4.1).  Wound models were measured of their length and 
width (Figure 4.1 B & D); these were multiplied to find the wound surface area in 
centimetres. Granulated sugar was gently poured on the wound models (see Figure 4.1. C & 
E), fully covering all the wound areas. Sugar was poured from the wound model onto a 
digital kitchen scale (see Figure 4.1 .F) GT- KSg-02; approximate size 15 x 22 x 1.7cm with 
coin battery CR2032 / 3 V- / 3-5 mA operation. The digital scale’s measuring range was 5g to 
5000g with measuring intervals of 1g / 1 ml with measuring precision of +/- 0.2 %. The 
ambient temperature was +10 
0











 (medium- large). The amount of 
sugar needed for each wound was found to be as follows: Small wounds =15g sugar and 
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 Acquisition of 15 and 30 grams single use aliquots 4.3.
Having determined the specific wound sizes and sugar dosages needed for each wound 
category, the 25kg bags of sugar acquired from Tate & Lyle and British sugar (with 
certificate of conformity (see Appendix 5) was delivered to the Manufacturing Pharmacy and 
wound specifications and dosages where given to the lead production manager and the sugar 
Supplied by British and 
Tate & Lyle Sugar 
Company with certificate 
of conformity 
 Aliquots Supplying 
Company supplies North 
Staffordshire NHS Hospital 
with sterile containers  
Sterile single use 
aliquots packed with 
15g & 30g granulated 
sugar  
Granulated sugar is 
applied on patient wound 
North Staffordshire NHS Trust 
Hospital Manufacturing Pharmacy 
Certificate of conformity  




was packaged into single use sterile aliquots of 15g and 30g (see Figure 4.2) under sterile 
conditions. Packages were serialised so that any adverse effects during clinical usage could 
be monitored and tracked to the packaging pharmacy or manufacturer. Figure 4.2 illustrates 
the schematic diagrams of the supply chain of the sugar from manufacturer to the patient. 
 Medical and Nursing Staff training on use of sugar dressing 4.4.
A series of meetings and training sessions were held to inform nurses and medical staff about 
the application and dressing changes. Both nurses and medical staff were concerned about the 
effects of sugar with diabetic patients, in particular hyperglycaemia. This was discussed and 
it was resolved that diabetic patients would be monitored for their blood sugar levels on 
admission and at regular intervals during the study. Although, there is evidence to suggest 
that sugar (sucrose) has no effect on blood sugar levels when applied topically (Yudkin et al., 
1971; Knutson et al., 1981; Ambrose et al., 1991; Toba et al., 1997; Tophan, 2000) it was 
necessary to monitor every diabetic patient who was recruited into the study whether they 
were non-insulin dependent or insulin diabetic. All diabetic patients admitted into the trial 
had their blood sugar levels checked on admission into the trial as a baseline reference. The 
monitoring of the blood sugar continued throughout the period of the study. 
 Compliance with Ethical and Medicine and Health Regulation 4.5.
Authority (MHRA) issues 
Researchers are bound by ethical and good clinical governance guidelines and this study was 
no exception. Therefore ethical approval was granted from the North Birmingham and 
Solihull Local Research and Ethics Committee prior to commencing the study. Ethical 
principles laid down in the National Health Service (NHS) Research Governance framework 
(DoH, 2008) were adhered to. The researcher had an honorary contract with the University 
Hospital Birmingham National Health Service Foundation Trust (UHBNHSFT). Full 
informed consent procedures were followed. Prospective participants were given time to read 
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the information (see Appendix 3) about the proposed study prior to inviting them to take part.  
The researcher was aware of the diversity of the population to be studied and the need for an 
informed decision to take part in the study. The UHBNHSF Trust has a robust and effective 
interpretation services that the researcher was able to use if there was language barrier. 
However, this was not required as all recruited participants understood English language 
sufficiently to make informed decision. All prospective participants were asked to sign 
consent form (see Appendix 7). 
Patients were informed of their right to withdraw from the study at any time. Confidentiality 
of data, subjects and study settings were maintained throughout this study in accordance with 
the Data Protection Act (Great Britain Parliament 1998). Anonymous data were stored at the 
research centre (the UHBNHSFT Research and Development offices) on a computer with a 
protected password. Hard copies of data were stored in a locked facility at the centre and the 
keys kept in a safe supplied by the Research and Development Supervisor. Following 
completion of the study all data were kept securely according to the UHBNHSFT Research 
and Development protocol. 
In addition to the ethical approval this study required authorisation from the Medicine and 
Health Regulation Authority (MHRA) as sugar when used on a wound is considered to be a 
drug. Permission was sought from MHRA before commencing. Authorisation was given on 
condition that patients will not be charged if there was to be an effect on the wounds, see 
MHRA correspondence in (Appendix 2). 
 Establishing data collection methods/tools/TELER system  4.6.
It is worth noting that, no study is superior to the quality of its data. This point is supported 
by Friedman and colleagues who stated that, “during all phases of a study, sufficient effort 
should be spent to ensure that all key data critical to the interpretation of the trial are of high 
quality” (Friedman et al., 1998, p. 157). Therefore, it was vital that an appropriate data to be 
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collected was identified clearly and data capturing tools determined prior to commencing the 
study. This study’s wound evaluation was based on treatment evaluation by Le Roux 
(TELER) system (Le Roux, 1995). The aim was to get a broad picture of the impact of sugar 
on the wound. The TELER is a generic system for making clinical notes and measuring 
patient centred outcomes of treatment and care (Le Roux, 1995). The system has two main 
elements, clinical note making and clinical measurements. These domains assess information 
regarding the pattern of change, or lack of, in a patient condition. This is coded at individual 
patient level using indicators based on measurement theory. The TELER indicator is an 
ordinal measuring scale for tracking change using six clinically significant reference points, 
or codes from 0-5 (see Table 4.2). These indicators are used to determine whether outcomes 





Table 4.2 An example of TELER indicator: Pain Impact of Dressing Change. 
Code Indicator Definition 
0 
Unbearable dressing change medication needed during pre & post dressing 
change 
1 Distressing dressing change, medication needed 
2 Unpleasant dressing change, medication needed 
3 Disagreeable dressing change, no medication needed 
4 Some unpleasantness 
5 Dressing change alright 
 
Code 5 defines the goal of treatment and care, and is agreed upon with the patient. For 
example, ‘Dressing change alright’ (see code 5 in Table 4.2). When a starting code is 0 and 
an outcome code is 4 or 5, the latter is statistically significant, denoting 4 or 5 significant 
improvements. When a starting code is 1 or 2, and the outcome code is 5, this denotes 4 or 3 
clinically significant improvements respectively (Le Roux, 1995). Data recorded measures 
whether a patient outcomes are attributed to the care received or by chance (Brown et al., 
2004). With five clinically significant improvements the probability that the outcome 
occurred by chance is believed to be less than 2.5% (Le Roux, 1995; Grocott, 2000; Browne 
et al., 2004). The system is believed to discriminate treatment effects, dressing performance 
failure, gaps in clinical knowledge and wound care skills, including product use (Grocott and 
Browne, 2005). The definitions capture observable, patient-centred treatment and objectives. 
This forms outcomes that are clinically significant because they can be justified by 
appropriate theory or knowledge. Without clinical knowledge, the definitions lack meaning 
and will not be repeatable and fail. 
 
The decision on whether the wound was debrided and healing was made by the clinical staff 
(doctors and nurses) following ward round wound assessments. It is during this clinical round 
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that expert opinion on wound healing was significant as judgement was based on subjective 
and objective observation required by TELER system. 
 Digital photography 4.7.
Digital photography has increasingly become part of healthcare management within the 21
st
 
century providing much needed aid in patients’ diagnosis. In wound care, digital imaging has 
proved invaluable as clinicians can share knowledge internally and externally allowing easy 
exchange of knowledge and ideas. This is the reason why it was decided to use digital 
photography in this research. This process was to help with the monitoring of wounds and 
comparing the initial photography to the subsequent images. It helped with review of wounds 
by those senior surgeons who would have missed the ward round review/assessments due to 
other commitments. Digital photography varies from amateur to high-tech photographers. In 
this research, it sufficient to have clear and consistent photographs, and there was no need for 
formal training in photography. 
During admission, the admitting nurse or the researcher without any formal photography 
training photographed all wounds using a digital camera (Canon EOS-1000- ESF 18-55mm 
with 0.25m/0.8ft that complies with the Canadian ICES-003 Class B specifications; CANON 
INC. MADE IN JAPAN with single CCD chip ..32megabites colour. There was no specific 
protocol on imaging. However, there were basics guide-lines to follow:  
 Camera- Auto focus, auto flash, auto exposure 
 Lighting -window shade closed, overhead examination light on 
 Position of patient – supine and comfortable to patient 
 Wound presentation – Incontinent pad under extremity; yellow disposable 
ruler and identifier number adjacent to the wound 
 Photographs taken (image set) 
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 View of wounds (camera 25-35cm from wound) 
All 22 wounds were photographed initially followed by interactive and convenience 
photography. Wounds were photographed weekly for a period of four weeks, however some 
wounds were considered debrided earlier than four weeks so their wounds were photographed 
at that point. Images were stored as highest-quality JPEG (PC Webopaedia 1997 online) files 
(Joint Photographic Experts Group, a comparison algorithm for digital images) and were 
converted to a Microsoft PowerPoint slide presentation to be viewed on a computer monitor 
at the maximum attainable resolution). 
Wound descriptors that guided clinical staff regarding wound progress and non-progress were 
wound exudate, odour, gangrenous, necrosis, erythematous tissue, cellulitis/infection, pain, 
ischaemic or granulating tissue presence. The wound management decision would either be 
wound healing without problems, wound not healing, there is need for alternate management 
or there is granulation and sugar is no longer required. At times the decision was the study 
period is over; however continuing with the sugar if there was patient benefit. 
 Other auxiliary data collection tools  4.8.
In addition to the TELER system and digital photography, there were two other tools: a 
purposively designed patient satisfaction survey questionnaire (see Appendix 10) that was 
aimed at reporting the opinions of patients on the use of sugar, and a purposively designed 
staff satisfaction survey questionnaire (see Appendix 11). These were administered at the 
start and end of the trial. 
 
 Patients’ classification and site of recruitment  4.9.
Patients were mainly recruited via the vascular surgeons who supported the project; however 
there were some referrals from different wards with patients with wounds of other aetiologies 
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beside vascular. Recruitment took place from January 2009 to July 2009. Eligible patients 
included those who had recently undergone a lower extremity bypass procedure or 
amputation or were admitted for a wound healing problem (non-healing ulcer, necrotic or 
gangrenous toes, cellulitis, fasciotomy, pressure ulcer, or abdominal surgery). Table 4.3 
illustrates the inclusion and exclusion criteria. 
Table 4.3: Patient selection criteria 
Inclusion 
Patients who independently and willingly consent 
ABPI* of 0.8-0.6 
Exudating wounds 
Necrotic escar not present 
Diabetic & Non Diabetic with all of the above 
Exclusion 
ABPI less than 0.6 
Presence of necrotic escar 
Pregnant + nursing mothers 
*ABPI =arterial brachial pulse index 
In addition to the above list, a known allergy to sugar products (although very rare on my 
previous experience and that of reported literature) or those already recruited for another 
trial were excluded. 
All patients who fitted the above inclusion criteria were invited to take part, any eligible 
patients who did not participate were excluded as a result of factors beyond the control of the 
study, (see study flow diagram Figure 4.3). Reasons included clinical staff scepticism of the 
suitability of sugar to treat the wound; busy clinical activity and oversight; scepticism of 
patients and refusal to consent (2 patients). The number of wounds per extremity and wound 
category were assigned on the basis of the clinical staff examining and documenting on 
wound care chart (see Appendix 8). If a patient had more than one wound, all the wounds 
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were considered for the sugar trial if he/she had consented to the study. For post-operative 
incisions, any area of the incision with a wound complication that might independently 
influence wound evaluation was considered a separate wound. A brief history of age, gender, 
reason and date of admission, medical and surgical history, diabetic history and treatments 
rendered from admission to the time of admission to the trial on each patient was obtained 
and recorded on patients’ notes and only relevant history was recorded on the purposely 
designed wound assessment chart. 














Patients invited into the study 
N=30 
 
Patients meeting inclusion criteria & 
consent to the study 
N=25 
Patients who completed the study: 
Diabetic Patients: N=7 
Non-Diabetic Patients: N=15 
Total: N=22  
 
Withdrawn from the study 
(OPD pts) 






Patients excluded due to not 







Figure 4.4:  Study design. Using the adapted TELER system indicators and purposively 
developed questionnaire and bedside wound examination as the gold standard, the 
feasibility of sugar trial for wound management in an NHS hospital was measured by 
concordance between the patient and clinical staff at the bed-site evaluation 
 clinical staff: 1-2 nurses and 2-3 vascular surgeons 
examines wound 
 decision is made regarding progress/stop or continue 
with sugar 
 digital wound photography is taken by the 
nurse/researcher attending to the wound dressing 
 wound cleaned and redressed   
 nurse complete TELER indicators 
 clinical staff: 1-2 nurses and 2-3 vascular surgeons 
examines wound 
 decision is made regarding progress  and recruited into 
sugar trial 
 Patient further reviewed by nurse/researcher for 
questions and answers 
 Patient is given information booklet for 24 hours 
 Patient sign consent form 
 Purposively designed wound questionnaire 
administered by admitting nurse 
 Wound swabs taken 
 Wound measurements, digital photography and 
completion of TELER indicators -admitting 
nurse/researcher 
 Sugar treatment is commenced 
 Researcher administer purposively designed staff 
satisfaction survey questionnaire 
 clinical staff: 1-2 nurses and 2-3 vasular surgeons 
examines wound 
 decision is made regarding progress/stop or continue 
with sugar 
 digital wound photography is taken by the 
nurse/researcher attending to the wound dressing 
 wound cleaned and redressed   
 nurse complete TELER indicators 
Only at week 4 
Administer patient questionnaire 




On-site Wound Evaluation: 
NHS Trust Hospital  
 Vascular ward rounds: 
Bed-side 
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 Wound swabs and microbiological assessment 4.10.
It is known that a healthy skin is home to natural commensals ranging from Staphylococcus 
epidermis, Mycobacteria, Propionibacterium (anaerobic) and Corynebacterium most of which 
are gram positive aerobes. According to White and Cutting (2008) chronic wounds often 
contain necrotic or sloughy tissue which can harbour bacteria and act as a barrier to healing.  
It also follows that all open wounds will be colonised by commensal flora and depending on a 
range of factors both internal and external to the patient, may or may not cause infection. 
Wound infection is caused by pathogenic microorganisms evading the victim’s 
immunological defences, entering and establishing themselves within the host’s tissues, 
thereby multiplying causing a host reaction (Gardner et al., 2001; Gardner and Cook, 2004; 
Edwards and Harding, 2004). Accurate management of wound infection is dependent on 
identifying and treating the infecting organism. It was on this basis that swabs were taken on 
admission to the study and weekly to determine the colonising microorganisms and 
subsequently checking the effect of the sugar on the reduction or increase of microbial 
activity on the trial wound. Gardner and Cook, (2004) and Edward and Harding, (2004) go on 
to describe devitalised tissue as an increased risk of harbouring infection as microorganisms 
evade the host immunological defences and establish themselves, multiplying causing host 
reaction. Therefore early removal of necrotic tissue should reduce the risk of contamination 
and infection thereby facilitating healing, and this is what sugar is believed to facilitate 
(Tophan, 2000; Tophan, 2002; De Feo, 2003). 
 
Base-line wound swabs were taken for every patient admitted on the trial. These were 
collected after signing the consent form. Swabs were subsequently collected weekly after 
commencing the sugar until end of week 4 but whenever any patients showed signs of 
infection additional swabs were collected and send for microbial assessment. 
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In addition to collecting and analysing wound swabs, clinical staff evaluated the wound 
during ward rounds for signs and symptoms of infection as mentioned earlier. Follow up 
weekly swabs were taken if the initial swab was positive of staphylococcus aureus and the 
wound had signs and symptoms of infection. This was stopped if there were two consecutive 
negative swab results with no sign of clinical signs and symptoms of infection. If the wound 
swabs remained positive and there were signs and symptoms of infection or at end of the 
study if the wound showed signs of infection like inflammation, painful, covered with 50-
100% necrotic malodourous or non-malodourous tissue then an alternative wound care 
product and antibiotic was to be commenced. 
 
Swabs were cultured for MRSA and other routine and serious wound pathogens in 
concordance with standard laboratory wound management policy of the trust. Swabs were 
taken before the wound were cleaned to maximise the size of microorganism collected; the 
swab was zigzagged across the whole wound under gentle pressure while being rotated 
between the fingers (Cooper and Lawrence, 1996) and immediately stored in transport 
medium and dispatched to the laboratory as soon as possible. All identified ward nurses who 
participated in the study were educated before the trial on how to swab the wounds. 
 
 Definitions of importance in this study  4.11.
Wound infection is defined as a positive swab associated with pain at the wound site, 
increased exudate, odour, swelling, heat, or local redness. Colonisation was defined as a 
positive wound swab with no clinical indication of infection. 
Debridement is defined as the removal of sloughy, necrotic, or damaged tissue from a wound 




 The method of applying sugar dressings 4.12.
All wounds were cleansed using standard wound cleaning methods (cleaning with normal 
saline or washing with tap water in a wash bowl). After dabbing dry with sterile gauze, sugar 
was dusted over the wound until it was fully covered see   
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Figure 4.5 a. Any excess sugar was discarded. The sugar was held in place by an absorbent 
pad secured with a tape or bandages see   
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Figure 4.5 b). Dressings were changed daily or twice a day, depending on the exudate level. 
 
 Sugar dressing on leg ulcers 4.13.
Applying sugar on leg ulcers or superficial wounds posed difficulties. To ensure sugar was 
held in place, a ridge of yellow paraffin was made around the periphery of the wound. The 
ridge enabled the sugar to stay on the wound without spilling on clothes and bed. Thereafter a 
wound absorbent pad was applied and secured with a bandage. The rest of the procedure 
followed that mentioned above. The treatment continued until there was completely clean, 






Figure 4.5:  Sugar covering the wound of an above-knee amputee (a), secured in place 





4.13.1. Additional wound care treatment required 
Pain is a significant problem in wound care and needs to be routinely assessed and treated in 
both young and older adult population. Therefore patients were given analgesics such as 
paracetamol, co-codamol, and tramadol or morphine sulphate as prescribed by the medical 
team. Those with leg ulcers and receiving sugar treatment were nursed without compression 
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bandaging, but with their legs elevated for the duration of the treatment. Patients with 
methicillin-resistant Staphylococcus Aureus (MRSA) and Staphylococcus Aureus infections 
were treated with sugar alone. No patients received antibiotics during treatment or 
immediately after treatment period. 
 
 Clinical team wound evaluation 4.14.
Wound healing progress 
All wounds were evaluated by clinical staff (1-2 nurses and 2-3 vascular surgeons) at the bed-
side or in vascular out-patient clinic rooms. Following the clinical team evaluation, the 
researcher or attending nurse trained to use the sugar would take digital photography, and 
wound measurements (if it was time for these procedures to be done) otherwise, they cleaned 
and redressed the wound with sugar and complete the TELER indicators.  
 
Ease of dressing change 
Dressing change is one of the procedures that clinicians rely upon to enable wound healing. It 
is also the time when some patients dread as some dressing products adhere to the wound 
causing severe pain on removal. This experience does affect the quality of life of most 
patients. Ease of dressing change was assessed during wound dressing times. Patients were 
asked questions related to pain on removal of dressing and after applying sugar according to 
TELER indicator component. The responses were recorded on the case report form. During 
ward rounds patients were constantly asked about the treatment and how they were feeling 
and their feedback was recorded in their study. 
Patient acceptability of sugar dressing 
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Patients’ attitudes towards sugar dressing were assessed using before and after adapted 





Appendix 10). The questionnaires were administered by either the researcher or trained 
nurses who had received training on the study. In addition to the questionnaire being 
completed, patients were asked for their feelings about the treatment and this was 
documented on the clinical notes. Besides asking then during ward rounds, patients were also 
asked informally in case they felt intimidated during wards rounds and failed to explain fully 
how they felt; and the responses noted in their clinical notes. 
Blood sugar levels 
One of the concerns of many clinicians was the possible rise in blood sugar levels of diabetic 
patients when commenced on the sugar trial. This issue became one of the focus areas of the 
study. Patients with insulin/non-insulin dependent diabetes mellitus had their blood sugar 
level checked before the start of the study and routinely according to the trust policy and 
diabetic management protocol until the end of the study. This was logged using the diabetic 
chart. 
 
 Other wound evaluations undertaken during ward rounds 4.15.
Wound Appearance, Malodour, Exudate and Debridement  
Lack of blood supply causes death at a cellular level and the dead cells accumulate in either a 
dry or wet mass which is recognised as necrotic tissue or slough. Slough and devitalised 
tissue will act as a bacteriological culture medium and inhibit the action of leucocytes in a 
wound and thus predispose a wound to infection (White et al., 2006; Kirketorp et al., 2008; 
Percival and Dowd, 2010). This process will influence the appearance, malodour status, and 
exudate production of a wound. Consequently, evaluating these characteristics was vital to 
the clinical team as a guide to wound healing progress. Evaluation was undertaken during 
ward rounds and dressing change times and findings were recorded in clinical notes and case 
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report form. This continued until the wound was debrided and sugar was no longer required 
or when the study period ended. 
 How patients were managed during out-patient appointment 4.16.
The study was not limited to in-patients only. There were two patients recruited from a 
vascular out- patient clinic. Here participants’ wounds were dressed as described earlier. 
They were shown how to re-dress the wound at home. Thereafter, they were given a week’s 
supply of sugar, together with dressing packs for their use at home.  They were also advised 
to discard all left-over sugar once the container had been opened. They were asked to attend 
their normal weekly check-up at the hospital, on the day of the out-patient appointment, the 
nurses and doctors assessed the wound progress as described earlier and documented findings 
on clinical notes and case report forms accordingly. 
 
 Staff acceptability of the sugar dressing 4.17.
The nursing staff were given a purposely designed self-administered Likert scale satisfaction 
questionnaire (see Appendix 11: Nurses Questionnaire) at the start and end of the trial to 
complete. This was to determine whether there was a change in attitude and knowledge from 
that of initial recording. 
 
 Overall findings of the feasibility study 4.18.
A total of 25 purposively sampled patients were admitted into the study. Two were admitted 
from the out-patient department and the rest from in-patients. One patient withdrew from the 
study after a day of treatment because the clinical staff preferred to use Vac therapy. Two 
patients both from out-patient withdrew; one did not attend the follow up appointment and 
the other refused to continue citing it was too much work.  The rest of the patients’ results 
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were included in this analysis. Table 4.4 below illustrates recruited patient characteristics. 
Table 4.4 Table: Recruited patients characteristics recruited. 
Age range(s) 34-96 
Average age(s) 68 
Diagnosis 
 
Diabetes –on insulin + Leg ulcer 3 
Diabetes-Non-Insulin + Leg ulcer 1 
Diabetes –on insulin + Pressure ulcer 3 
Leg ulcer 5 
Pressure ulcer 3 
Surgical wounds – incisions + amputees 7 
Total 22 
 
The age distribution was fairly inclusive (34-96 years) of young adults and old. In addition 
patients had wounds of different aetiologies that gave a broader understanding of the impact 
and applicability of the sugar. There were more of the leg ulcers and surgical wounds that 
portray the nature of the ward on which patients were recruited (vascular ward). One of the 
aims of the study was to determine the effects and acceptability of the sugar treatment to the 
patients.  
The patients’ self-reported attitudes using the adapted Wayne Naylor (2000) (Appendix 10) 
wound symptoms Self-Assessment Chart indicated that, wound pain and wound pain during 
dressing change, fluid leak, and malodour and itchy strongly interfered with their everyday 
life before the sugar treatment. When the same questionnaire was completed at the end of the 
sugar treatment, the self-reported responses strongly indicated less wound pain and less pain 
during wound dressing change. The wound leakage had decreased, with none of the initially 
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reported wound smell to patients whose wounds had an odour before the trial. The mood of 
the patients was improved according to the responses see   
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Figure 4.6. The most noted improvement was on wound bleeding, smell and itching that 
ceased to exist or did not bother patients sufficiently for them to report. Overall, patients’ 
attitudes, mood and feeling of embarrassment were improved. For this reason, the data was 
summarised as a whole, using boxplots on page 80. 
The study aimed at exploring the suitability and acceptability of the sugar by the patients; 
therefore it was important to understand how patients felt on their wound dressings were 
being changed. From the results it is clear that patients felt that dressing changes were 
satisfactory. The 22 patients experienced little or no pain at all, see   
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Figure 4.6. Again informal reports during ward rounds and dressings changes did support 
this phenomenon. Most patients had reported some form of pain at baseline information and 
the follow-up questionnaire illustrated that the patients had their pain intensity improved. 
They even reported a better sleeping pattern. Within this figure the bold line indicates the 

















4.18.1. Effects of granulated sugar on necrotic exuding wounds 
In this feasibility study, there was a need to explore the effects of sugar on sloughy, necrotic 
and infected exuding wounds. The researcher wanted to understand whether sugar would help 
in cleaning the wound in preparation for a larger study. The following are the general 
findings that illustrated the outcome of the study. 
 
Wound debridement:  
All wounds of the 22 patients admitted into the study were heavily or moderately exuding, 
with 50 -100% sloughy and/or necrotic tissue categories 0-3 of the TELER system. Ten 
(45.5%) patients had clinically infected wounds; 14 (63.6%) patients had necrotic tissue, and 
one patient had hard necrotic tissue and moderate slough. 
 
On day 14, the wounds of 9 (40.9%) patients wounds were granulating, 3 (13.6%) patients 
wounds had healed and been discharged, 10 (45.5%) wounds had either non odorous necrotic 
slough, or thin layer of slough. 
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Figure 4.7: (A1 -F1) illustrates the before and after debridement effect of sugar on a variety 
of wound profiles treated. E1 illustrates the debriding effect of sugar and the residual sugar 
left when the wound is debrided. There will not be any devitalised tissue for the sugar to 




Figure 4.7: Wound samples showing debridement effect of sugar 
 
      
       
A1:  Above knee amputee (before treatment) A1:  (after 14 days sugar 
treatment) 
      
B1: Diabetic leg ulcer (after treatment)    B1: (after seven days sugar 






       
C1: Leg ulcer (before treatment)   C1: (after seven days sugar 
treatment) 
 
        
D1: Infected laparotomy wound (before treatment)   D1: (after seven days sugar treatment) 
 
      




       
F1: Infected above knee amputee (before treatment)   F1:  (after seven days sugar 
treatment) 
 
Further to exploring debridement, it was vital to understand the effects of granulated sugar on 
exudate management. Base-line data using TELER system and the before and after 
questionnaire showed that 15 (68%) patients had categories 1-2 exudate and 7 (32%) had 
category 3. In all 22 (100%) patients, varying degrees of strikethrough and some heavy 
exudate was reported at the start of the study but exudate leakage had decreased by day 7.   
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Figure 4.7 A1 before and after photographs illustrates this outcome. There were similar 
results from other 21 patients treated, although their wounds were of profiles were different. 
Although the study did not set to explore wound odour and pain specifically, these two 
wound characteristics were reported. Eleven (50%) patients’ wounds were malodorous at 
base-line assessment by the end of the study none (100%) reported malodour. Similarly, at 
base-line assessment 22 (100%) patients scored 2-5 moderate to severe wound pain. At the 
end of the study all 22 (100%) patients indicated 0-2 pain score, showing a reduction in 
wound pain. 
 
4.18.2. Effects of granulated sugar on blood sugar levels in diabetic patients 
One of the key areas of this study was to understand the effect of sugar on both non-insulin 
and insulin dependent diabetic patients. Base-line capillary blood sample results tested; mean 
level 5.6mmol/l (range 3.8-10.1) versus 5.6mmol/l (range 3.6-7.83) at the study end. Insulin 
dependent patients required no additional insulin throughout the study.  
 
4.18.3. Effects of granulated sugar on bacterial load 
All 22 patients’ laboratory wound swab results were monitored; 4 (18.2%) showed MRSA 
colonisation and the rest 18 (81.8%) patients were of mixed flora/microorganisms of no 
significance. At the end of the study the four wounds with MRSA were found to be negative 
to MRSA. 
4.18.4. The nursing staff’s reaction to the sugar treatment. 
This feasibility study explored nurses’ experiences and acceptability of the sugar treatment. 
Twenty one nursing staff of various years of experience was purposively recruited into the 
study. For a full list of the characteristics see Table 4.4 underline. There was a general 
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distribution of the nursing grades and experience in line with the number employed whole 
time equivalent staff in that vascular ward. The majority of nurses were from band 5, 
(qualified registered nurses who have 6 months and over post qualifying clinical nursing 
experience) a category that mainly deals with wound dressings. It can be noticed from the 






Table 4.5: Illustration of recruited staff characteristics 
 
Category Staff 
Years of Experience 
≤10 Years 10-20 Years ≥20 Years 
Nursing Band 7 1 0 0 1 
Nursing Band 6 4 1 3 0 
Nursing Band 5 10 6 5 0 
Student Nurse 1 1 0 0 
Nursing Band 1-4 3 2 1 0 
Total Recruited 21 11 9 1 
 
Initially, the responses to the questionnaires completed at the end of the trial were compared 
between those nurses with less than 10 years’ experience, and those with a longer duration of 
experience. However, none of these comparisons were significant. For this reason, the data 






Figure 4.8: Nursing staff responses to use of granulated sugar 
 
































Figure 4.8, it is clear that the vast majority of nurses are satisfied with most of the questions 
having over 80% of nurses giving the highest possible score. All of the nurses expressed that 
they would definitely use granulated sugar again on exudating wounds, and would 
recommend the treatment to a ward that needed it. Only one nurse was unsure on the 
treatment and this related to how easy the protocol was to follow. 
 
4.18.5. Does granulated sugar have adverse effects on patients? 
Adverse effects in this study were defined as any event/experience that was not only life 
threatening but caused severe wound pain and damage leading to deterioration in wound 
healing. This issue was monitored closely and none of the 22 (100%) patients recruited and 
treated with sugar experienced any of these events during the trial period. 
 
 Discussion 4.19.
The practical usage of granulated sugar for managing sloughy, necrotic and infected exuding 
wounds in the modern day NHS health care systems was questionable given the advanced 
technology available within this area. Historically, sugar dressing has been used to treat 
varying wounds aetiologies and reports has been slowly emerging (Herszage et al., 1980; 
Trouillet et al., 1985; Gordon et al., 1985 Ambrose, 1986; Archer et al., 1990; Mphande et 
al., 2007). Even with available evidence, there is little knowledge to guide expansion of this 
method of wound care. The principal attainments of this study were that it is feasible to use 
sugar in modern day NHS hospital. Ethical and the Medicine and Health Regulatory 
Authority does allow sugar to be used as an alternative wound care dressing product. It is also 
feasible to use sugar as a dressing product for diabetic patients without affecting their blood 
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sugar levels. Furthermore, both health care professionals and patients exposed to the use of 
sugar accepted this method.  
The process of establishing the study was robust, seeking both MHRA and ethical 
authorization. Sugar when used as a wound care product becomes a drug (MHRA 2010); 
therefore it was important that, the study follows the guidelines of good clinical principles of 
research study. The study was given a EudraCT number for future reference.  
 
Determining the sugar dosage was important if the study was to develop an applicable sugar 
protocol. There is evidence from this study to show that sugar treatment used on both cavity 
and non-cavity sloughy or necrotic wound tissue seems to be an effective way of wound 
debridement and is capable of debriding a wound of small or large surface area. However, the 
most appropriate follow up dressing product after wounds are debrided is not very clear. It 
was noticeable in the study that after applying sugar on the wound for a couple of days or 
weeks when the wound is debrided the sugar remained undissolved on the wound. This is an 
indication showing the wound is adequately cleaned of slough. It is important to clarify the 
follow up treatment in order to minimise re-sloughing. This will enable developing an 
effective clinical protocol.  
 
It was also feasible to establish ways of preventing cross infection and maintaining a chain of 
sterility by designing the use of different sizes of single use aliquots containing 15 and 30 
grams of sugar (Figure 4.2 see page 60). These aliquots came with certificate of conformity 
and batches serial numbers that enabled tracing back to the manufacturer as well as the re-




There is evidence from this study that sugar administered on type 1 and type 11 diabetic 
patients does not influence their blood sugar level concurring with the work by Yudkin and 
colleagues (1971), that simple sugars are the forms in which carbohydrates are absorbed into 
the blood stream and hydrolysis of dietary carbohydrates is an important digestive function 
that involves catalytic enzymes (Yudkin et al., 1971 p. 156). In this study, sugar is 
administered topically and there is no enzymes (amylase) involved to convert sucrose into a 
monosaccharide glucose and fructose that are easily absorbed. However, it is further 
explained (Yudkin et al., 1971 p. 168) that simple sugars glucose and galactose are actively 
absorbed using a carrier mechanism similar to that of sodium gradient movement in and out 
of the cell, and this dependent on cellular metabolism; a process not supported by topical 
application of sugar on a wound. This notion is further evidenced by the studies of (Trouillet 
et al., 1982; Tophan, 2000; Biwas et al., 2010) who did not encounter any rise of blood sugar 
levels in patients receiving sugar treatment but already suffering from diabetes mellitus. 
Previous research of sugar, Mphande et al (2007) cited patients experiencing pain using 
sugar. Subjects’ pain experiences were therefore assessed at each dressing change as well as 
weekly evaluations. Patients’ reported varied experiences some had tingling pain when the 
initial dose of sugar was applied with no further pain. The majority of subjects did not 
experience pain at all, reporting feeling reduced pain sensation. Overall, there was no patient 
withdrew due to pain issues. Although this was a small study a visual assessment score of 
pain was monitored as Sussman (2001) concludes that pain and discomfort can be a deciding 
factor when choosing reliable and efficient dressing. However, Gardner et al (2001) found 
increasing wound related pain and wound breakdown to be among the sensitive indicators of 
wound infection. They advocate relieving pain as an encouragement to concordance with 




Subjects’ reports indicated that there was good adherence with the study treatment, with the 
majority stating that malodour and exudate management was good. The level of comfort of 
the dressings was varied but the majority of subjects rated the treatment as comfortable and 
rated the level of comfort on the high level, a state that we did not anticipate. The majority of 
subjects described satisfaction with the study treatment. Positive evaluations of the treatment 
were also provided by the majority of nurses who rated ease of application and removal of 
dressing as “very simple” and “simple”. 
 
This study provided evidence to show that sugar treatment debrided wounds of various 
aetiology considerably more quickly (3-14 days) although this needs verifying with a larger 
comparative study. The results also showed a lower incidence of wound infection signs using 
sugar treatment. However, it was not possible to analyse the actual quantity of colonising 
microbes before and after. This proved costly given the small budget available. But, it must 
be pointed out that the four MRSA positive swabs at the start of the trial were negative at the 
end of the study without any use of antibiotics. This experience is encouraging, but needs 
further verification with a larger sample size. 
 
There was a systematic evaluation of side-effects or complications and none were concluded 
during the intervention. This study participants did not experience any adverse effects or 
complications, concurring with the findings of the previous researchers (Seal and Middleton, 
1991; Tophan, 2000; Mphande et al., 2007 and Chiwenga et al., 2009. Chirife et al., 1982) 
who did not experience either adverse effects or complications.  The results of this feasibility 
study enabled the development of a protocol on the use of sugar in the management of 




To the best of our knowledge this trial was the first sugar study to evaluate the possibility of 
sugar dressings affecting/not affecting the diabetic patients’ blood sugar level. The researcher 
concluded that patients who are on insulin or treated with diet and tablets can be treated with 
sugar dressing without affecting their blood sugar levels.  
 
The study enabled us to determine the sizes of the wound and their respective sugar dosages. 
We concluded that wounds will be categorised as small- medium and medium to large and 
treated with doses of 15 and 30 grams respectively. Although this study was not aimed at 
exploring debridement effect as a primary outcome, the researcher noticed that sugar was 
effective on wound debridement. The positive outcome of the short survey of nurses’ 
acceptability of the sugar added on to our assumption that clinical staff would support 
undertaking a RCT.  
 
This study failed to produce a tangible mechanism of monitoring the quantity of colonising 
bacteria and this meant it was impossible to explore this in the larger study. It was concluded 
that the reduction or increase of wound infection using laboratory analysis was to be omitted 
in a future study, since the funds were not sufficient at the time. But the trial would assess the 
clinical signs and symptoms of infection coupled with routine microbial analysis of wound 
swabs periodically.  
 
The patient survey suggested that sugar dressings were tolerated with or without minimal 
pain reported. But it must be noted that it is unusual for any pain associated with changes in 
dressing to cause patients to withdraw from studies that involve chronic wounds (Jull et al 
2008), as patients would try to persevere in order to find a cure for their wound. One of the 
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unexpected findings was a reduction in the use of opiates. Systematic effects in a small study 
could not explain this, but if it really were reduced even by frequency of use it would lessen 
the cost of medication and improve the quality of patients’ lives. Of course there are many 
factors that may contribute to the reduction of pain and use of opiates and further research is 
required to account for any possible confounding factors for example adhesive dressings, 
infections or cultural issues. 
 
This study has shown that a randomised trial is feasible in this group and that a single non-
comparative study cannot draw any firm conclusions about efficacy of sugar dressings.  
However, a full RCT is feasible with minor modification to the study design. 
Finally, the proposed RCT is to be a multi-centre involving different study settings, so this 
has to be accounted for in the planning. The results and experience allowed for a comparative 
study to be developed. A power calculation was done from the given study results. Therefore 
the following chapter will describe the RCT. 
5. Chapter The use of granulated sugar on managing sloughy necrotic 
and infected exuding wounds: a pragmatic randomised controlled 
trial (RCT) 
 
 Background  5.1.
In chapter 4 the use of granulated sugar was demonstrated to be useful for debriding sloughy, 
necrotic and infected exuding wounds. The study also concluded that granulated sugar in 
direct contact with the wound creates a wound bed environment of higher sugar osmolality 
that interferes with bacterial growth. This process results in an increased volume of exudate 
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production initially, reducing in amount as the treatment continues. This process enables easy 
cleaning of wound debris and allowed new tissue to develop i.e. granulation. Chapter 4 
illustrated the method and feasibility of undertaking a sugar trial in a modern NHS hospital. 
However, the study was not randomised and lacked comparison with current treatments. It 
was important to undertake a RCT in order to determine the effectiveness of sugar on wound 
debridement. According to Silverman et al. (1992) and Jadad and Rennie (1998), the RCT is 
one of the simplest and most powerful research tools to assess effectiveness of treatments. 
Therefore, this trial was to employ this gold standard study design to compare granulated 
sugar and standard wound dressing care, to determine whether there was any difference in the 
wound debridement times. It is understood that the destructive action of bacteria on wound-
bed tissue influences an increased production of slough and necrosis, hence wounds in which 
slough is the predominant tissue will heal more slowly than clean granulating wounds 
(Falanga, 2000). This chapter describes the RCT undertaken to assess the effectiveness of 
granulated sugar dressing on managing sloughy, necrotic exuding wounds in a modern NHS 
trust hospitals and Community Healthcare NHS trust setting.  
Aim 
The aim of this study was to evaluate the clinical effectiveness of granulated sugar therapy 
compared with standard autolytic debridement dressings.  
Objectives 
The objectives were set within specific research questions as follows: 
Primary:  
 How effective is a granulated sugar dressing on debriding, sloughy, necrotic and 
infected exuding wounds compared with standard treatment in terms of debridement 




 Does use of granulated sugar reduce pain and odour? 
 Does of use granulated sugar reduce the wound surface area 
 Does use of granulated sugar reduce amount of exudate and percentage of slough? 
 Does the use of granulated sugar dressing improve the quality of life of patients with 
sloughy, necrotic and infected exuding wounds?  
 Methods  5.2.
Trial design 
The study was a prospective pragmatic stratified multicentre open randomised controlled trial 
with equal randomisation, carried out in 3 centres in the United Kingdom from June 2010 to 
June 2013. Randomisation was stratified by wound size and type (chronic or acute). The 
methods used were based on those developed by Dumville et al (2009) and Toba et al (1997) 




Participants were recruited from two acute NHS hospitals from the vascular surgery wards, 
leg ulcer clinics and one NHS community hospital, as well as community caseloads including 
home treatments. All patients had sloughy, necrotic or infected exudating wounds and were 
either hospital in patients or attending out-patients clinics. Eligible participants had wounds 
between 5 cm
2
 and 40 cm
2
 in area, with at least 25% of the wound covered in by slough or 
necrotic tissue. Diabetic and non-diabetic patients were included. Patients who had arterial 
brachial pulse index (ABPI) less than 0.6, pregnant patients and patients whose wounds had 
necrotic eschar were excluded. See Table  5.1: below.  




Wounds with a minimum of 25% slough with infected or necrotic tissue present 




Patients who had previously been in this trial 
ABPI less than 0.6 
Presence of hard necrotic eschar 
Pregnant patients 
*ABPI =arterial brachial pulse index 
Interventions  
Trial group A (Sugar arm) 
After the initial wound assessment and past medical history was recorded, a short EQ-5D 
QoL questionnaire (see Appendix 13) was given to all patients in both arms to complete. 
Following completion, the dressing procedure and wound swabs were performed as follows: 
 
Wound photographs: 
Nurses/researcher took digital photographs using auto focus mechanism (as previously 
explained in chapter 4) at the start of the study then weekly, when the wound was considered 
to be debrided or at the end of the study period (end of week 4). 
Wound swabs: 
Before cleaning the wound; swabs were taken by moving the swab probe zigzagging gently 
across the wound; thereafter swabs were placed into the transporting media labelled and 
dispatched for laboratory analysis as per trust policy. 
Wound dressing procedure: 
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Wounds were cleaned according to normal trust wound cleaning procedures. However, 
nurses were requested to wash wounds with plenty of water or irrigate with normal saline as 
earlier explained in chapter 4. Sugar was applied and secured as illustrated in chapter 4. The 
frequency of dressing change was every day or every other day decided by the treating nurse. 
The approximate sugar dosage was 30 gram aliquots or more depending on the wound size 
for all categories of wounds. For smaller wounds, the remaining sugar was discarded. 
 
Control group B (Standard dressings arm) 
Dressing procedure followed a similar process to that explained above, except that 
participants received debridement agents (according to local trust protocols). Frequency of 
dressing change was decided by the treating nurse. 
Adjuvant treatment 
Patients with leg ulcers had compression bandage as well as assigned wound care products as 
adjuvant treatment in both arms. Those with pressure ulcers were treated with pressure 
relieving methods accordingly. 
 
Post debridement 
The nurse assigned to attend to the wound dressing made most of the decisions on the day to 
day care of the wound, according to the sugar protocol including whether the wound had 
debrided or not. On some occasions there was disagreement between assigned nurses on 
whether the wound was debrided or not and the disagreement was resolved by members of 
the clinical team (doctors and nurses) during ward rounds. The ward round team would assess 
the wound and make the final clinical judgement on whether the wound was debrided or not. 
Sugar treatment was applied during the period of achieving debridement only. In the phase 
102 
 
after debridement, all participants received appropriated available trust formulary dressings 
decided by the treating nurse. The date on which this occurred was recorded. 
 
Wound photography was taken and recorded in the case report form (CRF) (see Appendix 8). 
At this point participants were asked to complete validated Euro-quality of life (EuroQoL 
2010) health questionnaire (EQ-5D) see Appendix 13. The maximum length of follow up was 




The initially proposed primary outcome in the registered protocol was “time to debridement 
truncated at four weeks” monitored and recorded on case report forms using the TELER 
indicator system, as in the text box below and Appendix 6. However, this was amended to 
“debridement rates at week 4” in the two groups because it was impossible to follow up 
every day. Date of debridement was determined by the nurse doing the dressings and 
confirmed by discussion with doctors on their daily ward rounds and recorded on the case 
report forms using the TELER indicator system, as in the text box below and Appendix 8.  
 
0 Deep necrotic offensive, infected wound, down to bone  
1. deep infected wound, heavy exudates, and damage to muscle  
2. sloughy wound, infected and offensive, to subcutaneous fat  
3. no infection, no exudate, granulating, odour free  
4. superficial damage, some inflammatory change, broken 
“healthy” skin  




Based on the TELER indicator, scores between 3-5 was considered indicative of 
debridement. 
 
Secondary Outcomes were: 
Reduction in wound area in cm
2
; wounds were measured by the attending nurse using 
flexible wound dressing paper tape measure on admission into the study, then at the end of 
each week until the end of the study period (4 weeks). The longest and shortest size of the 
referral wound were measured and then multiplied to find the area in centimetres. 
  
 
Wound exudate leakage and wound exudate appearance: both wound exudate volume 
and exudate characteristics were assessed on admission into the study and at the end of each 
week. In addition regular monitoring of exudate volume and characteristics were carried out 
during dressing change using the TELER indicators on a Likert scale of 0-5, as shown in the 




















In both categories assessments were done at every dressing change. However, the initial and 
final week four assessment or the final recorded entry was used for the statistical analysis. 
Patients whose score movement points were between 2 to 4 were considered to have 
experienced some change equivalent to the minimally important clinical significance for their 
state of health at the time of the final assessment within the study period of 4 weeks. 
Wound slough was assessed using a subjective slough percentage (%) estimation of wound 
surface area covering, as well as digital photographic evidence on admission into the study, 
and at the end of each week, until end of the study (4 weeks). In addition, regular monitoring 
and recording were carried out during dressing changes and recorded on the CRF.  The 
0. Dressing(s) and bed clothes are soiled  
1. Dressing(s) and bed clothes are wet  
2. Dressing(s) wet and bed clothes are damp 
3. Dressings wet and clothes are soiled in patches, size of 50p piece 
4. Dressing(s) only is wet 
5. Dressing only is soiled. 
0. With sanguineous, predominantly blood  
1. Serosanguineous, i.e. blood stained but not bleeding frankly  
2. Odorous purulent, i.e. odour + cloudy, thick yellow/blue/green tinge  
3. Non-odorous purulent, i.e. cloudy, thick, yellow  
4. Serous, i.e. thick, pale, straw/clear  
5. No exudate to describe  
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percentage of slough was to be independently assessed using the supplied digital 
photographic evidence by an assessor who was blind to the study arms. The results were to be 
compared to those reported on the CRF by the nursing staff. 
Wound Pain assessment on three domains; (a) wound pain and its interfering with daily life 
activities, (b) wound pain disturbing sleep and (c) wound dressing pain. The score was 
measured using TELER indicator system with a Likert scale of 0-5, higher scores showing a 
desirable outcome. For example (a) wound pain interfering with patient’s ability to: relax (0), 
mobilise (1), concentrate (2), socialise (3), sleep (4) and no pain at all (5). 
Other pain domains were wound pain disturbing sleep and were scored as wakes frequently 
difficulty to sleep (0), wakes frequently (4 or more times a night) (1), wakes infrequently (3 
or less times a night) (2) sleeps through 1-3 nights a week (3), sleeps through 4-6 nights a 
week (4) and sleep undisturbed every night (5). The third domain was, wound dressing pain 
and was measured on how dressing changes were affecting the patient such as; unbearable 
dressing change, medication needed during pre and post change (0), distressing dressing 
change, medication needed (1), unpleasant dressing change, medication needed (2), 
disagreeable dressing change, no medication (3), some unpleasantness (4) and dressing 
change alright (5).  
Patients whose overall TELER indicator movement points of between 2 to 4 were considered 
to have experienced some change equivalent to the minimally important clinical significance 
for their state of health at the time of the final assessment within the study period of 4 weeks. 
At every dressing change the nurse/researcher asked the questions using the TELER 
indicators and recorded the scores in the CRF as well as the weekly evaluation scoring.  
Odour was recorded using the same TELER system indicator with a Likert scale of 0-5. The 
worst result being, odour is obvious in the house/clinic/ward and scored as (0), odour is 
obvious at arm’s length from patient (1), odour is obvious at less than an arm’s length from 
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patient (2), odour is detected at arm’s length (3), odour is detected by patient only (4) and no 
odour (5).(see Appendix 8). As mentioned earlier, a 2 to 4 point movement was considered 
clinically significant as compared with the baseline score. Assessing and recording of odour 
stopped when there was three consecutive recorded scores of 5 (no odour) on daily dressing 
change assessments. When the score was agreed by the clinical team, the final agreed score, 
day and date was recorded in the case report form (Appendix 8). The initial and final 
recorded score were compared statistically at the end of the four week period.  
Health-Related Quality of Life (HRQL) was measured using EQ-5D (Appendix 13) (The 
EuroQoL Group, 1990). In previous studies, this tool was found to be sensitive to changes in 
the healing statistics and participants’ perceptions of health related quality of life both at 
baseline assessment and end of trial. The patients scored on a visual analogue scale, marked 
with 100 increments, such that a score of 100 indicated “full health”.  
In addition to the visual analogue scale, on entry into the study and at 4 weeks, patients were 
asked questions relating to the five domains of the EQ-5D, namely mobility, self-care, usual 
activities, paint/discomfort and anxiety/depression. The response to each of these questions 
was on a 3-point Likert scale. The changes in scores from baseline to four weeks were 
compared between the treatment arms. 
Participants in both arms completed their first HRQoL questionnaire after signing the consent 
form. They were given the second questionnaire after the wound was agreed by the clinical 
team to be debrided and the sugar was no longer required or after 4 weeks if sugar treatment 
continued till the end of the study period. The questionnaire is validated in English language, 
and all patients were encouraged to complete on their own, but some used relatives to assist, 
due to poor sight or arthritis problems. Where relatives were not available and the patient 
needed help with the questionnaire, the nurse assessing and dressing the wound asked the 
patient questions from the questionnaire and completed according to the patient’s response.  
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 Sample size  5.3.
In consultation with hospital's statistician, the study was powered based on a proportional 
hazards survival analysis model, comparing the times to debridement in the two treatment 
groups. The statistical methodology described by Brysbaert (2011) was used as the basis for 
the calculation. The median times to debridement were assumed to be 11 days in the sugar 
treatment group, based on the information from a feasibility study chapter 4, (Murandu et al., 
2011 see Appendix 17), and 21 days in the standard treatment group, based on Gethin and 
Seamus (2008). For a total of 28 days of follow-up for each patient, a sample size of 54 
patients per group was found to be sufficient to detect a difference between treatments at 80% 
power and 5% alpha if the median times to debridement are 11 and 21 days, as 
forecasted.  Hence, the target for recruitment in the study was 108 patients to randomise 
between the two treatment groups. 
 
 Randomisation  5.4.
Randomisation was performed centrally and the block randomisation table was designed by 
the hospital statistician. This type of design makes it difficult to reveal the allocated number 
of the patient which can occur when smaller equally sized blocks of randomisation are used 
(Schulz and Grimes, 2002). Consecutively numbered opaque envelopes were prepared for all 
hospitals. Equal numbers of blocks of 2, 4, 6 and 8 were prepared with block sizes 
determined using a random numbers.  
 
Sequence generation 
Within each block, a further series of random numbers was generated, one for each patient in 
the block. Those falling between 0-0.499 resulted in an allocation of intervention and those 
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between 0.500-0.999 resulted in a control. Once half of a block had been allocated to either 
an intervention or control, the remaining places in the block were allocated so as to result in 
equal distribution of intervention or control within each block. Further stratification was 
performed according to type of wound/s; “chronic or acute” and wound size using separated 
sets of numbered envelopes for those with chronic or acute wounds. The initial randomisation 
tables were constructed by the lead hospital trust’s senior statistician four months prior to the 
start of randomisation and the consecutively numbered envelopes prepared by the 
administrative secretary.  
 
 Allocation concealment 5.5.
Allocation took place away from the research sites. When the patient was assessed by the 
clinical team and found to be suitable, that is, meeting the inclusion criteria as mentioned 
earlier in Table 4.3 the patient was informed of the trial taking place by the doctor or nurse. 
If the patient was willing to be considered for the trial, a nurse/researcher with the knowledge 
of the sugar trial was informed. Either the nurse or the researcher explained in detail the trial 
procedure and gave the patient an information sheet (Appendix 3) to read and consider 
overnight. If the patient agreed to take part in the trial he was requested to sign a written 
consent form that was countersigned by the admitting nurse or researcher (see Appendix 7). 
After the consent form was signed the researcher/attending nurse phoned the secretary 
holding the allocation envelopes at the allocation centre a site away from the research sites 
without knowledge of the trial, patients and the trial team except the researcher. The trial 
secretary opened the next available numbered envelope taking into account the categories, 
chronic (leg ulcers or pressure ulcers) or acute (traumatic wounds and non-healing surgical 
wounds), small to medium (5 to 19.9 cm
2
) and medium to large (20 to 40 cm
2
). Thus both 





Once patients were allocated a treatment, they were assessed as per study protocol. For 
complete patient flow through the study see Figure 5.1. 
 
 Statistical methods 5.6.
Baseline measurements for each group were compared, to ensure that any differences 
between the groups were not attributable to a difference in the case mix. Mann-Whitney tests 
were used for continuous variables, and Fisher’s exact tests for categorical variables (Huck 
and Cormier, 1996). 
The primary outcome was considered to be the debridement rates at week 4 and was intended 
to be compared between the two treatment groups using survival analysis techniques. Kaplan-
Meier curves would be produced to show how the rates of patients achieving debridement 
changed over 4 weeks, and a Log-Rank test was used to compare the two treatment groups. 
For secondary outcomes, the difference between the initial measurement, and the final 
available measurement was calculated for each patient and compared between the treatment 
groups. Comparisons were made using Mann-Whitney tests, and the results reported as 
medians and quartiles.  
For the analysis of the “Health Today” EQ-5D questionnaire (see Appendix 13), Mann-
Whitney tests were used to compare the initial measurements, and the changes from the start 
of the study to the end of follow-up between the two groups. The data were then summarised 
using medians and quartiles. The individual domains of the EQ-5D questionnaire were then 
analysed separately. For each patient, the difference between the score for each domain at 
baseline, and at 4 weeks was first calculated. Since the score was only a 3 point scale, and 
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few patients registered more than a 1 point difference, the changes in the scores were grouped 
into three categories: increases, reductions and no change. Since this could not be treated as a 
continuous variable, the data were analysed using Kendall’s tau-b test for ordinal categorical 
variables. 
The data was analysed on an intention to treat basis (Hollis and Campbell, 1999). Where data 
was not available for week four of the study, the most recent measurements were used 
instead. All analyses were performed using IBM SPSS 19, with p<0.05 deemed to be 
indicative of statistical significance. 
 
 Adverse events 5.7.
Adverse events were classified as serious or non-serious. Some events were always classified 
as serious (death, life threatening event, admission to hospital in case of out-patient and home 
treatment, persistent or significant disability or incapacity). The seriousness of other events 
like infection and deterioration of wound, was judged by the treating nurse. Nurses and 
doctors indicated whether or not they believed the event was related to trial treatment.  
 
 Results  5.8.
5.8.1. Change to Protocol 
After finalising the protocol, due to financial and logistical issues, it was not possible to 
assess patients daily as initially planned. As a result of this, the exact dates of debridement 
(primary outcome) would not be known, making survival analysis impossible. Instead, the 
primary outcome was taken to be the debridement rates at week 4 in the two groups. In 
addition to this, the target sample size was not attainable, and so the study was performed 
with the maximum achievable number of 41 patients. Based on these two points, the sample 
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size calculation for the primary outcome was repeated. Assuming a 30% debridement rate at 
4 weeks in the control group, a rate of 78% in the sugar group would give 80% power at 5% 
alpha (Lenth, 2012).  
5.8.2. Patients Lost to Follow Up. 
Patients lost to follow up were analysed using a Last Observation Carried Forward (LOCF) 
approach, i.e. the last available measurement was used in the (endpoint) analysis (Pledger, 
1992). 
5.8.3. Participant flow 
Between June 2011 and June 2013, 55 patients were assessed for eligibility 41 (75%) met the 
inclusion criteria and were randomised. Ten (10) did not meet the inclusion criteria, one (1) 
declined and three (3) were seriously ill. Twenty two (22) were allocated to sugar dressings 
and 19 to standard dressings.  
Of the 22 that were allocated to receive sugar treatment, one (1) did not receive the allocated 
treatment because of a misunderstanding by the clinical team, but remained in the group, due 
to the intention to treat methodology. The remaining 21 (95.5%) patients received sugar 
treatment and one (1) was lost to follow up as the home address was of no fixed abode. Of the 
19 patients allocated to receive standard treatment, one (1) did not receive allocated treatment 
instead received sugar treatment, due to mix up of the clinical staff receiving the allocation 
number. One patient died a week into the study, and the cause of death was unrelated to 




Figure 5.1: The study flow 
  
Excluded (n=14) 
 Not meeting inclusion 
criteria (n=10) 
 Declined to participate 
(n=1) 
 Other reasons (n=3) 
Analysed (n=19) 
Discontinued intervention (n= 1) 
patient cause of death not related to the 
treatment 
Allocated to standard (n= 19) 
 Received standard (n= 18) 
 Did not receive allocated 
intervention (n= 1) treated with 
sugar 
Lost to follow-up) (n= 1) patient 
discharged and never returned for 
follow up 
Allocated to intervention sugar (n= 22) 
 Received sugar (n= 21) 
 Did not receive allocated 
intervention (n= 1) treated with 
standard dressing 









5.8.4. Demographic and other baseline characteristics 
The distributions of baseline demographics were similar in the two interventions. The median 
age in the sugar dressing group was 66 years (quartiles: 60 – 77), and in the standard dressing 
group 67 years (quartiles: 58 – 78). Similarly, 64% of the sugar dressing group were male, 
compared to 47% in the standard treatment. Rates of diabetes and the modes of injury were 
also similar in the two groups see Table  5.2. There were fairly distributed wound aetiologies 
between groups; with the majority of the patients presenting with chronic wounds of medium 
to large size see Table  5.2. There were no patients presenting with acute small-medium 
wounds in the intervention group; with only 1 patient in the control group. 
Baseline wound characteristics were evenly matched between the treatment arms as reported 
in Table  5.2. In addition, the quality of life measurements from the visual analogue scale 
question of the EQ-5D did not differ significantly between the groups at baseline with 




Table  5.2: Baseline characteristics 
 Characteristics 
Intervention 
(n = 22) 
Control 
(n = 19) 
Wounds 20 cm
2
 to 40 cm
2
 (%) 
16 (73%) 14 (74%) 
Chronic/Acute wounds (%) 
19 (86%) 15 (79%) 
Males (%) 
14 (64%) 9 (47%) 
Age
#
(Interquartile range) (IQR) 
66 (60, 77) 67 (58, 78) 
Diabetics (%) 6 (27%) 3 (16%) 
Surgical wounds (%) 6 (27%) 4 (21%) 
Leg ulcer (%) 7 (32%) 5 (26%) 
Pressure ulcer (%) 2 (9%) 0 (0%) 
Renal disease (%) 0 (0%) 0 (0%) 
Trauma (%) 1 (6%) 0 (0%) 
HRQOL – EQ5D IQR) 51 (40, 60) 50 (30, 60) 
Wound Area (cm
2
, IQR) 35.9 (21.2, 90.2) 32 (24.8, 45.0) 
Slough (TELER, IQR) 10 (89, 100) 10 (80, 100) 
Wound Healing (TELER, IQR) 2 (2, 2) 2 (1, 2) 
Exudate Leakage (TELER, IQR) 2 (1, 3) 2 (1, 3) 
Exudate Appearance TELER, IQR) 2 (2, 3) 2 (2, 3) 
Odour (TLER, IQR) 3 (2, 5) 3 (2, 4) 
Pain – Component (TELER, IQR) 3 (2, 4) 3 (3, 4) 
Pain – Sleep (TELER, IQR) 2 (2, 4) 3 (2, 4) 
Data reported as “N (%)”, with p-value from Fisher’s Exact test 
#
Data reported as “Median (Quartiles)”, with p-value from Mann-Whitney test 
Wound characteristics at baseline 
 
Table  5.3: Sites of recruitment to the study 




32 28 - Non-healing post-
surgical wounds 
4 -Leg ulcers 
Moseley Community 
Hospital (in patients and 
community home visits) 
6 All Leg ulcers 




Primary Outcome  
In the sugar group 19 (86%) achieved debridement at 4 weeks compared to 6 (32%) in the 




Table 5.4: EQ-5D HRQoL secondary outcomes; change from baseline to end of study: 
IQ range  















Slough (% of surface area) -83 (-91, -39) -20 (-40, 0) 0.001* 
Wound Healing (TELER Score) 1 (1, 2) 1 (0, 2) 0.393 
Exudate Leakage (TELER 
Score) 
2 (1, 3) 1 (0, 2) 0.124 
Exudate Appearance (TELER 
Score) 
2 (1, 2) 1 (0, 2) 0.005* 
Odour (TELER Score) 2 (0, 3) 0 (0, 2) 0.059 
Pain - Interference (TELER) 2 (0, 2) 0 (0, 1) 0.009* 
Pain - Sleep (TELER) 2 (0, 2) 0 (0, 1) 0.020* 
HRQOL (EQ-5D) Change after 
4 weeks 
30 (5, 40) 0 (-2, 15) 0.005* 
Data reported as “Median (Quartiles)”, with p-value from Mann-Whitney test  
*Significant at p<0.05 
 
In patients treated with sugar, the median change in wound area from baseline to week 4 was 
-10.7 cm
2
 (quartiles -28.7, -1.1). This was a statistically significantly larger improvement 
than in the standard care group -1.8 (-9.7, 0.6) cm
2
 (p=0.024). Furthermore, the median 
change in wound surface area of slough from baseline to 4 weeks was -83% (quartiles -91, -
39) in the sugar group. This was a statistically significantly larger improvement than in the 
standard care group -20 (-40, 0) % (p=0.001). This was further supported with digital 
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photographic evidence that was independently assessed and coded (see Figure  5.2). There is 
evidence of debridement on both wounds within the range of 3-12 days. 
Figure  5.2: Sugar effect (estimate %) on slough at baseline, during and end of trial 
 
Figure  5.2 C 1-C4 illustrates the effective of sugar as a debriding agent. There was evidence 
of total healing at week 4 (see Figure  5.2). 
  A – baseline (97%) slough A – follow up 3 days (10%) 




Of the TELER scores, exudate appearance showed a significantly greater improvement in 
sugar dressing patients (median 2 points) than the standard dressing group (median 1 point), 
(p=0.005). In the sugar dressing group, pain scores for the interference with daily life 
(p=0.009) and whilst sleeping (p=0.020) both showed statistically significantly greater 
improvements in the sugar dressing group (median 2 points), compared to no change in the 
median in the standard dressing group. 
Although the sugar treated group saw the largest median improvements in all three of these 
measures, there was no statistically significant difference between the two groups was 
detected in the TELER scores for wound healing (p=0.393), exudate leakage (p=0.124) or 
C2 –  4 weeks (0%) 




odour (p=0.059). All patients’ wounds treated with sugar either had complete or partial 
debridement at the end of four weeks (see Figure  5.2). It must be made clear that patients 
whose wounds were debridement stopped using sugar and were prescribed other appropriate 
wound dressing products according to local trust protocol. 
Health related quality of life HRQOL (EQ-5D) 
By the end of the study, the sugar dressing group showed a median improvement of 30 points 
compared to no change in the standard dressing group (Table 5.4 p=0.005). 
EQ-5D HRQoL domains  
For each patient, the difference between the baseline and final score was calculated for each 
EQ-5D domain and compared between the sugar and standard dressing groups. Very few 
patients showed 2 point changes from baseline final score and Kendall’s tau-b tests were used 
to make the comparisons between the groups. For simplicity, the data was summarised as the 
number of patients who had improved scores at the end of follow-up (i.e. the change was -2 
or -1), the number with worse scores (i.e. the change was +1 or +2) and the number with no 
change (see Table 5.5). 
It is important to report that, the change in mobility, self-care usual activities and 
anxiety/depression from the start of the study to the end of follow-up did not differ 
significantly between the two groups (p=1.000, 0.098, 0.060, 0.432 respectively). However, 
the responses relating to the levels of pain/discomfort did differ significantly between the 
groups (p=0.012). In the patients treated with the sugar dressing, 13 (59.1%) reported an 
improvement in symptoms, compared to only 5 (21.1%) in the standard dressing group. No 
patients in the sugar dressing group reported a worsening of pain/discomfort, compared to 2 








   
Sugar 
Dressing  
N = 22 
Standard 
Dressing 
N = 19 p-Value 
Mobility 
Improvement 3 (13.6%) 2 (10.5%) 
1.000 No Change 19 (86.4%) 17 (89.5%) 
Worsening 0 (0.0%) 0 (0.0%) 
Self-Care 
Improvement 6 (27.3%) 4 (10.5%) 
0.098 No Change 16 (72.7%) 15 (78.9%) 
Worsening 0 (0.0%) 2 (10.5%) 
Usual  
Activities 
Improvement 6 (27.3%) 2 (5.3%) 
0.060 No Change 16 (72.7%) 17 (89.5%) 
Worsening 0 (0.0%) 1 (5.3%) 
Pain/ 
Discomfort 
Improvement 15 (59.1%) 6 (21.1%) 
0.012* No Change 7 (40.9%) 13 (68.4%) 
Worsening 0 (0.0%) 2 (10.5%) 
Anxiety/ 
Depression 
Improvement 10 (45.5%) 9 (36.8%) 
0.432 No Change 12 (54.5%) 10 (52.6%) 
Worsening 0 (0.0%) 2 (10.5%) 
P-value from Kendall’s Tau-b test on 5 categories 
*Significant at p<0.05  
 
 Adverse events 5.9.
In this study, no adverse events were reported from any patients in the sugar or standard 
dressing groups.  
 Discussion 5.10.
5.10.1. Summary of findings  
In this randomised controlled trial, sugar debrided exuding necrotic, infected or sloughy 
wounds of acute or chronic aetiology within 1 week up to 4 weeks. Debridement is the 
removal of non-viable tissues from the wound bed. This according to Falanga (2001), 
EWMA (2004), Wolcott et al (2009) and Strohal et al (2013) is essential component if ever 
wound care practitioners are to achieve wound healing goals. Strohal and colleagues (2013) 
further consider debridement as a global approach with a universal goal of not only focusing 
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on debriding the wound bed but accounts for the preparation of the wound edges and peri-
wound skin. It is important to understand that chronic wounds often contain necrotic or 
sloughy tissue, which can harbour bacteria and act as a barrier to wound healing. In their 
study of wound and bacteria, White and Cutting (2008) comments that, in sloughy, necrotic 
wounds, the availability of nutrients as well as oxygen and the presence of ischaemic tissue 
make the wound bed an ideal environment for both aerobic and anaerobic bacterial 
proliferation. The same authors (White and Cutting, 2008) pointed out that, this proliferation 
of bacteria results in malodorous and infected wounds. Therefore, debridement of sloughy, 
necrotic tissue is one of the key component of good wound care practices that reduces 
bacterial burden within the wound bed (Vowden and Vowden, 1999a; Vowden and Vowden, 
1999b). The ability of granulated sugar to debride wounds observed within this study as well 
as its ability to stop bacterial proliferation Murandu et al (2011) makes this wound care 
product a potential effective method of treating sloughy, necrotic and infected wounds. 
Patients’ wound pain and odour was improved. Furthermore, there were statistically 
significant changes in pain and discomfort (p=0.012); and improvements in mobility, self-
care, usual activities and anxiety and depression which did not achieve statistical 
significance.  
Under the current focus of wound care and that of the present study (including wounds of 
mixed aetiology), sugar treatment as shown in this trial facilitated reduction in wound odour. 
Wound aetiology distribution was fairly similar (see Table  5.2), with less patients in the 
acute wound category. This finding is similar to the findings of Tophan (2000) and Chiwenga 
and colleagues (2009) who observed that patients treated with sugar had their wound odour 
reduced or removed. In Murandu and colleagues’ study of 22 patients’ odour was reported to 
have been removed within 24 hours or up to 3 days (Murandu et al., 2011). It is important to 
recognise that patients assigned to this sugar arm had already been on other forms of 
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standard/conventional methods of dressing products; and sugar treatment was used as an 
alternative to these products other than as an initial dressing, so odour was an indication of 
failed management from these standard dressing products. It is therefore apparent that effects 
observed from the sugar arm would have been that of sugar. Others may argue that it might 
have been the residual effect of the standard treatment observed, but the fairly normal 
baseline characteristics distribution and comparable wound aetiology as well as consistence 
with other previous research results demonstrates the effectiveness of the sugar treatment on 
odour management. 
In this study, the overall self-reported quality of life scores using the EQ-5D questionnaire 
were improved. There were changes in mobility, self-care usual activities and 
anxiety/depression at the end of the study. Usually in studies like these as acknowledged by 
Persoon et al (2004) which are new in clinical areas patients will at times report intolerable 
side-effects that result from receiving the treatment and at times complicate their lives too. 
Often it is thought that most patients especially elderly suffering from chronic wounds would 
rather keep quiet and not report pain (Hofman et al., 1997); therefore this result is 
encouraging. 
Of note the TELER pain indicator median score of 2(0, 2) in the patients receiving sugar 
supports the belief that patients with poorly managed pain do at times live with feelings of 
depression and QoL deficits. An improved pain control conversely affects the quality of life 
of the patients; a scenario observed in this study. Most patients with wounds, be it acute or 
chronic, do suffer from severe to moderate pain sensation. Pain can arise from different 
wound care products, such as inappropriate dressing choice, mechanical debridement of 
devitalised tissue, wound cleansing and dressing change observations highlighted by 
Richardson and Upton, (2011). Soloweij et al (2009) go on to postulate that pain and stress 
play fundamental roles in wound care whether in acute or primary care setting and such pain 
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or anticipation of pain does have detrimental effect on the physical functioning of patients. It 
causes psychological distress as well as reduced quality of life as observed in this study. 
Although this study did not set to explore in-depth reported qualitative experiences of 
patients, it was important to communicate some of the reports as they formed core findings to 
this research. The researcher concluded that, patients’ wounds, if treated with sugar improves 
the overall health related quality of life of patients. Several patients reported pain reduction as 
suggested from this quote extracted from several of anecdotal evidence reported by patients 
during clinical visits: 
The pain was unbearable, I could not sleep, and all I could do was glare at the ulcer 
and rub my leg, hoping that the pain would go away. I took strong painkillers; 
tramadol, morphine but they had no effect. I would doze a bit but afterwards I would 
wake up in agony. A few days of using sugar brought relief. I could sleep and the pain 
was less and was able to manage the pain with only paracetamol. (Quote from patient 
No. 38) 
 
The use of TELER indicator scoring assessments of wound during every dressing change 
including weekly evaluations enabled a more rigorous approach to understanding patients’ 
pain in contrast to that reported by earlier researchers (Toba et al., 1999; Mphande et al., 
2007; Biswas et al., 2010). These previous studies did not explicitly monitor vigorously the 
pain in relation to sugar treatment but just commented on pain in general a point reported in 
the QoL review by Persoon and colleagues (2004) that nurses’ did not monitor and manage 
patients’ pain appropriately. Mphande and colleagues (2007) asserted that patients in their 
sugar group reported more pain than those in the honey arm a result contrary to our findings 
or other findings. Of note is the insufficient information of baseline pain scores recorded in 
Mphande and colleagues (2007) study that makes it difficult for readers to establish and 
conclude the pain score differences. Contrary to Mphande and colleagues’ findings is the 
study by Jull et al (2008) who noticed that patients treated with honey reported increased pain 
sensation. These findings concur with the earlier findings by Dunford and Hanano (2004) 
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who reported relieved symptoms on patients receiving sugar treatment. Arguably in Mphande 
and colleagues’ (2007) study the base-line pain score was not similar as mentioned earlier 
and there were discrepancies on their conclusions of the pain difference in the two arms to 
suggest that this was the true effect of sugar or honey. In hindsight Molan and Betts (2004) 
attributed honey pain to its acidity and production of hydrogen peroxide a reaction not 
experienced in sugar treatment. With this explanation, it can be argued that patients treated 
with honey may tend to suffer more pain than those treated with sugar conclusions made in 
this study. 
An earlier study by Roe and colleagues (1993) had found out that 55% of nurses did not 
report patients ‘pain experiences as part of their assessment Four years later there was still no 
change as, Hofman and colleagues (1997) reported that pain was not adequately reported 
during assessment by nurses or medical teams even though pain is viewed as one of the most 
debilitating symptom of wound sufferers. It was acknowledged in this sugar study that pain 
needed special attention if it was seen as part of the domain in wound care. It is was also 
important to assess pain adequately because dressing changes were carried out every 2-3 days 
and if pain is not fully understood and managed appropriately then patients will suffer 
unnecessarily. 
It is essential in this regard to note that in addition to the more frequent changing of 
dressings, the participants had an opportunity to discuss their wound progress with the nurse 
attending to their wound dressing. Unlike having to wait for either 2 or 3 days for a dressing 
change sugar treatment allowed dressing changes to be more frequent depending on the 
wound exudate. The patients had better opportunity to meet the nurse and discuss their 
wound progress. This is an important factor if patient concordance with adjuvant care is to be 
achieved. It must be added that an individual patient centred wound care management is 
paramount, as it plays a major role in each aspect of patient including that of good nutritional 
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intake. Providing a patient centred approach to care will cultivate concordance with adjuvant 
treatment including that of nutrition, this inversely increases the chances of improved healing 
rates (Dealey, 2005). 
This sugar trial was also associated with good treatment adherence as well as easy dressing 
changes. The therapy was relatively painless to most patients. Dressings were changed easily 
because sugar is a water soluble substance and does not adhere to wounds. Dressings were 
easily removed by soaking in tap water or moistening with normal saline. Sometimes 
secondary dressing would easily be removed by cutting off the bandages. Additionally, 
sugar’s hygroscopic effect helps reduce oedema in wounds (Yedkin et al 1971), thereby 
minimising inflammation and pain, allowing easy removal during dressing change. On very 
few occasions 2 patients complained of mild pain due to the granularity of sugar on initial 
application, however subsequently they found the dressing changes to be non-painful and 
soothing, a scenario reported by Chiwenga and colleagues (2009). Analgesics requirements 
were therefore minimal even to those who had been requiring opiates regularly prior to 
entering into the study.  
It must be pointed out that not all the EQ-5D domains were statistically significant. The 
change in mobility, self-care and usual activities and anxiety/depression from before and after 
the study was not statistically significant as previously reported. There are two possible 
explanations; firstly, Brooks et al (2003) recommended the use of EQ-5D tool when 
incorporating economic evaluations into the trial, and the limited information on the 
utilisation of this instrument into leg ulcers, given that most of our wounds were leg ulcers. 
Probably the use of Price and Harding (2004) Cardiff Wound Impact Questionnaire, Short 
Form 36, generic and wound specific would have yielded a more specific result or the use of 
Palfreyman (2008) Sheffield tool, Ulcer 5-D, venous and healed Euro QoL SF-6 Generic and 
Ulcer specific. However, the reported information does point to the fact that granulated sugar 
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dressing has a potential to improve the quality of life. The second explanation can be that of 
Schrag et al (2000) and Marra and colleagues (2005) whose trials concluded that the EQ-5D 
needed a longer period of more than 12 weeks to be responsive to changes. 
This was further supported by Jull and colleagues (2008) who surmised that the EQ-5D was 
not responsive to short-term changes. However, Iglesias and colleagues (2009) found the tool 
to be effective over three months (shorter-term) supporting the results of this sugar study. In 
addition, Persoon et al’s (2004) review identified four themes related to quality of life on 
wounds or leg ulcers; these are pain, impaired mobility, sleep disturbances and problems 
related to wound characteristics such as odour and wound discharge. Soon and Action (2006) 
and Soloweij et al (2010) pointed out that there is a link between pain and the development of 
stress and if wound pain is well managed a large proportion of stress may disappear. 
Importantly, the use of the TELER indicator system allowed the clinicians to change or adjust 
analgesics in order to combat pain. Therefore the patient’s quality of life must be seen as 
directly related to the comfort and experience of pain or no pain; or wound discharge leakage 
or persistent wound odour. 
5.10.2. Strengths of the study 
To date this is the first randomised controlled trial of sugar dressing that used a specifically 
calculated sugar dose for different wound categories. Sugar doses varied from 15g up to 90g 
in divided doses of 30g in each aliquot. This helped indicate specific doses of sugar required 
for different wound categories as well monitoring the amount of sugar administered to each 
patient wound. It would have been problematic to monitor the sugar dose had patients’ 
wounds not been categorised prior to commencing the study. Thus, patients’ wounds were 
stratified according to wound aetiology and size a method not previously reported. This 
stratification assisted with balancing the baseline characteristics and aided minimisation of 
confounding prognostic indicators amongst the researched sample. 
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Allocation was concealed up to the point of randomisation by using an out of research sites 
central telephone service. Furthermore this trial included a multicentre approach and this was 
not mentioned in any of the reviewed literature. However, the participants were not equally 
distributed from the three centres. Most patients (n=32) were recruited from the leading site 
see Table  5.3. In addition an independent assessor (A Tissue viability nurse specialist) 
autonomously and randomly reviewed the digital wound photographs from each arm and 
reported on their percentage of slough see Figure  5.2 and   
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Appendix 15: . The tissue viability findings were compared to those reported by the nurses on 
the TELER indicator score assessment form Appendix 8. The findings were in agreement 
with the nurses’ entries on the case report forms. This may have been enhanced by the fact 
that, the nurses decision to record debridement or not debridement that were disputed 
amongst themselves were reviewed by the clinical team during ward rounds as previously 
explained. The outcome was 95-99% slough reduction with visible granulation tissue within 
3-12 days of sugar treatment. This is possibly the first RCT to have managed to have reported 
this form of comparative independent wound assessment. All the RCT literature reviewed did 
not mention this type of independent comparative assessment. Therefore it can be argued that 
in terms of assessor bias, the trial employed an appropriate method that reduced researcher 
bias related to outcome assessments and increased the reliability of the results.  Intention to 
treat analysis was undertaken with the inclusion of all participants randomized, and follow-up 
was virtually complete with only one (n=1) participant lost. 
5.10.3. Limitations/weaknesses of the study 
This study like any other research study had limitations and weaknesses. Firstly, the trial 
recruited fewer participants than anticipated, 41 patients instead of the powered 108. Despite 
increasing the sites and extending the recruitment period the study failed to meet the targeted 
sample size. It did not recruit enough participants to retain 90 percent power, although the 
anticipated loss to follow-up did not occur. Secondly, funding limitations precluded longer 
follow-up. It meant no research nurses were employed to help with data collection. Most data 
collection and dressing changes were carried out by the research coordinator, a task that 
limited the recruitment process. Although there was minimal support from the ward and 
community nurses on data collection and dressing changes, it was not enough to enable 
constant flow of participants into the study. In addition, some potential participants were not 
approached and considered for the study due to clinical staff scepticism. At times the clinical 
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staff only considered the patients when they found it difficult to manage with standard 
treatment; a process that led to missed recruitment opportunities.  
The two arms were balanced at baseline this allowed consistency between study groups. 
However, there was very little difference in wound aetiology and size from the two categories 
acute or chronic. Therefore, it was impossible due to the small sample size to analyse the data 
in four strata as initially proposed. The analysis was therefore done after combining each arm 
according to one size (Medium – large) and aetiology strands. 
It was the intention of this study to compare differences after adjustment for baseline 
(ANOVA) and not to just compare differences from baseline to follow up (Huck and Cormer, 
1996; Scott and Mazhindu, 2007; and Brysbaert, 2011). The researcher was aware that 
measurements that are most extreme (farthest from the mean) at the start of the study will 
always seem to improve more because everything which is an extreme values tends to be 
closer to the mean with repeated measurements i.e. regression to the mean. However, the 
limited funds and subsequently the nursing staff to carry out the frequent assessments as 
previously envisaged meant the above was not possible. Additionally, the data were not 
normally distributed due to the skew (wound area/slough/exudate) or discreteness (Likert 
scales), so the data did not meet the assumptions of ANOVA. If this assumption of ANOVA 
was to be carried out it would have resulted in an unreliable model. In addition, since the 
patients were randomised, it was expected that participants were reasonably well matched at 
baseline as mentioned earlier. Therefore, the testing was done using comparisons of the 
baseline levels of the outcomes between the two groups, none of which found any significant 
differences. As for the regression to the mean, since the groups were matched at baseline, this 
was expected to occur equally in the two treatment groups. Therefore it was not expected to 
bias the comparison between groups.  
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This combination could have not by any means influenced the outcome of the results in 
favour of the intervention arm as the baseline characteristics were comparable. An 
independent assessor was employed to minimise the possibility of bias on reporting the 
percentage of wound slough a plausible process, however human subjectivity on 
measurements and judgement cannot completely be discounted. This study was not blinded – 
that is also a weakness 
 
 Risk of Type 11 error 5.11.
There is a potential for type 11 error in the repeated unadjusted analysis for a similar size, e.g. 
reduction with a small sample size of 42. However, this is unlikely to be the case, as the alpha 
was set to a significance level of 0.05 prior to commencing the study. Furthermore, Re Loux 
(1995) reckons a change in TELER indicator points denotes a clinically significant level 
either positively or negatively. Therefore, the change observed on the TELER indicators is 
considered clinically significant, rejecting the possibility of type 11 error mistakes. The 
change in the method of analysis following the low recruitment rate could be a source of type 
11 error. To overcome this problem a repeated power calculation was undertaken (see chapter 
five results section). 
 
 Comparison to existing literature 5.12.
Importantly, the results from this randomised study for sugar treatment are consistent with the 
findings from the previous RCTs (Dawson, 1996; Toba et al., 1997; Mphande et al., 2007; 
Bajaj et al., 2009 and Ruhullah et al 2013) and observational studies (Chirife et al., 1982 and 
1983; De Feo et al., 2000; De Feo et al., 2003; Chiwenga et al., 2009) that concluded that 
sugar treatment was effective for wound cleansing and promotion of granulation tissue. In 
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another non comparative observational study undertaken in Italy by De Feo and colleagues 
(2000) and De Feo et al (2003) granulated sugar was observed to be effective in debriding 
post open heart surgery with mediastinitis. All patients survived the treatment and their 
wounds were reported to have been sterile after 11.22+/- 1.6 days of receiving the sugar 
treatment. They further reported that within 4.3 +/- 1.3 days temperature had normalised. 
From this study as well as other previous studies reported earlier, there is potential for sugar 
becoming a wound care dressing product. But it must clearly be pointed out that sugar in 
itself does not affect healing but creates a wound bed environment appropriate for wound 
healing.  A moist environment also helps with easy removal of dressings during dressing 
change. Persoon and colleagues (2004) concluded that factors influencing QoL were not 
clearly distinguished and advised of further research in the area of QoL related to patients 
suffering from wounds or ulcers.  
In this study, patients treated with sugar reported greater improvement in wound malodour 
and exudate leakage than those treated with standard dressings see Table 5.5. Walshe, (1995) 
and Hyde et al. (1999) believe leakage and odour are at times accepted as a sign of having 
wounds or ulcers. But these signs and symptoms can lead to embarrassment and difficulties 
in maintaining dignity and outward appearance. In this sugar trial clinicians observed that 
wound malodour can affect patients both socially and psychologically and this was also 
reported by Benbow (1999). In other reports assert that noxious odour is sometimes 
misinterpreted as poor hygiene leading patients to feel embarrassed (Van-Toller, 1995; 
Haughton and Young, 1995; Hack, 2003). The odour at times is constant stimulating nausea 
and vomiting that will eventually lead to lack of appetite and poor wound healing (Flanagan, 
1997; Benbow, 1999). It is understood that chronic and infected wounds particularly venous 
leg ulcers, diabetic foot ulcers, pressure ulcers and fungating malignant lesions are the most 
common wounds associated with malodour (Lee et al., 2006) a trend observed in this study. 
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The later can be a justification for the difference in health related quality of life in favour of 
sugar. It can be argued that, the presence of infected or non-infected necrotic tissue within a 
wound bed acts as a focus for infection, encouraging multiplication of anaerobic bacteria, 
which causes wound malodour (O’Brien, 2002), in return this can be a burden to patients and 
relatives and clinical staff who have to live and interact with such odorous wounds. 
Therefore, removal of malodour and necrotic tissue can be a relieving factor to patients and 
their quality of life. The study findings supported Armstrong, et al. (2002); Sherman et al., 
(2002) and O’Brien (2002) who believed that, removing devitalised tissue from the wound 
surface is an important factor if healing is to be achieved and can encourage patient 
concordance to the treatment given. In this study, clinical observations showed patients 
whose wounds were no-longer odorous had their appetite improved. They were also more 
receptive of visitors than previously observed.  
This can be asserted by one reported case in the sugar arm that of a patient who had suffered 
from bilateral leg ulcers for several years and stated: 
My wounds smelt that my daughter’s dogs tended to smell my legs every time I and 
my wife were dog sitting. It was such an embarrassment that I did not want to look 
after the dogs whenever they went away. I was so embarrassed that I did not go out on 
family meals or visiting friends. 
 
After one day of sugar treatment the wounds were odourless:  
I noticed that the first thing the dogs did when my daughter visited was to jump on my 
chest, they did not smell my legs; it was such a relief. (Patient No. 37) 
 
These comments highlighted that odorous wounds can lead patients into isolation a factor 
reported in (2002) by Holloway and colleagues. Further reports by Bale et al. (2004) 
acknowledged that malodorous wounds does pause social isolation, depression, shame, 
embarrassment and poor appetite, resulting in a negative impact on QOL. It is without doubt 
that odorous wounds are a burden that can affect patients’ QOL and that if this symptom is 
eradicated patients can have an improved quality of life. 
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Following the improvement in mobility, pain, sleep patterns and removal of malodour, 
appetite was reported to have improved too. The improvement in appetite can be seen as a 
positive effect towards wound healing and recovery; especially that many patients with 
chronic wounds are elderly and susceptible to malnutrition. 
Overall, this study recognised that patients with wounds of either acute or chronic have 
significant poor quality of life (QoL) affecting their ability to mobilise, and disturbing their 
sleep. The study employed the TELER indicator system to enable an understanding of the 
pain associated to specific pain domains such as sleep, mobility and wound dressing. In that 
way pain was reported according to each domain and the clinician was able to quantify and 
understand how pain was affecting each patient’s quality of life. The treating clinician was 
then able to prescribe an appropriate plan of care and monitor accurately the pain progress 
and patient’s QoL. It was also valuable to observe the treatment effect of sugar on an 
individual patient rather than as a group as patient experiences of pain sensations are 
different. This method of assessment (TELER) supported by the use of EQ-5D questionnaire 
enabled clear understanding of the effect on the intervention on each individual treatment 
arm. The mobility was improved (see table 4) this can arguably be seen as the effect of sugar 
since sugar reduces oedema, cleanses wounds of microorganism and dead tissues lessening 
pain and malodour. The clean wound with visible granulating tissues allows wound 
epithelialisation and wound healing a positive process towards wound healing. In support, 
Strohal et al (2013) sees debridement (removal of devitalised tissue) as an integrated part of 
the wound management plan that focuses on patients’ attending to the wound with the aim of 
creating a healthy wound bed as well as healthy wound edges and peri-wound skin. In this 
positive framework, patients will show signs of improved mobility; less frustrations and 
improved self-esteem which are a positive a factor in wound healing. Strohal and colleagues 
(2013) further disputes Gethin and colleagues’ (2010) view of debridement as a wound bed 
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preparation. Strohal and colleagues argued that debridement is a universal wound bed 
preparation that accounts not only wound bed but wound edges as well as the peri-wound 
skin (Strohal et al 2013). They further posit that if this global approach is successful clinical 
benefits such as wound healing and improved quality of life can be achieved a scenario 
experienced in this study. Patients on the sugar treatment had several clinical benefits such as 
pain reduction, odour removal, reduction in wound leakage. These clinical attributes are 
associated with increased quality of life in wound care. 
 
 Conclusions / Research & Policy implications 5.13.
The data from this RCT though small in sampled patient numbers showed that granulated 
sugar applied topically is an effective debriding agent and well tolerated treatment option in 
patients with exuding necrotic or sloughy wounds. The wounds rapidly debrided, with normal 
granulation formation observed. This treatment effect may be the result of impetuous removal 
of microorganisms colonising the wound. Because the wounds were rapidly removed of 
slough which usually harbour bacterial contamination they became clean, enabling new tissue 
development an experience reported in earlier studies (Knutson et al., 1981; Tophan, 2000, 
Mphande et al., 2007 and Chiwenga et al., 2009). The effectiveness of sugar depends upon its 
antimicrobial high osmolar effect. Experiments performed both previously at Delta Medical 
Centre concluded that sugar is effective inhibiting growth of both gram-positive and negative 
bacteria (Kunutson et al., 1981) and currently as described in chapter two of this work; sugar 
inhibits microbial proliferation at a solution of 25% sugar concentration (Murandu et al., 
2011). Similarly, sugar works in the same way when applied topically on wounds surfaces 
competing with microorganisms for water causing osmotic shock to bacterial survival 
(Chirife et al., 1983). As a result of these factors there is decreased bacterial colonisation as 
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bacterial eradication increases from the wound. Of note, sugar dressing is a moist absorbing 
wound care dressing that does not have any specific indications therefore it can be used to 
treat either acute or chronic wounds of various aetiologies. Therefore, on this aspect the 
results should be considered as generalizable to various wounds regardless of their clinical 
aetiology until further evidence suggests otherwise. Similarly, the results should be 
considered as applying to both sugar of cane and beet origin.  
The dose (carefully measured quantity) of sugar in this present study merit comment, in 
particular the dose in different wound categories. The study also explored the securing 
mechanism of each type of wound and identified the practical mechanisms that are possibly 
appropriate to each given wound with a reproducible protocol.  
It is important in this regard to keep in mind that in addition to the randomisation and 
allocation concealment nature of the study, the current sugar trial had several important 
additional design features that may have contributed to the positive observed outcome. The 
protocol required daily or alternate dressing change, with daily wound assessments as well as 
weekly evaluation starting from week 1 ending at week 4 of the study. This also included 
washing of wound and surrounding area with tap lukewarm water. Thus, the particular 
attention on wound washing/thorough cleaning within this study provided a situation rather 
different from what can often be achieved in clinical practice and may have significantly 
contributed to the acceptability of the study in both arms.  
It is important that future studies allow sufficient time to provide training on the dressing 
technique on both intervention and control even if nurses were already trained and were 
competent. This will minimise the one sided enthusiasm of nurses and patients. If this is 
effected nurses will feel motivated to undertake dressing changes for both intervention and 
control probably avoiding the Hawthorne effect.  
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This study as well as the previous RCTs lacked sufficient powering a factor that needs to be 
affected in future planned sugar studies. There is also need to include clinical trials units to 
enabled planning of more effective statistical test that will be factored into the study.  
 
 Ethics and good clinical practice 5.14.
Following the feasibility study it was principle that further ethical approval of the RCT was 
attained. Therefore, all necessary permission was obtained from North Birmingham and 
Solihull Local Research and Ethics Committee as well as permission from the three Trusts’ 
Research and Development Departments. The researcher had honorary contracts with all 
designated trusts. MHRA permissions previously discussed in chapter 4 applied to this study 
as this was a continuation of the same work. Participation was entirely voluntary, and patient 
care was not affected in any way by their decision to participate or not to participate. Patients 
were explained of the study and given an information leaflet to read over-night at their own 
time. Having read the information and those who were happy to partake into the study were 
requested to sign a full written informed consent form that was counter-signed by the 
admitting nurse or researcher prior to joining the study. The trusts had robust and effective 
interpretation services that the researchers were to use if there was language barrier. All 
patients understood English and the use of interpreting services were not needed.  
The following chapter will summary up the processes and stages of this thesis. Challenges 
will be identified and explored. The researcher will conclude with lessons learnt and 




6. Chapter: Overall discussion and conclusion 
 Introduction 6.1.
The overall aim of this work has been to explore whether that it is possible to use sugar as a 
dressing in a modern NHS hospital and explore its potential as an effective debridement 
agent. The purpose of this chapter is to summarise both the outcomes and the challenges that 
have arisen during the course of the work. 
 
 Preparing sugar as a dressing \and MHRA issues 6.2.
6.2.1. Sugar the origin and its development into a wound care product. 
Sugar is known to have been used in the treatment of infected wounds (Herszage et al., 
1980). It is believed to be easy and painless to apply (Tanner, 1998). But there is a need to 
explore how sugar sterility can be maintained from the manufacturer to the consumer. During 
production sugar has gone through a highly tested process that involving burning the 
cane/beet with high furnace temperatures where microorganisms will not survive. It is then 
processed to produce the white crystal anhydrous disaccharide 99.9% material sugar (glucose 
and fructose). A certificate of conformity is produced (see Appendix 5) for each 25kg bag of 
sugar. Serial numbers are printed on the bags and they fall into different categories depending 
on the date and year of manufacturing.  
The sugar is purchased from the manufacturer and delivered to a recognised pharmaceutical 
production centre for re-packaging of the 25kg bag of sugar into small 30g aliquots with 
serial numbers, each with a certificate of conformity. This will allow easy follow up if there 
are any adverse effects that require tracing back to the manufacturer. The 30g aliquots are 
distributed to the different hospitals. The sugar is now ready to be used on wounds and can be 
monitored for its effects and side-effects.  
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6.2.2. Medicine and Health Regulatory Authority issues –  
The study in chapter 2 highlighted the effectiveness of sugar on microorganisms and 
its potential for use on treating sloughy, necrotic and infected exuding wounds. 
Having established the microbial effect an application was made to the Medicine and 
Health Regulatory Authority (MHRA) for the sucrose to be tested as a dressing 
product. At first the MHRA classified sugar (sucrose) when used on wounds as a 
dressing of medicinal product. This affected categorisation of the sugar feasibility 
study as a clinical trial of a medicinal product (CTMP) that requires a fee to register. 
This was negotiated by the researcher. The researcher explained to the MHRA, that 
the research was not for commercial and profit generation but for patient benefit, 
financed privately by the researcher. After negotiation the MHRA categorised the 
study as clinical trial of non-medicinal product. Having been granted MHRA 
permission, applications were made to the local Research Ethics Committee and the 
NHS hospital trust Research and Development committee for their approval. The two 
committees both granted authorisation and the small feasibility study commenced in 
2009. 
 
 Potential for use on infected wounds 6.3.
6.3.1. Laboratory studies and the rationale for frequency of dressing changes 
By definition sugar is not an antibiotic. According to Oxford dictionary for nurses (2003) 
supported by Simonsen et al (2006) an antibiotic is a substance produced by or derived from 
a microorganism that destroys or inhibits the growth of other microorganisms. In order to 
understand the possibility of the effects of sugar on microorganisms’ laboratory tests were 
carried out to identify the susceptibility of microorganisms to different types of sugars and 
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help with the planning phase of “the feasibility study” (chapter 4). It was important to 
establish how the sugar affected microorganism in order to decide on whether to use the 
sugar as a wound care product, if and also determine the frequency of application. Previous 
laboratory explorations of sucrose (Chirife et al., 1983) established that sugar prevented 
microorganism proliferating but did not identify how specific types of sugars affected various 
microbiological species. The current laboratory examination explored these areas and 
concluded that both refined and un-refined sucrose affected microorganisms’ ability to 
proliferate. The un-refined (Demerara/brown) sugar required a solution of slightly higher 
concentration than that of white sugar. Overall, sucrose prevented microbial proliferation by 
osmolality; the higher the sucrose osmolality the more effective the sucrose was in preventing 
the growth. The researcher became aware that if the level of high osmolality of sucrose is 
achieved, then sucrose would probably act as a local universal antimicrobial agent that can 
affect healing process positively. This formed the basis of planning the frequency of dressing 
changes because it highlighted that dressing changes needed to be frequented to enable 
retention of high sucrose content on the wound bed. It was agreed that dressings changes 
were to be undertaken daily or every other day, depending on the level of exudate for each 
given wound. It also agreed that treatment was to be individualised to cater for wound 
aetiology and size. 
 
 Infected wounds  6.4.
It is generally agreed that sugar is effective in inhibiting microbial proliferation (Knutson et 
al., 1981; Chirife et al., 1983; Trouillet et al., 1985; Toba et al., 1997; Mphande et al., 2007; 
Chiwenga et al., 2009; Murandu et al., 2011; Ruhulla et al., 2013); this is supported by this 
current work.  
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The sugar effect can possibly be explained in the context of hyper tonicity environment 
created on the wound-bed (see Figure 6.1) when sugar is applied on the wound. It manifests 
as suggested by Chang (2006) osmotic pressure phenomenon; that body fluid as well as water 
from bacterial cytoplasm is drawn into sugar granules. As a result the sugar granules liquefy 
thereby creating hypotonic area within the wound-bed. In response the heart increases, the 
blood flow to the wound-bed to create an equilibrium isotonic wound-bed environment. This 
process will possibly allow an increased flow of blood with it oxygen, nutrients and 



















Clearly, the antimicrobial activity in sugar dressing that prevents and treats infections is 
fundamental to its wound healing properties (osmotic shock or osmotic vacuum). The 
emerging evidence points to a more diverse role (Tophan, 2000; Knutson et al., 1981; DeFeo 
2000; De Feo et al., 2003) including debridement. Observed therapeutic effects attributed to 
using sugar include rapid healing ( Mphande et al., 2007; De Feo 2003; Ruhullah et al., 
2013), stimulation of the healing process (Murandu et al., 2011) clearance of infection (De 
Feo et al., 2003; Murandu et al., 2011). Wound healing is a complex dynamic process that 
involves several systems and cell types. Molecular and cellular components are responsible 
for the degradation and repair of tissue that occur during healing (Cooper, 2001). While the 
exact mechanisms for all the observed effects of sugar when applied to wounds are yet to be 
defined, the earlier explored in vitro studies (chapter 2) supported by Chirife and colleagues 
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(1983) point to water activity (Aw). Table 6.1 provides a summary of possible properties of 
sugar as observed from this study and reviewed literature. As a medical treatment, sugar is 
innocuous. Other than occasional stinging when applied to wounds no adverse effects have 
been reported. In addition, allergy to sugar is rare.  
 
 Protocol for the use of sugar 6.5.
6.5.1. Treatment protocol and use of sugar in the NHS hospital 
One of the weaknesses of previously reviewed sugar studies was the lack of clear guidelines 
on how to apply and the frequency of application of the sugar on wounds. The sugar wound 
dressing protocol. It became obvious that there was a need to develop a clear and publishable 
sugar protocol.  
Applying sugar treatment to leg ulcers, and other complex superficial wounds, such as toe 
and below knee amputees without cavities can be challenging. A special technique to enable 
retention of sugar on the wound was developed. In RCT study 29 (70%) patients’ leg ulcers 
and 8 (20%) patients toe and below and above knee amputees were involved and these 
wounds required special sugar application such as; the surrounding skin area of the wound 
was ridged with yellow paraffin to allow stability and retention of sugar. In other cases 
yellow paraffin was applied on the gauze and sugar was damp dusted over the Vaseline until 
completely covered in a thick layer. The gauze and the sugar were gently lifted and placed 
onto the wound, slowly covering the whole wound with sugar, before securing with an 
absorbent wound dressing pad. The cavity wounds were easier to apply the sugar as opposed 
to those of superficial wounds. It can be argued that superficial wounds may at times have 
failed to retain enough sugar as opposed to cavity wounds a scenario that could have been 
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viewed as advantaging the cavity wounds. This factor needs consideration when planning 
further sugar studies. 
The follow-up time frame chosen (4 weeks) might have been limited for monitoring wound 
debridement, but given the previous studies (Trouillet et al., 1985; De Feo et al 2003; 
Mphande et al., 2007; Murandu et al., 2011), it was within an acceptable time period to 
enable evaluation of effects of granulated sugar on wound debridement. There are reported 
evidences that if the wound is completely debrided (wound bed preparation) that wound will 
progress to healing (Falanga, 2000; O’Brien, 2003). In the feasibility study (Murandu et al., 
2011) concluded that, sugar debrided wounds within a minimum period of 5-14 days 
supporting previously reported findings of Dawson, (1996), De Feo, (2000), and De Feo, 
(2003). 
Previous studies (Debure et al., 1987; Beading, 1997) had both reported that diabetic patients 
who had been treated with sugar had slightly raised blood sugars. However, these studies did 
not contradict the use of sugar on diabetic patients. Although the knowledge of treating 
wounds has been cascaded from generation to generation, there are no clear guidelines set on 
the effects on blood sugar levels and how to manage this side-effect if ever it was to be 
reported. The feasibility trial results did not report any increased blood sugar level in any of 
the treated diabetic patients. It must be added that none of these patients required 
supplementing insulin above the prescribed dosage, or changing the route of treatment from 
oral tablets to insulin injections. This effect supported the conclusion of Yudkin and 
colleagues (1971) that sugar to be absorbed requires enzyme sucrase situated in the brush 
border of the small intestine. These facts were crucial in persuading the clinical staff to 
support the sugar study. It must be added that, during the RCT running, there were diabetic 
patients who were treated with sugar, though not specifically monitored as part of the study; 
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they kept checking their blood sugar levels and did not report any increase in their blood 
sugar level.  
 
 Challenge of staff scepticism to sugar 6.6.
6.6.1. Attitudes to use of sugar 
The initial thought of using sugar was received with scepticism and doubts from different 
clinical staff. Initially, vascular consultants from different NHS trusts were approached and 
declined to work with the researcher. Some cited difficulties in obtaining ethical approval and 
others just felt sugar would cause more harm than good. Following discussions between the 
supervisory team and the researcher, the lead supervisor helped to secure the cooperation of a 
vascular consultant surgeon who had previously worked in Kenya and seen sugar being used 
in wound care. A meeting and presentation to the vascular medical team was arranged, 
questions were raised and answered accordingly. After the meeting, most of the medical staff 
agreed to support the study. Many clinicians felt sugar would encourage proliferation of 
microorganisms on the wound bed, a scenario they were not prepared to risk. The researcher 
used the in vitro study results as evidence of the potential for sugar as a wound care product. 
This information helped to convince the doctors to support the feasibility and the RCT 
studies. 
An additional question and answer meeting was arranged between the senior nurses, 
researcher and the supervisor to discuss the study. Although the senior nurses were sceptical 
at the start of the meeting they agreed to support the study. A further meeting, including all 
nurses and the lead PhD research supervisor, led to a provisional date being arranged for 
commencing the study. During these meetings several questions were asked and the 
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researcher explained to the best of the available evidence. The questions helped in the 
formulation and designing of the research methodology. 
Following the results of the feasibility study, an interest arose from two top surgeons of the 
British military medical team. The interest resulted in several strategic meetings organised 
between the researcher and the military medical team. The researcher presented the work 
with the support of the lead supervisor. Several questions were asked and answered to the 
best knowledge available at the time. After the meeting it was agreed that the military would 
like to be involved. This meant amending the protocol and seeking further permission from 
the Local Research Ethics Committee (LREC) and the Ministry of Defence Research Ethics 
Committee (MODREC). This was pursued by the researcher and the lead supervisor and 
permission was granted by the LREC (see Appendix 1). The researcher and the lead 
supervisor were invited to present the protocol and the planned RCT study at the MODREC 
meeting. The MODREC, agreed that there was a potential, but wanted the researcher to 
undertake a systematic review and meta-analysis in order for the committee members to 
assess whether it will benefit the injured soldiers. One particular comment from one of the 
ministry of defence chiefs to his colleagues was, “imagine if the public was to hear that the 
military is using sugar to treat our injured soldiers? It will make newspaper headlines”. The 
researcher did not have much time and resources to follow up on the MODREC request, 
however it is still the wish of the researcher to explore this effect as most soldiers die or loose 
limbs due to infection. If sugar can be of use to the injured soldiers, it is worth researching. 
May be the simplicity of the method makes many people doubt or overlook its potential. The 
researcher hopes that, in the future with research grants available and involvement of lead 
researchers into wound care, clinical trials team, microbiologists and infection control nurses, 




 Challenge of world-wide interest before study completed 6.7.
6.7.1. World-wide media interest 
During the trial running there were visible and commendable results. Some of the patients 




Appendix 16). This media interest continued throughout the whole research period up to the 
present date. The researcher appeared on the BBC West Midlands six o’clock news as well as 
the BBC One Show. In Zimbabwe several newspapers reported on the study, as well as other 
countries like Canada, Russia, and Greece. Enquiries were made on a regular basis that led to 
more newspaper publications Pouring granulated sugar on wounds 'can heal them faster than 
antibiotics' The Daily Mail 15th February 2013. 




Appendix 16). The amount of enquiries is a reminder that people suffering from non-healing 
wounds are looking for every opportunity to find a cure. The wide geographical enquiries 
also suggest that non-healing wound problem is not only confined in the UK, but it is world-
wide problem that needs collaborative research in order to increase chances of finding 
research funding and be able to generalise the findings. Of positive note is the awareness of 
the sugar as a potential dressing product whereby several vascular surgeons from the UK and 
abroad are willing to engage in the sugar research. Although the world-wide media interest 
can be viewed as a positive way forward in this research area, it can be a hindrance in terms 
of recruitment. Patients were contacting the researcher, to be included into the study. What 
they really wanted was to be tried on sugar. They had been on different types of dressings and 
had failed to heal, so sugar was an alternative they wanted to be tried. Randomising would 
not have been an option to them. The dilemma to the researcher would be to balance patients 
interested in the treatment and the need to fulfil the criteria for a RCT, i.e. to randomise the 
potential patients who are to enter into the study. For treatment to be accepted there is need 
for large a RCT confirming its effectiveness. In previously published non-randomised sugar 
studies, there is a possibility that researchers felt compelled by the duty of care to provide the 
treatment (sugar treatment) that they thought was effective at the time. Patients may have 
wanted to be considered into the sugar because other treatments have failed (Herszage et al., 
1983; De Feo et al., 2003) and researcher would have considered them for sugar. This was 




 Outcome of failing to recruit desired numbers 6.8.
6.8.1. Limited sample size and recruitment issues 
The number of patients suffering from chronic wounds is at an increase and the cost of 
treating these wounds is also high (Holloway et al., 2002; Hampton, 2007; Hampton, 2009). 
If this is correct, then the number presumably reported for consideration (55 patients) is not a 
reflection of the literature statistics. It can be argued that less than potentially eligible patients 
for the study were randomised to the intervention and control. Because it is known that NHS 
spends billions of pounds treating patients affected with chronic wounds (Posnett and Franks, 
2007), there could have been more patients who were overlooked. If this is the case, then 
nurses needed more education on RCTs and the need for identification and invitation of 
potential patients to be considered for the study. 
It might be possible that nurses and doctors did not fully understand the purpose of the trial 
which conversely led to the inadequate recruitment of patients. It is most reported that non 
entry into the RCT studies is due to staff preferences (McCulloch et al., 2002; Abraham, et al 
2006; Cadwell et al., 2010), and some dislike the idea of randomisation. This can be a 
possibility and was never teased out. Another reason may be that of scepticism of the product 
by clinical staff. If staff are not familiar with a dressing product there would be difficulties of 
knowing whether patients are refusing to be in the study or it is just the clinician who was 
ignorant of the study. To combat this phenomenon, training was continued. 
Training for the use of sugar and TELER system indicators took place during the initial 
feasibility trial period and continued into the RCT study. There were series of drop in training 
sessions that allowed clinical staff to attend without prior appointment. This was to suit the 
busy activities and routines of the wards and help nurses understand the study. It was hoped 
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that this process will keep the nurses focused on the progress of the study and also help with 
identification and recruitment of potential participants. 
It would also have been advantageous to train the trainers. The researcher would have trained 
one or two nurses on each site to deliver training to other nurses on how to deliver the 
intervention. This method was not chosen for two main reasons: firstly, had one or two nurses 
been responsible for the training, it was much less likely that the intervention would have 
been the same for each individual in the study; secondly and more pragmatically, it was felt 
that using clinical nurses might have led to practical problems in finding free time that they 
would devote to the study, let alone training other nurses. Furthermore, as a senior lecturer 
and specialist nurse with high workload, the researcher was aware that utilisation of clinical 
nurses’ time in a study might not have been particularly popular with the hospital trust 
management. This had been the experience observed during the running of the feasibility 
study. 
The researcher assumed that all nurses undertaking wound dressing procedures were aware of 
the trust policy on dressing change and type. It must be added that, initially nurses were 
applying the sugar treatment with hesitancy, but with continued exposure and support from 
the researcher there were better understanding on the application and the effects of sugar. It 
will be unfounded to suggest that diminished staff morale led to under-recruitment. Most of 
the nurses trained to use sugar, wanted to apply sugar to every patient who fitted the inclusion 
criteria, throughout the study and even after the study. The researcher kept reminding the 
nurses that it was a study, not a licensed product and there was need for randomisation to all 
patients entering into the study. 
With respect to the study settings, poor recruitment may have simply been due to lack of 
information, clinical staff commitments and forgetting/overlooking to recruit, which is not 
necessarily an absolute barrier to sugar treatment in this context. There is increasingly 
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staffing issues in NHS hospitals that patient care takes precedence for the nurses. The staff 
morale is at a low level due to limited staffing levels and this could have affected staff 
morale, thereby lacking motivation. The sugar study would have been seen as an added 
burden to the already stretched staff as described earlier. In a trial like this, it is difficult to 
tease out the real problem of low recruitment, but the most likely issue is the poor funding 
received for this study. There were no dedicated research nurses for this study and this 
contributed immensely to the low recruitment levels. This would suggest that recruitment to 
RCT in sugar studies needs to be effected by more in-house education of the role of clinical 
trials on enhancing evidence based practice and providing the most reliable evidence for 
evaluating the effects of health care interventions (Sackett et al 2000; Barton, 2000), such as 
sugar. The acceptability of the sugar as a wound care product in NHS hospitals, depend upon 
successful large clinical trials. This study, like many preceding sugar trials failed to recruit 
sufficient sample sizes. This reduces the power to detect significant intervention effects 
(Swanson and Ward, 1995). This inversely affects generalizability of the study findings and 
can incur increased trial costs. Some nurses may have felt less supportive of the study 
because they did not see any incentive in participating. In this study, there was a general 
willingness to support the study however the nurses were stretched in numbers, relying on the 
researcher to randomise the patients.  
 It is worth mentioning that at times clinical staff felt the intervention was an alternative to 
the failed standard treatment and it was constantly re-emphasised that this was a trial running 
and there was need for randomisation and to abide by the protocol guidelines. Also, patients 
were made aware of the type of dressings they were having and none reported a change of the 




 Lack of cost-effectiveness data 6.9.
6.9.1. Cost-effectiveness of granulated sugar use 
This sugar study initially included cost-effectiveness analysis in the planning stage, but this 
was impossible due to financial constraints. In this study, we concluded that granulated sugar 
is a simple dressing that is cheap, costing £1.49 per dressing change, compared to charcoal 
7.5x 10cm dressing for odour reduction, £2.7 which might need an additional debriding 
agent. Other comparative is vacuum assisted closure costing £20.00 per canister £19.43 total 
£39.43 per treatment. Sugar does control odour as well as debriding the wound at a cost of 
£1.49 a reasonable saving, if the products were to be compared. However, it is not just the 
unit cost but time to debridement that needs to be considered when measuring cost-
effectiveness. Though, this can be viewed as supporting earlier studies by Knutson and 
colleagues’ (1981) conclusions that sugar is readily available and cheap (Knutson et al., 
1981; Tophan, 2002; Bajaj et al., 2009). In a more recent study by Ruhullah and colleagues 
(2013), exploring use of sugar on 25 patients suffering from pressure ulcers, similar findings 
were reported that sugar is relatively cheap and can be used without difficulties. They also 
report quicker granulation results that led to early skin graft and discharge.  
 However, this notion was based on the fact that previous researchers used ordinary sugar 
from the shops or supermarkets. In this study sugar was specifically prepared and was tested 
in a controlled environment and given a certificate of conformity with a serial number for the 
purpose of quality control. This has never been done before and the process allowed effective 
monitoring of the sugar products used on each wound. Given this process; it was observed 
that the sugar was costing extra per container than if we had to get a bag from the shop. 
Although there is an increased cost following the extra test and packaging, if this product 
were to be adopted and produced in bulk the cost per product, as compared to standard 
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treatment, can still be cheap. The £1.49 was costed using single request; it may be cheaper if 
the production is undertaken on a large scale. But it goes without saying that sugar treatment 
requires frequent dressing changes that may increase the nursing time per dressing 
management. Even though, sugar can crudely be seen to be cheaper, there is need for in-depth 
understanding of the real unit cost as well as total wound care cost including staff time and 
hospital costs. Future research must include cost-effectiveness in their bid for research grants. 
 
 Need for more research 6.10.
6.10.1. Randomised controlled trials of sugar in the UK and funding issues 
Lack of awareness of the potential of sugar treatment can be viewed as the reason why there 
are no relevant RCTs registered or published in UK. Hence, in making generalisations 
beyond the settings of this work, it is important, from an NHS perspective that such 
evaluation of relatively simple and possible cheap interventions with potential to make a 
difference to daily wound care practice takes place in UK hospitals and abroad. Surprisingly, 
there is not much funding available for research in wound care, although of late there has 
been an increase in government grants such as National Institute for Health Research for 
Patient Benefit (NIHRfPB). It is with regret that sugar research has not been fully explored of 
its potential in wound care, and this may remain the same if private/business enterprises or 
charity organisations are not involved. It is most likely that sugar research is overlooked due 
to its status as a food product and chances of development are limited. In addition, the 
difficulty in obtaining patents means that if private pharmaceuticals fund the research there 
will be enough research nurses to recruit participants increasing the chances of meeting the 
required powered sample size. However, the funding into sugar trial is up to now a problem 
as identified in this work. One problem identified is the inability to have a sufficiently 
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powered study that can convince the reviewers and funders into believing the worthiness of 
this product. The small sporadic RCT studies to date, though reporting encouraging 
outcomes, are not very convincing and lack quality and sufficient power. It is therefore 
important that future proposals for sugar research are well powered. It is hoped that this work 
and the knowledge gained undertaking this RCT can help in future designing and planning of 
high quality rigorous sugar research studies. Government grants are the best possible source 
of funding to take this work forward if there is to be any properly powered and funded RCTs. 
However it must be acknowledged that competition is fierce for limited funds. 
 
 Conclusions and researcher’s musings 6.11.
This study demonstrated that it is possible to prepare granulated sugar for single use on 
wounds. It was also feasible to use the sugar on sloughy, necrotic and infected exuding 
wounds in a modern NHS hospital. Participating nurses and doctors eventually accepted the 
treatment and now are hoping this method can be explored further so that it can be used more 
frequently. There is a sugar dressing protocol available. The protocol was used successfully 
to undertake a RCT. There was evidence of effective debridement of sloughy, necrotic and 
infected exuding wounds of various aetiologies. This rapid debridement and granulation has 
been supported by in vitro studies on animal models (Eto et al., 1989; Shi et al., 2007) and by 
Anania et al (1985). Also, the role of debridement in wound bed preparation has been well 
documented (EWMA, 2004; Wolcott et al., 2009; Falanga, 2000; Strohal et al, 2013).Patients 
felt the treatment was friendly and did not cause any extra pain when removing wound 
dressings. When a wound care product is effective it is associated with reduction in exudate, 
odour and the appearance of granulation tissue in the wound (Vowden and Vowden, 2011). 
Moreover, the formation of granulation tissue can only take place in a moist wound 
environment (Winter, 1962; Winter, 1965). This effect was observed during the 4 week trial 
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of this study. Figure 2.2 illustrates observed sugar effects during this current study as well as 
of those already reported (Pieper and Caliri, 2003; Mphande et al., 2007; Murandu et al., 
2011; Ruhullah et al., 2013). 
Although the results were plausible, the sample size of 41 subjects was small. There is a need 
to conduct a fully funded and well powered study in the future. The methodology used in this 
sugar study is reproducible in practically every practice in the country and internationally and 
utilises skills already held by trained and semi-trained nurses in both acute and primary care 





Table 6.1: Summary of findings observed from this current work and reported by previous researchers possible wound healing capabilities of 
sugar 
Property  Anticipated Clinical Outcomes Suspected Mode of Action 
Antimicrobial 
activity  
Sterilization of wound 
Inhibition of potential wound 
pathogens that destroy tissues 
Deodorization of malodorous 
wounds 
Protective barrier to prevent cross-
contamination 
Increased self esteem 
Improved social interactions 
Acidity 
Action of non-peroxide components (phytochemicals) 
Stimulation of immune system multiplication of β-lymphocytes and T-lymphocytes; 
activation of neutrophils; release of cytokines by monocytes; supply of glucose for 
“respiratory burst” and for energy production in macrophages 
Glucose metabolism by the infecting bacteria to lactic acid instead of metabolism of 
amino acids from serum and dead cells to malodorous ammonia, amines and sulphur 
compounds 
High viscosity (when sugar dissolves when in contact with body fluids) creates physical 




Resolution of oedema and 
exudates 
Reduction of pain 
Reduction in keloids and scarring 
Increased limb mobility 
Less sleep disturbance 
High osmolality leading to fluid outflow to create layer of dilute solution of sucrose in 
plasma or lymph, resulting in moist conditions necessary for healing and no adhesion to 
the skin surface of the wound 
Decrease in leucocytes associated with inflammation 
Inhibition of reactive oxygen intermediates (ROI) production as a result of antioxidant 
activity 





Increased autolytic debridement 
Increased angiogenesis 
Promotion of granulation tissue 
Cell proliferation 
Collagen synthesis 
Stimulatory effects of glycosylated sucrose protein or other components on 
macrophages 
Clearing of debris with moist dressing 
Increased nutrification of tissue secondary to the outflow of lymph and the liquification 
of sucrose 
Increased oxygen supply secondary to the outflow of lymph and the acidity of sucrose 
Controlled low hydrogen peroxide production with antioxidant protection that modifies 




6.11.1. Unanswered questions and future research 
Sugar allows retention of wound moisture and facilitates healing (Chirife et al., 1983). 
Whether my father knew this principle or not, I never had a chance to ask him and now he is 
old and has dementia and can hardly remember anything he did in the community in terms of 
managing wounds. This is how most of African traditional treatment was lost. This failure to 
document has prevented the use of this information by the new generation. Today many 
useful treatments lie in the grave because of this tradition. Part of the knowledge gained from 
working on this thesis is the importance of documentation, a tradition emphasised in the 
developed countries and not so much in the developing countries. This knowledge of using 
sugar was not documented; it was just cascaded down the generations. 
The present study supports the view that sugar therapy is an antimicrobial agent as discussed 
in chapter 2 and it is effective in inhibiting microbial growth by high osmolality depleting 
water activity. However, there is need to explore at what level does the sugar effect wound 
healing is it at molecular/cellular or tissue level? 
Another area to explore is the cost-effectiveness of sugar therapy. Whilst bulk purchased 
sugar is inexpensive, it is impractical for clinical usage. In this study, additional costs were 
incurred to repackage the sugar into single use containers. This cost could be reduced if a 
single use product was mass produced. Further studies are warranted to test whether the 
additional cost of the sugar product would be sufficiently offset by the improvement in 
outcomes of the treated patients. 
Maybe other area of research is to explore how much do African elders know about wound 
care treatment? If any; can that knowledge be translated into the western health care system 
research topics as suggested below? 
 Is sucrose an antibiotic or antibacterial? 
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 What role does sucrose have on MMPs? 
 Does sugar prevent fungi growth? If so how? 
 Does sugar increase oxygen levels onto the wound-bed?  
 The list goes on and the researcher is sure that with more interest the scientific 
world can establish more and solve more too. 
6.11.2. Researcher’s musings 
In Africa like any other continents, there are many different ailments including wounds that 
require treatment; and receiving the best treatment in developing countries many a times 
depends on the ability of the family to pay for the private doctors. Because of poverty, these 
wounds will sometimes develop into chronic wounds and delay healing. They become a 
burden to communities who do not have enough proper resources to manage them. It was in 
these scenarios that my father used his knowledge of granulated sugar treatment to facilitate 
healing of these wounds; a treatment method he learnt from his forefathers. There were no 
documented protocols, or methods of using the sugar treatment, other than by word of mouth, 
a noted African tradition. The dose and type of sugar varied according to the availability of 
the sugar. This poses difficulties to the scientific world that requires evidence to support 
treatment. In the western world, a treatment without a protocol is not accepted. This is 
contrary to the delivery of healthcare in the developing countries, where every available 
treatment is valued as an effort towards alleviating suffering. Patients receive the treatment 
without questioning the evidence or effectiveness and safety of that treatment. Having 
worked and studied in the western world, I understood and valued the purpose of evidence 
and how each available treatment must be critiqued if patients’ safety is to be maintained. 
This reflection led me to recall the sugar treatment that my father used when I was a child. I 
wanted to explore its applicability to modern western hospitals and help develop a sugar 
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treatment protocol (incorporating the dose and type of sugar) that will avail in developing and 
developed countries. 
The researcher hopes you can agree that this was a worthy cause that requires doctoral 
recommendation and this work has carefully explored sucrose a food substance turned into a 
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Appendix 3: Patient Information  
 
Patient Information Sheet 
 
Study Title: A randomised controlled trial to investigate the clinical and cost-effectiveness 
of sugar dressing compared with standard treatment in the management of exudating wounds 
with parallel economic evaluation 
 
Study Number:  
 




1.1 Invitation paragraph 
 
We would like to invite you to take part in a research study.  Before you decide you 
need to understand why the research is being done and what it would involve for 
you.  Please take time to read the following information carefully.  Talk to others 
about the study if you wish.  (Part 1 tells you the purpose of this study and what will 
happen to you if you take part.  Part 2 gives you more detailed information about the 
conduct of the study).  Ask us if there is anything that is not clear or if you would like 
more information.  Take time to decide whether or not you wish to take part. 
 
The research is an experiment investigating the clinical and cost-effectiveness of 
sugar dressing compared with standard treatment in the management of exudating 
wounds.  Sugar has been used in the management of wounds in Argentina, Italy, 
Africa and the United Kingdom at Middleton Hospital in the 1980s.  It is also 
recorded that sugar has been used for this purpose for many years during the earlier 
centuries and was particularly effective in managing exudating and odorous wounds.  
Sugar generally cleans wounds in less than two weeks.  Sugar dressings are 
sterilised and provided in small individual packets for ease of application.  The 
researchers are also interested into finding if there is any change in blood sugar 
levels to those suffering from diabetes.  This is a pre-study to provide information for 
a larger study in the future.  It is going to be used to develop a procedure that will be 
used in the main study and also to determine the number of patients required for the 
main study. 
 
1.2 What is the purpose of the study? 
 
The purpose of the study is to determine whether using granulated sugar on 
exudating wounds will have an effect compared to standard dressings on wound 
healing.  We also want to know if there are any cost-effectiveness when using 
granulated sugar.  The other reason for carrying out this study is to develop a 




1.3 Why have I been invited? 
 
You are chosen to participate in this study because you have a heavily exuding 
chronic wound and you are a patient at Queen Elizabeth Hospital or Walsall Manor 
Hospital. 
1.4 Do I have to take part? 
 
It is up to you to decide.  We will explain the study and go through this information 
sheet, which we will then give to you.  We will then ask you to sign a consent form to 
show you have agreed to take part.  You are free to withdraw at any time, without 
giving a reason.  This would not affect the standard of care you receive. 
 
1.5 What will happen to me if I take part? 
 
You will be expected to be in the study for no more than three weeks. 
The researcher will clean and dress your wound or supervise the team caring for you 
until you no longer require the sugar dressing.  During this period your wound will be 
photographed using a digital camera prior to commencing the study and then weekly 
for up to three weeks.  These photos will be compared to see if there is any change 
in the size of the wound and its appearance. 
Wound swabs will be collected from your wound and sent to the laboratory for 
analysis of bacteria.  Finally you will be asked to fill in a questionnaire that will enable 
the researcher to determine your satisfaction/dissatisfaction with the use of this 
product. 
 
If you decide to take part in this experiment your wound will be treated with 
granulated sugar or standard dressings on a daily basis.  It might be two-times a day 
to begin with depending on the amount of fluid your wound produces.  This will slow 
down to daily, then once in two days until healing begins.  If you suffer from diabetes 
your blood glucose level will be checked before putting granulated sugar on the 
wound throughout the study period (3 weeks).  After the study your blood glucose 
level will be monitored for a period of three weeks.  During the period of study you 
will be given some questionnaire asking you about the treatment.  Your wound will 
be measured with a clinical ruler, photographs and wound swab taken. 
 
1.6 What will I have to do? 
 
You do not have to do anything in particular other than signing the consent form if 
you decide to take part and completing the questionnaire at the beginning and at the 
end of the study. 
 
1.7 What is the device that is being tested? 
 
Your wound will be treated with either granulated sugar specifically prepared for 
wound treatment only or with standard treatment that is normally used with wounds 
similar to yours.  The granulated sugar comes in pre-packed single use packets.  
Your wound will be cleaned as normal then granulated sugar will be applied covering 
the whole wound.  There are no known risks associated with using granulated sugar 
on exudating wounds. We also carried out a small study with 22 patients and we did 
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not encounter any problems.  However, the team will keep a close monitoring of all 
those who are in the study to see if there is any problem arising from this method of 
wound management. 
 
There are no known side effects reported in previous studies related to granulated 
sugar treatment.  However to those who are Diabetic we would monitor blood 
glucose closely to exclude any change in blood sugar levels. We had no problems 
with blood sugar levels during the small study we undertake with 22 patients. 
 
1.8 What are the alternatives for treatment? 
 
This method of using granulated sugar is an experimental treatment compared with 
standard treatment that would otherwise be received.  There are many different 
dressings that may be used if you wish not to take part or should you decide to 
withdraw at any point in the study.  The clinical staff will inform you of the dressing 
they consider to be most suitable. 
 
1.9 What are the possible benefits of taking part? 
 
We cannot promise the study will help you but the information we get from this study 
will help improve the treatment of people with chronic exudating wounds. 
If the trail is successful it will also help with the possible funding of the major study to 
follow. The product might become widely used in the United Kingdom and possibly 
other European and Developing countries. 
 
1.10 What happens when the research study stops? 
 
You will still be monitored as usual to determine the progress of your wound.  If the 
ward staff consider that there is still benefit for you in continuing to use sugar 
dressing on your wound they will do so. 
 
1.11 What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. 
 
1.12 Will my taking part in the study be kept confidential? 
 
Yes,  We will follow ethical and legal practice and all information about you will be 
handled in confidence.  The details are included in Part 2. 
This completes Part 1. 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 








If you decide to withdraw from the study, we will destroy all your identifiable samples, 
but we will need to use the data collected up to your withdrawal. 
 
2.2 What if there is a problem? 
 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak to the 
researcher/research team who will do their best to answer your questions 
  If you remain unhappy and wish to complain formally, you can do 
this through the NHS complaints Procedure (or Private Institution).  Details can be 
obtained from the hospital switchboard on 0121 627 1627 or Patient Advice Liaison 
Service on telephone 0121 627 8820, if you are a patient at Queen Elizabeth 
Hospital. If you are a Walsall Manor Hospital Patient details can be obtained from the 
hospital switchboard 01922721172.  
 
Harm 
There is no harm expected however should any harm occur you can contact Patient 
Advisory Liaison Services (PALS) on 0121 627 8820 or you can ask the hospital 
switch board on 0121 627 1627 to put you through to PALS office if you a Queen 
Elizabeth Hospital Patient. If you are Walsall Manor Hospital use the hospital switch 
board at 01922721172. 
 
NHS Based Research 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for a legal 
action for compensation against University Hospital Birmingham NHS Foundation 
Trust, or Walsall Manor Hospital NHS Trust, but you may have to pay your legal 
costs.  The normal National Health Service complaints mechanisms will still be 
available to you (PALS). 
 
2.3 Will my taking part in this study be kept confidential? 
If you join the study, some parts of your medical records and the data collected for 
the study will be looked at University Hospital Birmingham NHS Foundation trust if 
you are a patient at Queen Elizabeth hospital. If you a Walsall Manor Hospital NHS 
Trust patient some parts of your records will be looked at Walsall Manor Hospital, by 
authorised persons only.  The data may also be looked at by people from the Ward, 
by research supervisors of Birmingham University and by authorised people to check 
that the study is being carried out correctly.  All people who will look at the data have 
a duty of confidentiality to you as a research participant and we will do our best to 
meet this duty. 
 
All information, which is collected, about you during the course of the research will 
be kept strictly confidential, and any information about you which leaves the 
hospital/ward will have your name and address removed so that you cannot be 
recognised. 
 




Samples taken from your wound will be sent to the laboratory for the purpose of 
analyzing the bacteria in your wound only. 
 
2.5 What will happen to the results of the research study? 
 
The results of the study will be disseminated to the whole tissue viability nursing 
team within each trust.  It is also hoped that the outcome of this study be shared with 
those with interest on wound management by publishing the results in professional 
journals and presentation of papers at conferences.  During publication of results in 
professional journals all participants will remain anonymous. 
 
2.6 Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity.  This 
study has been reviewed and given favourable opinion by Birmingham, East, North & 
Solihull Research Ethics Committee. 
 
2.7 Further Information and Contact Details 
 
The study is independent and aimed at finding ways of helping patients suffering 
from chronic exudating wounds.  A PhD student from Birmingham University School 
of Health Science initiated this research project.  He has used this method of wound 
treatment before in Lesotho, South Africa and Zimbabwe with favourable results.  A 
small study was carried out from January 2009 to July 2009 to build on information 
that can help develop an appropriate protocol to be used with this major study.  The 
Principal investigator has witnessed the use of this method whilst on sabbatical in 
East Africa. 
 
If you require more information or talking through this treatment you can contact the 














You are not obliged to take part, however should you decide to take part it might be 
of interest to you and might benefit your wound treatment. 
 
If you are unhappy with the study inform any research team member who will consult 




Or you can contact the patient advisory liaison services at the contact details below: 
 
The Manager 
Patient Advice Liaison Services 
University Hospital Birmingham NHS Foundation Trust 






The Manger  
Patient Advice Liaison Services 
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Appendix 7: Patient Consent Form 
CONSENT FORM  
 
NHS Study Number:  
 
Title of Project: A randomised controlled trial to investigate the clinical and cost-
effectiveness of sugar dressing compared with standard treatment in the management of 
exudating wounds with parallel economic evaluation 
 
Name of Researcher: Moses Murandu  
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated 
19/08/2010 
(Version 1) for the above study: I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected.    
 
3. I understand that relevant sections of my medical notes and data collected during 
the study may be looked at by individuals from [University of Birmingham], from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking part 
in this research. I give permission for these individuals to have access to my records.                                      
                                                                                                       
4. I agree to have a photograph taken of my wound                                                     
 
5. I agree to have a wound swab taken from my wound 
 
6.  I agree to take part in the above study 
_______________               _______________          _________________  
Name of Patient:                  Date:                  Signature:  
 
_______________               ________________         _________________ 
 

























































R&D Study No:  
 
A randomised controlled trial to investigate the clinical and cost-effectiveness of 
granulated sugar dressing compared with standard treatment in the 
management of exudating wounds with parallel economic evaluation 
 
 PATIENT INITIALS ________________ 
 




Principle Investigator: Mr Malcolm Simms Vascular 
    Consultant  
    Selly Oak Hospital  
    Birmingham 
     
 
  
Clinical Investigator: Moses Murandu 
    PhD Student 
    University of Birmingham 
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Study explained to patient        
 
Patient has read the information sheet      
 
Consent form completed and signed      
 
Copy of consent form placed in patient’s notes           
 
Confirmation of consent form signed      
 
Baseline characteristics recorded and complete    
(Proforma 1)     
 
Photograph of wound taken on initial assessment    
 
Initial Wound Assessment         
(Proforma 1) 
 
Blood Glucose taken and recorded                                                      
 
 
Follow up Assessments Completed      
(Proforma 2) 
 




End of Study form completed       
(Proforma 4) 
 






Clinical Investigators signature when complete ________________ 
 









“A randomised controlled trial to investigate the clinical and cost-
effectiveness of sugar dressing compared with standard treatment in the 
management of exudating wounds” 
 
 Patient initials                      ________________ 
 
 Date of Birth   _____/_____/_____ 
 
 Hospital Number   ________________ 
 
 Study Number   ________________ 
 
 Date consent obtained  _____/_____/_____ 
 
I hereby confirm that informed consent has been given from the 
above patient to participate in this study. 
 
The patient signed the consent form. 
 
A copy of signed consent form will be retained in the patient’s medical 
records  
 
A copy has been given to the patient 
 
The third copy has been retained with the study records 
 
............................         ................................    
___/__/___ 
Investigators signature         Print Name             Date  
 
 
PROFORMA   - END OF STUDY FORM 
 
 
TO BE COMPLETED AT ANY STAGE WHEN THE PATIENT IS 
WITHDRAWN FROM THE STUDY 
 
 
1.  Patient study Number          ___________________ 
 




3.  Reason for withdrawal from study 
   (tick one box only)                                    Study wound healed 
       
     End of study period 
 
     Patient withdrawn* 
 
4.  *If patient withdrawn, please give reason(s) 
 
           #Adverse incident 
 
           *Lack of response 
       
           *Patients request 
 
           *Patient lost to follow up 
    
           *Other 
 
*Please give details_________________________________________ 
 








_________________                    _________________      _____/_____/_____   








Patient study Number          ___________________ 
 
Date of assessment             ______/______/______ 
 
 
The Clinical Investigator has determined that the patient has suffered a 
serious adverse incident.  This is defined as any undesirable clinical 
occurrence in the patient that may be considered to be directly or indirectly 
















The patient is therefore withdrawn from the study and the following 
personnel informed. 
 
1. Patient’s Consultant Diabetologist       
   
2. Principle Investigator       
   
3. Local Research Ethics Committee (via R&D)       





__________________             ___________________      _____/_____/_____ 
Clinical Investigator               Print Name                          Date 
 
 
STUDY NUMBER:  
 
RECORD OF WOUND ASSESSMENT AND DRESSING PLAN USING TELER 
METHOD 
Complete one form for each of the patient’s wounds at initial assessment     
Patient S/N:   
                           
Wound site:    










Photographed/ traced Y / N 
Measured using clinical ruler Y / N 


















Dressings Selected - complete at initial assessment and following any dressing 
changes 
Date and Time    
Skin Care/Cleansing    
Standard treatment  Y / N  Type:    
Granulated Sugar Y / N   Amount:    
Securing Mechanism    
Frequency of dressing change    
Print Name    
Signature    















Complete this section weekly for 1 month then monthly for 6 months or when 
healing is complete 
Number of weeks 
Week…. Week …. Week …. Week …. 
Date and Time 
    
     
SIZE    (in cms)  
Diameter     
Length     
Depth      
Area     
Photographed / traced    Y/N     
BLOOD SUGAR LEVEL     
     
INFECTION  
Slough   (in %)     
Swab sent? Y/N     
Swab results: MRSA Y / N     
1 Exudate Appearance  
0 Sanguineous, predominantly blood     
1 Serosanguineous, i.e. bloodstained 
but not bleeding frankly 
    
2 Odorous purulent, i.e. odour + 
cloudy, thick yellow/blue/green tinge 
    
3 Non-odorous purulent, i.e. cloudy, 
thick, yellow 
    
4 Serous, i.e. think, pale straw/clear     
5 No exudates to describe     
2. Exudate Leakage  
0 Dressing(s) and bed clothes are 
soiled 















1 Dressing(s) and bed clothes are wet     
2 Dressing(s) wet and bed clothes are 
damp 
    
3 Dressing(s) wet and bed clothes are 
soiled in patches, size of 50p piece 
    
4 Dressing(s) only is wet     
5 Dressing(s) only is soiled     
 
3.  Odour 
 
0 Odour is obvious in the 
house/clinic/ward 
    
1 Odour is obvious at arms length 
from patient 
    
2 Odour is obvious at less than an 
arms length from patient 
    
3 Odour is detected at arms length     
4 Odour is detected by patient only     
5 No odour     
 
4.  Uncomfortable Dressing 
 
0 Continuous discomfort from 
dressing sleeping and waking hours 
    
1 Occasional discomfort from 
dressing during sleeping hours and 
constant discomfort waking hours 
    
2 Regular discomfort from dressing     
3 Periodic discomfort now and then 
from dressings 
    
4 Discomfort now and then from 
dressings 
    
5 Aware of dressings but no 
discomfort 
    
5. Pain (component) Pain interferes 
with patient’s ability to: 
 
0 Relax     
1 Mobilise     
2 Concentrate     
3 Socialize     
4 Sleep     
No pain at all     
6. Pain disturbing sleep  
0 Wakes frequently difficulty getting to 
sleep 
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1 Wakes frequently (4 or more times 
a night) 
    
2 Wakes infrequently (3 or less times 
a night) 
    
3 Sleeps through 1-3 nights a week     
4 Sleeps through 4-6 nights a week     
5 Sleep undisturbed every night     
7.  Impact of Dressing Change  
0.Unbearable dressing change, 
medication needed during pre and post 
change 
    
2. Distressing dressing change, 
medication needed 
    
3. Unpleasant dressing change, 
medication needed 
    
4. Disagreeable dressing change, no 
medication 
    
5. Some unpleasantness     
6. Dressing change alright     
8. Pressure Sore  
0 Deep wound with infection and 
slough 
    
1 Deep wound with slough but no 
infection 
    
2 Deep wound without slough     
3 Evidence of granulation     
4 Healing from wound edges     
5 Healed     
9.  Achieving Wound Healing  
0 Deep necrotic offensive, infected 
wound, down to bone 
    
1 Deep infected wound, heavy 
exudates, and damage to muscle 
    
2 Sloughy wound, infected and 
offensive, to subcutaneous fat 
    
3 No infection, no exudates, 
granulating, odour free 
    
4 Superficial damage, some 
inflammatory change, broken 
‘healthy’ skin 
    
5 Healthy ‘pink’ unbroken skin.  
Healed wound. 
    
10.   Wound Appearance  
0 Clinically Infected     
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1 Hard Necrotic Eschar     
2 Necrotic/Sloughy     
3 Thin Layer of Slough     
4 Granulating     
5 Epithelialising     
6 Healed*     
PRINT NAME     
SIGNATURE     






Appendix 9: RCT protocol 
 
RCT Protocol final version 
 
Granulated Sugar Dressing Protocol 
 
Name of Student: Moses Murandu 
 
Course: Doctor of Philosophy 
 
Title of Research: A randomised controlled trial to investigate the clinical and cost-
effectiveness of granulated sugar dressing compared with standard treatment in the 
management of exudating wounds with parallel economic evaluation. 
 
Supervisors: Professor Carol Dealey and Professor Tom Marshall  
 
Background and justification of the two studies 
A wound is a breach of the epidermis of the skin that can lead to infection and sepsis. 
However, the body has evolved well defined protective systems to counter this potential 
threat.  It can be argued that, everyone has received minor wounds that were expected to heal 
in a reasonable amount of time, but for more serious scrapes, sores and cuts this may not 
happen, as different factors exacerbate wound healing to the extent some wounds slowly or 
never heal. A slow-healing wound tends to collect dead tissue or debris (slough). This process 
can lead to wound infection and delayed healing (Adam 2002, Jones et al 2004, Steenvoorde 
et al 2007). In order to facilitate wound-healing Sibbald et al (2000) advocated for wound bed 
preparation that entails debridement, wound-friendly moist interactive dressings and bacterial 
balance. Debridement is widely used to clear wounds of necrotic tissue and bacteria to leave a 
clean surface that will heal relatively easily. Debridement and appropriate dressings are often 
used to accelerate healing, although in the early stages of wound healing, debridement occurs 
autolytically through the action of neutrophil-derived enzymes including elastase, 
collagenase, myeloperoxidase, acid hydrolase and lysosomes (Schultz et al 2003). A study by 
Gethin and Cowan (2008) on 108 leg ulcer patients showed that after 4 weeks, 80% of all 
wounds had a reduction of less than 50% slough; although there was no statistically 
significant difference at week 4 between treatments. It is also worth noting that a slough 
reduction of at least 50% by week 4 was associated with a higher probability of healing at 12 
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weeks across all groups (p-0.029) i.e. at 12 weeks, 44% vs. 33% healed (p=0.037). Healing is 
defined by the Wound Healing Society as a “complex dynamic process that results in the 
restoration of continuity and function” (Lazarus et al 1994). To date most of the current 
understanding of wound healing management has been derived from studies of the healing 
process in acute wounds. These wounds, caused by trauma or through surgery generally 
follow a well-defined wound healing process that involves four main stages i.e. 
coagulopathy, inflammation, cell proliferation and repair of the matrix and epithelialization 
and remodelling of the scar tissue. While the chronic or non-healing ulcers are characterised 
by defective remodelling of the extracellular matrix (ECM) protein, a failure to reepithelialise 
and prolonged inflammation (Hasan et al 1997, Agren et al 1999, Cook et al 2000).    
Sugar dressing has been used to debride heavily exudating wounds. However, current 
evidence shows that there is a limited literature relating to sugar dressing in the management 
of exudating wounds though extensive research has been done on honey dressing. While 
sugar dressing has been used over 50 years ago in the United States of America (Dressing 
Times 2006), and Matthews and Binnington (2002) reckoning its use dates back to 1879 and 
since been used by surgeons at Ontario University College in the aid of wound healing of 
contaminated wounds. Despite this occasional use it is yet to be considered an alternative 
agent for wound care. According to Matthews and Binnington (2002) sugar dressing has been 
used less extensively than other debridement agents in human medicine although it is well 
recognised as a suitable adjunct therapy for decontamination of wounds in veterinary 
medicine (Tophan 2000).  It is believed that sugar therapy has been used in injuries such as 
degloving, infected surgical wounds, necrotizing fasciitis, decubitus ulcers, and self-
mutilation, crush injuries, deep tissue infections, or other skin defects that need a healthy 
granulated bed (Matthews and Binnington 2002). In 1985 Trouillet et al described 
successfully treating 19 patients with acute mediastinitis following cardiac surgery. Earlier on 
in 1976 Herszage and Montenegro of Argentina had used ordinary sugar to treat the wounds 
of two patients with post-surgical necrotic cellulitis. Following his successes, he further 
reported another 120 patients going through a successful therapy (Herszage et al 1980). Sugar 
paste has been used on most wound types but it has been found to be particularly effective for 
treating infected and malodorous wounds (Gordon et al 1985). Mphande et al (2005) 
compared the effects of sugar and honey dressings on wound healing and concluded that 
honey was more superior to sugar in terms of healing times, reducing bacterial contamination 
and less painful though the later needs more scrutiny. Furthermore honey is more expensive 
and there is a probability of increased blood sugar levels when used on diabetic patients; 
198 
 
given that enzymatic action of bees on nectar changes it to glucose. It is also understood that 
both sugar and honey have natural antibacterial properties that facilitate healing by reducing 
bacterial colonisation (Knutston et al 1981; Willix, Molan and Hartfoot 1992, Tophan 2000 
and Booth 2004).  
It is well documented that wound healing is impaired in the presence of devitalised tissue 
(Sieggreen and Malkebust 1997, Baharestani 1999, NICE 2001, Gregory et al 2004). The 
removal of slough, when consistent with treatment goals is considered the first step in wound 
bed preparation of both acute and chronic wounds (Falanga 2002, Adam et al 2002, and 
Schultz et al 2004). This premise is supported by the Gethin and Cowan study (2008) which 
found that the removal of devitialised tissue promoted wound healing. Wound bed 
preparation varies from patient to patient and on the condition of the wound bed and 
resources available. Methods range from surgical to natural autolytic debridement and at 
times influenced by the clinician knowledge and treatment goals.  
 
This research will evaluate the clinical efficacy and cost-effectiveness of sugar as a wound 
debriding product for managing sloughy, necrotic or infected exudating wounds. These are 
wounds which at times are odorous, leak fluid, sometimes in large quantities and pose a great 
difficulty in management. To patients, they are a source of poor quality of life. Therefore the 
provision of care for these acute and chronic wounds impacts heavily on the day-to day 
practice of health care professionals in both hospital and community settings and cost the 
NHS in excess of £2 billion each year (Posnett and Franks, 2007). Diseases associated with 
the ageing process such as diabetes and hypertension are a contributing factor to the problem 
of chronic wounds that often pose a health burden (Harding et al 2002) and health care 
professionals are left with a difficult challenge in managing these wounds. Therefore 
extensive research into the best methods/products of treatment is the way forward in order to 
provide quality of life assurances to patients. The method of sugar dressing has been used 
before in the United Kingdom around the 1980s at Northwick Park Hospital (Dealey 1994).  
 
A small pilot study of 22 patients with various aetiologies (Murandu et al 2011) undertaken 
within an NHS acute hospital produced plausible results that facilitated further work into this 
sugar product. Murandu et al (2011) concluded that sugar was safe to use on diabetic patients. 
Within the same study a small patient quality of life survey indicated that, their quality of life 
was improved. There was also reduction in bacterial load and patient use of strong analgesics 
was reduced. The practical concerns were determined by the involvement of all nurses and 
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medical staffs in the vascular ward were the study took place. The proposed research will 
compare desloughing efficacy of sugar dressing within four weeks with current standard 
treatments used for the same purpose.  
It is anticipated that the findings from this research will facilitate improvement of both patient 
reported and clinical outcomes. Overall the benefits include; an improvement in the patient 
experience and improvement in the experience of healthcare professionals who have to dress 
the wounds, shorter wound duration which benefits patients, healthcare professionals and the 
NHS as fewer dressings have to be used.  It is also hoped that there will be reduction in the 
costs of dressings to the NHS as sugar dressings are cheaper unit for unit than many of the 
modern wound management products used in daily practice. Therefore the study outcomes 
could demonstrate considerable cost savings for the NHS, having clear potential impact on 
clinical practice and ultimately on policy-making in this area.   
The proposed RCT will compare the debriding efficacy of sugar after four weeks in sloughy 
wounds of differing aetiologies with standard debriding treatments.  
Purpose of the Research 
The aim of this project is to investigate the effectiveness of sugar dressing as a wound 
debridement product on exudating sloughy, necrotic or infected wounds. 
Primary Questions 
How effective is sugar dressing in reducing the time to debridement of sloughy, necrotic or 
infected exudating wounds/ ulcers compared with standard treatment?  
Secondary Questions 
Does the use of sugar dressing reduce the bacterial load in a wound to a greater extent than 
standard treatment?  
Does the use of sugar dressing improve the quality of life patients with sloughy, necrotic 
and/or infected wounds?  
Is sugar a cost effective alternative to current treatment modalities? 
Is patient satisfaction improved when using sugar dressing? 
Potential Benefits Arising from the Study 
This study will restore the use of sugar dressing in the management of exudating 
wounds/ulcers. The potential benefits are improvement of wound care management of 
exudating wounds and data collected can be directly costed and compared to a control sample 
200 
 
(standard treatment) to determine the cost-effectiveness. The quality of life related outcomes 
will be measured using patients’ related outcomes on quality of life.  
Research Design 
The study will be a prospective pragmatic randomised controlled open trial of clinical 
outcomes comparing sugar dressing with standard debriding treatment. The methods used are 
based on those developed by Dumville et al (2009) for similar pragmatic randomised 
controlled trials of wound management products. 
Population, Sample and Location 
Definitions of the wound types and associated terminology can be found in Appendix 1. 
Eligibility  
Two hundred and thirty patients with sloughy, necrotic or infected heavily exudating, wounds 
will be recruited from in-patients at University Hospital Birmingham NHS Foundation Trust, 
Walsall Hospital NHS Trust and Moseley Hall Hospital by Research Nurses or suitably 
trained and designated hospital tissue viability nurses. The patients will be predominantly 
those with moderate-severe traumatic injury, non-healing surgical wounds or chronic 
wounds. It has been determined that it is reasonable to use this wide range of aetiologies 
because the treatment aims are the same at this stage in the healing process; namely control of 
exudate and debridement of sloughy necrotic or infected tissue (Schultz et al 2003, Schultz et 
al 2004). All patients should have ≥ 25% wound area covered in slough and able to provide 
written informed consent. The inclusion and exclusion criteria are listed in the table below.  
Inclusion Criteria 
Table: 1 
Inclusion criteria Exclusion criteria 
Patients who can independently and 
willingly consent 
Patients who are currently in a trial 
evaluating other therapies for their wound 
Sufficient vascular supply (Ankle 
Brachial Pressure Index of greater than 
0.6) 
Patients who previously been in this trial 






Women who are pregnant or lactating 
Wounds with a minimum of 25% slough 
with infected or necrotic tissue present  
Patients who are not able to tolerate a 
daily dressing change 
Wounds with no dry necrotic eschar 
present 
Patients who have neuropathic 
component to the underlying aetiology 
and require callus removal 
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Patients who are over the age of 18 years Less than 18 years 
 
*
Wounds with fungal infection  
*New change applies to Military participants only. 
Patients for whom English is not their first language are eligible to participate as long as they 
are able to give informed consent. The patient questionnaires used in this study are unlikely 
to have been validated in other languages, however, they are not self-administered and 
patients with some knowledge of English should be able to respond to the questions. Those 
unable to complete them will be followed up for wound data. 
Interventions 
All patients will receive relevant adjunctive therapies such as compression therapy or 
pressure relief as part of their treatment.  
Debridement Period 
Patients allocated to the sugar group will have daily dressings following the protocol 
developed during the pilot study. Sugar dressing will be discontinued once the wound bed is 
clean and granulating. The pilot study found the mean time to achieve debridement was 11.13 
days. Patients in the control group will have standard treatment for debridement following 
current hospital policy. Debridement treatment will be discontinued once the wound bed is 
clean and granulating.  
Follow Up Period  
After debridement all patients will revert to standard care for the follow up period and will be 
assessed weekly. They will remain in the study for a total of 4 weeks. It is anticipated that the 
majority of these patients will be in-patients for most of the time. If they are discharged they 
will either be followed up in the community by a research nurse in collaboration with the 
community nurses or in the outpatient clinic, whichever is most appropriate in relation to 
timing of reviews. 
Deterioration of Reference Wound  
If there is deterioration of the reference wound; i.e. increased in the wound size and increased 
slough percentage over period of two dressing changes the wound will be reviewed by the 
ward team and treatment stopped and changed to other appropriate dressing product. Even if 
the treatment is changed, the patient will remain in the study and the outcomes monitored.  
Withdrawal from the study 
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Patients will be withdrawn from the study if an allergic reaction occurs or if the patient 
request to withdraw from the study.  
Sugar Dressing Group 
Sugar dressing is supplied in single use sterilised containers of 15g and 30g. It will be applied 
to the wound and then covered with a sterile pad and secured firmly in place. Where there 
may be difficulty in applying and retaining the sugar in the wound, a thin layer of soft 
paraffin can be applied to the wound margins. The dressing should be applied daily. 
However, in the initial stages of treatment it may be necessary to change the dressing twice 
daily as there is often increased exudate as the wound starts to debride.    
Control Group 
A variety of wound management products may be used to debride wounds. Patients in the 
control group will be assessed and the most appropriate product will be selected according to 
patient need and current hospital policy and in collaboration with the ward team. Dressing 
change will be undertaken as required by the treatment in use. 
In discussion with a member of the ward team, research nurses will use their clinical 
judgement as to when the debridement treatment is no longer required, i.e. if the wound bed is 
clean and granulating, a wound photograph will be taken and recorded in the case report 
form (CRF). Appropriate standard treatment will then be selected by the clinical team. 
Although this approach appears to move control of the outcome away from the research team, 
it was found not to affect the results in the Dumville et al (2009) study. 
Adjunctive Therapies 
The use of any adjunctive therapies depends on the wound aetiology and patient assessment. 
They will be prescribed by the ward team and recorded by the research nurse in the case 
report form. 
Leg Ulcers: compression therapy may be prescribed for venous leg ulcers depending on the 
wound status, for example it is not current practice to use compression therapy on infected 
venous leg ulcers, but application of compression will recommence as the infection resolves. 





Patients will be approached by one of the Tissue Viability Nurses or other members of the 
ward team. If they express a willingness to consider participation in the study a member of 
the research team will be notified and asked to visit the patient. All members of the research 
teams in both hospitals will receive standardised training on all aspects of the trial including 
informed consent. A research nurse will provide written and verbal information about the 
study to the patient and be available to answer any questions. Patients will have a minimum 
of 24 hours to decide whether to participate or not. Written consent will be obtained from all 
patients participating in the study and the clinical team informed of this decision (A copy of 
the patient information sheet and the consent form can be found in Appendix 2). Once a 
patient has signed the consent form and before randomisation, the following data will be 
collected: 
Wound measurement; length, width and depth using wound measurement ruler. This will be 
recorded on the study wound assessment pro-forma and the approximate shape of the wound 
selected from a range of shapes. Wound size will be determined using the algorithm 
developed by Metcalfe et al (2008) to validate the use of the clinical ruler and then calculated 
using computer software. 
Wound appearance the percentage of slough, infected tissue and necrotic tissue (a minimum 
of 25%) will be recorded on the wound assessment pro-forma and a digital photograph taken. 
A masked observer (Tissue Viability Nurse) will later record the percentage of slough, 
infected tissue or necrosis seen in the wound using digital analysis to confirm reported 
proportion of slough and/or necrosis. 
Wound assessment exudate type and quantity, pain and odour will be undertaken using the 
Treatment Evaluation Wound indicators by Le Roux TELER (Le Roux, 1993). These 
indicators have been used in other studies (Grocott and Cowley, 2001); Browne et al, 2004a; 
Browne et al, 2004b) and also in the pilot study. They were found to provide objective 
measurements of exudate volume, odour and pain by using a series of indicator codes where 
5 is the desired outcome and zero is the worst possible outcome. Each code from 0 to 5 
indicates a clinically significant change that can be recorded as an ordinal measurement. The 






5 No odour 
4 Odour is detected on removal of the 
dressing 
3 Odour evident on exposure of dressing 
2 Odour evident at arms length from patient 
1 Odour evident on entering room 
0 Odour evident on entering ward 
 
Wound infection: all wounds will be assessed against a check list for clinical indications of 
infection and a wound swab will be taken. 
History: wound aetiology, longevity of the wound, Ankle Brachial Pressure Index (ABPI) for 
leg ulcers, nutritional status (BMI), mobility and antibiotic usage will be recorded. 
Health Related Quality of Life (HRQL) will be measured using EQ-5D (The EuroQoL 
Group, 1990). 
The research nurse/ward nursed trained to run the trial will then ring the University of 
Wolverhampton for randomisation number. Patients will be randomised to one of the two 
arms of the study. Allocation to treatment will be stratified by two variables, (wound type and 
wound size) to ensure equal balance between the two arms of the study for factors that may 
be prognostic for healing.  
Wound type: wounds will be divided into acute and chronic depending upon the underlying 
aetiology as shown below: 








It is recognised that acute wounds, by their very nature heal faster than chronic wounds, 
although there is limited information about healing rates. 
Wound size: 
















Wounds less than 5cm
2
 and greater than 40cm
2




The primary outcome measure will be time to complete debridement at 4 weeks and healing 
at 12 weeks. Complete debridement will be defined as a cosmetically clean wound (Dumville 
et al, 2009). Reference wounds will be photographed on entry to the study and then weekly. 
When the research nurse decides that the wound is debrided, she/he will ask a member of the 
ward team to confirm this. In the event of disagreement, the local Principal Investigator will 
be asked to review the wound status. The date of debridement will be recorded.  
Secondary Outcomes 
Reduction in Wound Size 
Wounds will be measured at enrolment and then weekly for the study period. The surface 
area will be calculated using the methods previously described.  
Reduction in Bacterial Load 
Wound swabs will be taken at baseline and then weekly for 1 month. They will be cultured 
for Gram positive and negative aerobes, anaerobes and fungi.  
Reduction in Pain and Odour 
Levels of pain and odour will be recorded using the TELER system (previously described) at 
baseline and at each dressing change until debridement is complete. 
Health-Related Quality of Life 
The EQ-5D will be used to measure quality of life. Measurements will be taken at baseline, at 
end of debridement before reverting to the standard treatment. 
The costs of using sugar dressing and standard treatment will be monitored by recording all 
the materials used at each dressing change until debridement is complete. The frequency of 
dressing change will also be recorded. Although sugar dressing is relatively cheap compared 
with other wound management products, it does require more frequent dressing changes than 
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some products. It is important therefore to monitor both the components of the dressings 
applied and the frequency of application and cost of deterioration 
Statistical Considerations 
The sample size for this randomised controlled trial has been calculated using the outcomes 
of the pilot study.  An a priori calculation found that 200 patients will be required for this 
study, assuming that there will be a median debridement time of 12 days in the sugar group 
and 17 days in the control group and a 4 week follow-up period. Allowing for a 15% loss to 
follow up, a total of 230 patients will be recruited giving an 80% power at the 5% 
significance level. It should be noted that this calculation is based on limited information and 
therefore an interim analysis will be done by an independent Queen Elizabeth Hospital 
Birmingham NHS Foundation Trust Statistician after 75 patients have been recruited to 
review the study outcomes and confirm the numbers required in the study to achieve a 
significant result. Any alterations in the required numbers will be communicated to East 
Birmingham Ethics Committee and amendment approval sought if necessary. 
Patients with heavily exuding wounds will be screened and those meeting the inclusion 
criteria will be randomised to either sugar dressing or standard treatment. The randomisation 
will be stratified both by acute or chronic wounds and by size as described previously.  
Both patients and researcher will be blind to allocation until after consent has been given. If a 
patient has more than one wound the largest with a minimum of 25% slough, infected tissue 
or necrosis will be selected as the reference wound. 
It is estimated that 3 patients per week will be recruited across the three centres and that 
recruitment will take a maximum of 24 months which allows for some under recruitment 
during holiday periods. 
Data analysis  
A range of parametric and non-parametric statistical tests will be undertaken as appropriate to 
determine the progression of the wound healing process. Data recorded during the study will 
be analysed using an ‘intent to treat’ analysis. 
 Differences in the time to debridement will be analysed using Life Table Analysis 
 Differences in the reduction of wound size in the two groups will be analysed using 
Mann-Whitney T-test 
 Changes in respect of odour, pain and bacterial load from baseline to end of 
debridement and end of debridement to week 4 in the two arms of the study will be 
compared with a Mann-Whitney T- test. Unadjusted p values will be reported, but that 
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the effect of multiple comparisons will be considered in the interpretation of the 
results. 
 Differences in the incidence of complications when using sugar dressing compared to 
that of current methods 
 Cost of using the sugar dressing to that of current methods will be contrasted. This is 
an additional study to be undertaken by an student undertaking MSc in Health 
Economics 
 The EQ-5D measurements will be used to facilitate the construction of QALYs. 
Procedure  
All patients in the study will be assessed on admission to the study, weekly until debridement 
is complete and monitored daily using TELER indicators. Thereafter participants will be 
followed weekly until 4 weeks is completed. 
Initial assessment  
 Assess wound bed and of surrounding skin 
 Measure and record wound size using a disposable clinical ruler 
 Record amount and type of exudate 
 Complete EQ-5D Quality of Life Questionnaire  
 Collect wound swabs for M C & S  
 Take Photograph of wound 
 Use TELER indicators to record odour, pain, and exudate 
Weekly assessments 
 Assess wound bed and status of surrounding skin 
 Measure and record wound size 
 Collect wound swabs for M C & S until debridement complete  
 Take Photograph of wound 
 Use TELER indicators to record odour, pain, and exudate 
Final assessment at 4 weeks 
 Assess wound bed and status of surrounding skin 
 Measure and record wound size 
 Take Photograph of wound 




Dressing procedure: Table 2. 
Experimental group Control group 
Assess wound and record on wound pro-
forma 
Assess wound and record on wound pro-
forma 
Take wound photograph Take wound photograph 
Collect wound swab  Collect wound swab 
Measure wound with clinical ruler Measure wound with clinical ruler 
Use TELER indicators to record Odour, 
Pain, and Exudate  
 
Use TELER indicators to record Odour, 
Pain, and Exudate  
 
Clean wound with normal saline and dab 
dry with sterile gauze 
Clean wound with normal saline and dab 
dry with sterile gauze 
Apply granulated sugar on the wound 
covering all areas 
Apply current product used according to 
dressing formulary and trust policy 
Apply dressing pad and secure 
appropriately  




Ethical approval was granted from the North Birmingham and Solihull local research and 
ethics committee prior to commencing the study. Ethical principles laid down in the NHS 
Research Governance framework will be adhered to. The researcher has an honorary contract 
with the UHBNHSF trust. Full informed consent procedures will be followed. Prospective 
participants will be given time to read the information about the proposed trial prior to 
inviting them to take part.  The researcher is aware of the diversity of the population to be 
studied and the need for an informed decision to take part in the study. The trust has a robust 
and effective interpretation services that the researcher will use if there is language barrier. 
All prospective participants will be asked to sign consent form.  
Patients will be informed of their right to withdraw from the study at any time. 
Confidentiality of data, subjects and study settings will be maintained throughout this study 
in accordance with the Data Protection Act (Great Britain Parliament 1998). Anonymous data 
will be stored at the research centre (the University Hospital Birmingham NHS Foundation 
Trust (UHBNHSFT) Research and Development offices) on a computer with a protected 
password. Hard copies of data will be stored in a locked facility at the centre and the keys 
kept in a safe supplied by the Research and Development Supervisor. Following completion 
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Appendix 11: Nurses Questionnaire. 
Healthcare Professional Satisfaction Questionnaire 
 
Please help us improve our product by answering some questions about the use of 
granulated sugar on exudating wounds you have been using for the past three weeks. 
We are interested in your honest opinion, whether they are positive or negative. Please 
answer all of the questions. We also welcome your comments and suggestions. 
Thank you very much we really appreciate your help.  
 
Circle Your Answer 
 
1 How many years of nursing experience do you have? 
   5                                  4                     3                                2                          1 
Less than a year         2-5 years       5-10 years              10-20 years          More than 20 years 
 
2 How would you rate the usefulness of granulated sugar on exudating wounds? 
   4                          3                            2                          1 
Excellent              Good                     Fair                      Poor  
 
3. Did you find it easy to use granulated sugar on exudating wounds? 
   1                                              2                                    3                                        4 
No, definitely not           No, not really              Yes, generally                 Yes, definitely 
 
4 To what extent has our training and support met your needs? 
        4                                                 3                                         2                                             1 
Almost all of my                   Most of my needs               Only a few of my                None of my 
needs  
 have been met                   needs have been met         needs have been met        have been 
met 
 
5 If a ward were in need of similar product, would you recommend this product to that 
ward?  
    1                                         2                                  3                                         4 
No, definitely not           No, not really             Yes, generally                  Yes, definitely   
 
6  How satisfied are you with the use of granulated sugar on exudating wounds? 
 
1                                           2                                           3                                         4 
Quite dissatisfied             Indifferent or mildly          Mostly satisfied               Very satisfied 
                                            Dissatisfied 
7. Have granulated sugar helped you deal with exudating wounds more effectively? 
4                                                    3                               2                                        1             
Yes, it helped                            Yes, it helped           No, it really didn’t           No, it seemed to   




8. In an overall, general sense, how satisfied are you with the use of granulated sugar 
on exudating wounds? 
        4                                      3                                            2                                          1 
Very satisfied               Mostly satisfied                   Indifferently or                  Quite dissatisfied 
                                                                                     mildly dissatisfied    
 
9. If you were to have chronic exudating wounds would you use granulated sugar 
again as your choice of treatment? 
 
1                                      2                                            3                                   4 
No, definitely                No, I don’t think so          Yes, I think so             Yes, definitely 
 
Any comments or suggestions?                             
218 
 
Appendix 12: Operational definitions 
 
Operational Definitions for Wound Types and Associated Terminology 
Wound 
Is defined by Schultz (1999) as a disturbance in the normal anatomy and function; tissue 
injury resulting in the loss of continuity of epithelium with or without the loss of underlying 
connective tissue. 
Acute Wounds 
Acute wounds can be defined as wounds of sudden onset and of short duration 
Dehiscent surgical wounds 
Dehiscence means the breaking down, or splitting open, of all or part of a wound 
Chronic Wounds 
Chronic wounds are defined as wounds, which have failed to proceed through an orderly 
and timely reparative process to produce anatomic and functional integrity over a period of 
3 months (Mustoe et al, 2006). 
Pressure Ulcers 
A pressure ulcer is localized injury to the skin and/or underlying tissue usually over a bony 
prominence, as a result of pressure, or pressure in combination with shear.  A number of 
contributing or confounding factors are also associated with pressure ulcers; the 
significance of these factors is yet to be elucidated (NPUAP/EPUAP, 2009) 
Leg Ulcers 
An ulcer on the leg and below the knee which has been present more than 8 weeks 
Diabetic Foot Ulcers 
Ulceration of the foot as a complication of diabetes mellitus 
Granulation  
A transitional substance that replaces the fibrin/fibronectin matrix, that begins to appear 
after about 4 days following injury. 
Debridement  
The process of clearing wound, of necrotic tissue and bacteria leaving it with a clean surface 
that will heal relatively easy.  
Wound Healing 
Is defined by the Wound Healing Society as a “complex dynamic process that results in the 




Appendix 13: EQ-5D Questionnaire 
 
Quality of Life Health Questionnaire: EQ-5D 
 
Health Questionnaire  
 
English version for the UK  
 
 
Title of the Study: A randomised controlled trial to 
investigate the clinical and cost-effectiveness of sugar 
dressing with standard treatment in the management 
of exudating(Weeping) wounds. 
 
Thank you for agreeing to take part in this Health 
Questionnaire today. Please kindly answer the questions as 
requested below, By placing a tick in one box in each group 
below, please indicate which statements best describe your 
own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  





I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  












   Worst 






To help people say how good or bad a health state 
is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can 
imagine is marked 0. 
We would like you to indicate on this scale how 
good or bad your own health is today, in your 
opinion. Please do this by drawing a line from the 
box below to whichever point on the scale 
























Appendix 14: Wound dressing procedure 
Wound dressing procedure: 
 Half-filled bowl with lukewarm water 
 Soaked wound in the water if wound was on the foot and washed surrounding area 
 Washed the wound and surrounding area if unable to soak; wounds such as sacral 
pressure ulcers 
 After soaking and washing; rinsed all wounds with normal saline or clean tap water 
 Dabbed dry the wound with sterile gauze and surrounding area with a clean towel 
 Applied yellow paraffin or ordinary Vaseline around the wound area to hold the 
excess sugar 
 Dust gently the granulated sugar on the wound until the wound is fully covered with 
no visible open area (approximately 0.1-0.2cm thickness of granulated sugar) 
 Applied  gently a dressing pad over the sugar 






Appendix 15: Wound images treated with sugar 
FIGURE(S) – A SELECTION OF RCT  WOUND SAMPLES TREATED WITH SUGAR 
         
       A1- Abcess (before treatment)                      A1 – (after 14 days of sugar 
treatment)  
       




       
C1 – Surgical wound (before treatment)   C1- (after seven days of sugar 
treatment) 
       
D1 – Ulcer (before treatment)   D1- (after seven days of sugar 
treatment)   





















Appendix 17: Academic publications 
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